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Poria cocos (also known as Fuling) is one of the most famous herbs used in 
Traditional Chinese Medicine for its diuretic, sedative and tonic effects.  The aim of 
this PhD project is to examine the efficacies of triterpenoids from Poria cocos against 
human cancers.  This project was initiated with separation and isolation of 
triterpenoids contained in alcoholic extracts of Poria cocos using flash column 
chromatography.  In total, eight compounds were obtained and identified as (1) 
pachymic acid, (2) dehydropachymic acid, (3) 3-acetyloxy-16α-hydroxytrametenolic 
acid, (4) polyporenic acid C, (5) 3-epi-dehydropachymic acid, (6) 
3-epi-dehydrotumulosic acid, (7) tumulosic acid, and (8) 29-hydroxypolyporenic acid.  
The antiproliferative activity of these triterpenoids was examined using a cell 
proliferation assay.   
Due to its relatively stronger antiproliferative activity, polyporenic acid C 
(PPAC) was subjected to further evaluation for its apoptosis-inducing effect.  PPAC 
was found to exhibit inhibition against anchorage-dependent and –independent 
growth of human lung cancer cells, which was accompanied by apoptosis induction 
as evident from increase in sub-G1 cell population, positive annexin V staining, and 
increase in cleavage of procaspase-8, -3 and poly-ADP ribose polymerase.  
Experiments using specific caspase inhibitors confirmed the involvement of 
caspase-8, but not caspase-9 in PPAC-induced apoptosis.  Thus it was suggested that 
PPAC induced apoptosis through the death receptor-mediated apoptotic pathway 
 x 
without the involvement of mitochondria.  Furthermore, PPAC was shown to 
suppress PI3-kinase/AKT signal pathway and enhance p53 activation, implying the 
involvement of an additional mechanism by which apoptosis was induced by this 
triterpenoid.   
Pachymic acid (PA), the main triterpenoid isolated from Poria cocos, was 
examined for its anticancer activity with a focus on its modulation of arachidonic acid 
metabolism.  A multi-factorial anticancer property of PA toward human lung cancer 
was demonstrated.  At high concentrations, PA induced apoptosis in lung cancer 
cells, accompanied by perturbation of mitochondrial membrane potential.  At 
non-lethal levels, PA decreased IL-1β-induced activation of cPLA2 and COX-2 by 
suppressing MAPKs activation and inhibiting NF-κB signaling.  Consequently, 
arachidonic acid and its downstream product prostaglandin E2 were downregulated.  
In view that arachidonic acid metabolism plays an important role in promoting cancer 
progression, these findings had indicated the chemopreventive potential of PA against 
lung carcinogenesis.  
The anticancer potential of Poria cocos-originated triterpenoids was further 
explored by examining their efficacy against phorbol ester-stimulated matrix 
metalloproteinase secretion and breast cancer cell invasion.  PPAC, PA and 
dehydropachymic acid were found to reduce the gelatinolytic activity of matrix 
metalloproteinase-9 with different efficacies.  PA, with the strongest anti-invasive 
potential, was demonstrated to significantly inhibit phorbol ester-stimulated migration 
of MDA-MB-231 cells in an in vitro Matrigel invasion assay.  The inhibition of 
 xi 
MMP-9 by PA was found to occur at the transcriptional level through the inhibition of 
NF-κB signaling.  It was thus concluded that by targeting NF-κB signaling, PA 
inhibited MDA-MB-231 cell invasion through decreasing MMP-9 expression.  
Together, the findings presented in this PhD study had expanded on the 
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Chapter 1:  Introduction 
Cancer is a class of diseases caused by abnormal and uncontrolled cell 
division that eventually invade nearby tissues and spread to other parts of the body 
through the blood and lymphatic circulation systems (Clark 1991).  Six essential 
characteristics have been proposed to differentiate cancer from normal tissue: 
“self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion 
of programmed cell death, limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis” (Hanahan and Weinberg 2000).  Cancer affects all 
parts of the body and is a major public health concern worldwide.  According to a 
recent statistical report, the most frequently occurring cancers among men are 
prostate cancer (25%) and lung cancer (15%), while the most common cancers in 
women are breast cancer (27%) and lung cancer (14%) (Jemal et al. 2009).  The 
transformation of normal human cells into highly malignant tumor cells is a 
multi-step process and can be represented by three stages that often overlap: initiation, 
promotion, and progression phases (Farber 1984; Clark 1991).  Cancer initiation 
begins when normal cells are exposed to a carcinogen and their genomic DNA 
undergoes damage that remains unrepaired or misrepaired.  In the cancer promotion 
stage, the cell damages are expanded, and eventually lead to the appearance of benign 
tumors.  Finally, during the progression phase, new clones of tumor cells with 
increased proliferative capacity, invasiveness, and metastatic potential are produced.   
To combat cancer, a variety of strategies have been proposed and developed.  
The conventional treatments of cancer include surgery, chemotherapy, radiotherapy 
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and immunotherapy.  More recently, gene therapy emerged as a promising 
alternative method for cancer treatment, owing to increased understanding of tumor 
biology and the process of tumorigenesis.  In addition, the concept of cancer 
prevention has received much attention since increasing evidence has shown that 
more than 30% of cancer can be prevented by modifying or avoiding key risk factors 
such as smoking (Danaei et al. 2005).  Therefore, chemoprevention, defined as the 
use of synthetic or natural agents to inhibit, retard, or reverse the process of 
carcinogenesis, has been employed as a strategy against cancer along with therapeutic 
treatments. 
In the search of effective chemotherapeutic and/or chemopreventive agents 
against cancer, natural products have proved to be valuable sources for discovery of 
lead drug compounds.  More than half of the currently used anticancer agents are 
developed in one way or another from natural products (Gordaliza 2007).  These 
anticancer drug candidates include vinblastine, vincristine, the camptothecin 
derivatives, topotecan and irinotecan, etoposide, and paclitaxel (Cragg and Newman 
2003).  One class of natural products that have attracted interest as potential 
anticancer candidate in recent years is the triterpenoids. 
Triterpenoids refer to a large and structurally diverse group of compounds 
derived from squalene or related acyclic 30-carbon precursors (Xu et al. 2004).  Due 
to their diverse biological effects, naturally occurring cyclic triterpenoids such as 
ursolic acid, tubeimoside and oleanolic acid have attracted much attention in cancer 
research (Connolly and Hill 2008).  Recently, two semisynthetic triterpenoids 
Chapter 1 
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developed from oleanolic acid were believed to be among the most effective 
anti-inflammatory and anti-carcinogenic agents (Liby et al. 2007).   
Triterpenoids are widely distributed in many traditionally used medicinal 
herbs, such as Poria cocos.  Alcoholic extracts of Poria cocos contain various 
lanostane-type triterpenoids which have been shown to possess anti-inflammatory and 
anticancer properties (Kaminaga et al. 1996; Cuellar et al. 1997; Akihisa et al. 2007).  
However, due to limited research on Poria cocos-originated triterpenoids, the 
cancer-preventive and –therapeutic potential of these lanostane-type triterpenoids 
remains largely unknown. 
The subsequent sections provide (1) an overview of natural products-derived 
anticancer agents, (2) a review on anticancer triterpenoids, and (3) a literature review 
on triterpenoids from Poria cocos.  In addition, three cancer-related topics, namely 
apoptosis, prostaglandins in cancer development, and matrix metalloproteinases and 











1.1 Natural products as source of anticancer agents 
Natural products have been used for treatment of various kinds of diseases for 
thousands of years.  Since the beginning of modern scientific research, natural 
products have been the source of most of the active components in medicines (Harvey 
2008).  Before 1996, more than 80% of medicinal drugs were derived from natural 
products or inspired by a natural product (Harvey 2008).  The continuing importance 
of natural products as sources in drug discovery can be seen from the statistical 
analysis showing that half of the drugs approved from 1994 to 2007 were derived 
from natural products (Newman and Cragg 2007).    
In the cancer field, natural products have been widely screened by researchers 
in search for new and effective anticancer agents.  According to a recent statistical 
report, of the 155 anticancer drug substances from 1940s to 2006, only 27% are 
synthetic compounds, with 47% essentially being natural products or derived forms 
of natural products (Newman and Cragg 2007).  These naturally occurring 
compounds are used as anticancer drugs themselves, precursors for semisynthesis or 
templates for synthesis of more potent and safer analogs.  In addition, more 
compounds derived from natural products are currently under preclinical or clinical 
evaluation as promising anticancer candidates. 
The clinically used anticancer agents with a natural product source include 
several groups of molecules with diverse chemical structures.  The first anticancer 
agents in clinical use are a group of vinca alkaloids, which were isolated from the 
Madagascar periwinkle, Catharanthus roseus and discovered as potential anticancer 
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agents in the 1950s.  Two natural occurring compounds of this group, vincristine 
and vinblastine were found to exert their anticancer activity through inhibiting tubulin 
polymerization and approved by Food and Drug Administration (FDA) as anticancer 
agents in 1963 and 1965 respectively (Cragg et al. 2009).  They have been largely 
used in combination with other cancer chemotherapeutic drugs for the treatment of a 
variety of cancers including leukemia, lymphoma, Kaposi’s sarcoma, advanced 
testicular cancer, as well as breast and lung cancers (Cragg et al. 2009). 
The second group of anticancer agents was developed based on the 
identification of podophyllotoxin, a bioactive lignan contained in Podophyllum 
species, as a potent cytotoxic agent (Damayanthi and Lown 1998).  Podophyllotoxin 
shows strong cytotoxic activity against various cancer cell lines, but its complicated 
and severe side effects make it unsuitable for clinical use as anticancer agent (Cragg 
and Newman 2005).  Further chemical modification successfully yielded two 
clinically effective anticancer agents, etoposide and teniposide.  Their anticancer 
mechanism has been revealed to be through inhibition of topoisomerase II and they 
are clinically used in the treatment of neoplasia such as lymphomas and bronchial and 
testicular cancers (Hande 1998).   
Derivatives of camptothecin constitute the third class of anticancer agents in 
clinical use.  Camptothecin was first extracted from the Chinese ornamental tree, 
Camptotheca acuminata, also known as the “tree of joy”.  Despite its remarkable 
anticancer activity, camptothecin failed clinical trial due to its adverse drug reactions 
including vomiting, diarrhea and severe bladder toxicity (Kehrer et al. 2001).  
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However, extensive research on analogues of camptothecin has produced two 
clinically used anticancer drugs, topotecan and irinotecan (Kehrer et al. 2001).  
Acting through their inhibitory effects on topoisomerase I, these agents are currently 
used for treatment of ovarian and colon cancers (Kehrer et al. 2001). 
The discovery of paclitaxel in the late 1960s has bred a new class of 
anticancer agents with unique molecular mechanism (Kingston 2009).  Paclitaxel 
was initially isolated from the bark of Taxus brevifolia, a pacific yew, and its 
cytotoxicity against cancer was discovered under a systematic screening program 
organized by the National Cancer Institute of the United States (NCI) (Wani et al. 
1971).  The following preclinical evaluation and clinical trials not only confirmed 
paclitaxel as an effective anticancer agent, but also revealed its novel anticancer 
mechanism as a stabilizer of microtubules (Kingston 2009).  Though hindered by its 
shortage of supply from natural source, paclitaxel was finally approved by FDA (as 
Taxol®) for the treatment of metastatic ovarian cancer in 1992.  In the following 
year, the successful semi-synthesis of paclitaxel using a readily available precursor 
solved the long outstanding supply problem (Kingston 2007).  Today, Taxol® is one 
of the most important anticancer drugs; it is used either alone or in combination with 
other anticancer agents in chemotherapy for the treatment of various cancers 
including ovarian, breast, and non-small cell lung cancer.   
Apart from the abovementioned clinically used anticancer agents, some 
anticancer candidates currently under clinical trials are also derived one way or 
another from natural products.  These include, but not limited to, flavopiridol, 
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combretastatin A-4 and roscovitine (Cragg and Newman 2005).  Based on the novel 
chemical structure of rohitukine from Dysoxylum binectariferum, flavopiridol was 
synthesized as a potential anticancer agent acting through inhibition of 
cyclin-dependent kinase.  It is the first cyclin-dependent kinase inhibitor under 
clinical development (Senderowicz 1999).  Combretastatin A-4 is a natural 
stilbenoid phenol isolated from the bark of the South African tree Combretum 
caffrum.  Acting as an inhibitor of tubulin polymerization, combretastatin A-4 is one 
of the most cytotoxic phytomolecules toward cancer cells with remarkable inhibitory 
effect on tumor’s blood supply (Griggs et al. 2001).  Roscovitine is a derivative of 
olomucine, a natural compound originally isolated from the cotyledons of the radish, 
Raphanus sativus.  Roscovitine is a cyclin-dependent kinase inhibitor and currently 
under clinical evaluations for its effect against lung cancer and lymphoma (Meijer 
and Raymond 2003).  Although these agents are still under clinical assessment, a 
larger inventory of anticancer agents derived from a natural source is expected in the 
near future.   
On the other hand, epidemiologic studies have indicated the potential 
anticancer activity of compounds contained in natural products such as fruits and 
vegetables (Block et al. 1992).  Consumption of such products was found to 
significantly reduce cancer occurrence.  In addition, many natural occurring 
compounds such as resveratrol from grapes, curcumin from turmeric, and 
isothiocyanates from cruciferous vegetables have been shown to possess 
preventive and/or therapeutic effects against various cancer types in vitro and 
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in vivo (Beliveau and Gingras 2007).  These findings further reinforce the 























1.2 Triterpenoids from Poria cocos 
1.2.1 Triterpenoids 
The triterpenoids are a large and structurally diverse group of natural 
compounds derived from squalene or related acyclic 30-carbon precursors (Xu et al. 
2004).  To date, more than 20,000 naturally occurring triterpenoids have been 
isolated and identified (Liby et al. 2007).  For centuries, natural products containing 
high content of triterpenoids have been a main source of folk medicines.  Scientific 
research also showed that triterpenoids have a wide range of biological activities, 
such as anti-inflammatory, anticancer, antimicrobial and antiviral effects (Dzubak et 
al. 2006).  The intense research interest on triterpenoids can be evidenced from the 
large amount of literature published.  Notably, the enthusiasm on antineoplastic 
triterpenoids has been increasingly prevailing over the past 20 years.  As shown in 
Figure 1.1, from 1987 to 2001, the number of publications on antineoplastic 
triterpenoids has dramatically increased from 3 to 74 (Setzer and Setzer 2003), and 






Figure 1.1 Manuscripts reporting antineoplastic triterpenoids as abstracted in 
PubMed for the period 1987-2001.  (Adopted from Setzer and Setzer, 2003) 
 
Among the triterpenoids identified so far, a number of triterpenoid structures 
including lupane, lanostane, dammarane, ursane and oleanane triterpenoids, have 
attracted much attention due to their remarkable anticancer activities.    
Lupeol and betulinic acid (structures are shown after this paragraph) are two 
natural pentacyclic triterpenes belonging to the lupane family.  The anticancer 
activity of lupeol has been demonstrated both in vitro and in vivo.  To prostate 
carcinoma cell lines, lupeol has been reported to inhibit the proliferation of LNCaP 
cells (IC50 = 75 µM) and cause arrest of PC-3 cells at G1-S phase (Prasad et al. 2008).  
In animal models, lupeol significantly reduces testosterone-induced prostate changes 
in mice and effectively attenuates tumor formation in nude mice bearing 451Lu 
melanoma xenograft (Prasad et al. 2008).  In addition, lupeol is found to induce 
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mitochondria-mediated apoptosis through elevation of Bcl-2/Bax ratio and cleavage 
of caspase-3 in prostate cancer and melanoma cells (Prasad et al. 2008; Prasad et al. 
2008; Saleem et al. 2008).  Apart from its cytotoxic effect, lupeol has also been 
demonstrated to be effective against carcinogenesis, evident from its preventive effect 
on 7, 12-dimethylbenz[a]anthracene (DMBA)-induced DNA breakage in a mouse 
model (Nigam et al. 2007).  Betulinic acid, also a lupane-type triterpenoid, is known 
to inhibit DNA polymerase β, topoisomerases I and II and to possess broad 
cytotoxicity against lung, colorectal, breast, prostate and cervical cancer cell lines 
(Kuo et al. 2009).  Betulinic acid has been shown to be an effective anticancer agent 
both in vitro and in vivo by inducing apoptosis through increasing permeability of the 
mitochondrial membrane (Kuo et al. 2009).  Intriguingly, as compared to clinically 
used anticancer agents such as cisplatin and doxorubicin, betulinic acid has 
demonstrated better anticancer activity while exerting less toxic effect on non-cancer 
cells (Sarek et al. 2003; Jeremias et al. 2004).  Owing to its remarkable anticancer 
activities, betulinic acid is now under development under the Rapid Access to 
Intervention Development program at the NCI (Tan et al. 2003).   
OH








Lanostane-type triterpenoids include those contained in Ganoderma lucidum 
and Poria cocos.  Ganoderic acid D, a lanostane triterpenoid isolated from 
Ganoderma lucidum, is reported to inhibit proliferation of human cervical carcinoma 
HeLa cells with an IC50 value of 17.3 µM (Yue et al. 2008).  Flow cytometric 
analysis revealed that ganoderic acid D caused cell cycle arrest at G2/M phase and 
resulted in apoptotic cell death of HeLa cells (Yue et al. 2008).  Lanostane-type 
triterpenoids isolated from Poria cocos have also been demonstrated to have 
anticancer activities and their pharmacological activities will be reviewed in details in 






ganoderic acid D 
The dammarane-type triterpenoids include ginsenosides isolated from Panax 
ginseng, a famous herb widely used in Traditional Chinese Medicine.  The 
chemopreventive effects of Panax ginseng have been successfully tested on a wide 
range of animal models which include cancers derived from the mammary glands, 
colon, liver, cervix and central nervous system (Dzubak et al. 2006).  In addition, 
Panax ginseng has shown preventive effect in patients with esophageal and 
endometrial precancers (Dzubak et al. 2006).  Lending support to this observation 
are three epidemiological studies showing the correlation of consumption of Panax 
ginseng with lower cancer risk (Yun et al. 2001).  Ginsenosides isolated from Panax 
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ginseng have been shown to possess various anticancer activities; for instance, 
ginsenoside Rh-1 induces melanoma cells differentiation; Rh-2 inhibits proliferation 
of human and murine cancer lines; Rg-3 not only inhibits carcinogenesis by 
suppressing key enzymes involved in the origination of tumors (as demonstrated by 
its inhibition on phorbol ester-induced expression of pro-inflammatory enzyme 
cyclooxygenase-2 and ornithinedecarboxylase in mouse skin), but also inhibits cancer 
invasion (Dzubak et al. 2006). 
 
     




The anticancer triterpenoids belonging to the ursane group include ursolic 
acid and boswellic acids.  Ursolic acid has been shown to exert anticancer activity 
through its suppressive effect on the nuclear factor kappa B (NF-κB) signaling 
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pathway, thereby leading to down-regulation of the downstream oncogenes (Ikeda et 
al. 2008).  Furthermore, ursolic acid has been shown to inhibit skin tumor formation 
by interfering with the initiation of carcinogenesis (Ikeda et al. 2008).  Boswellic 
acids, as inhibitors of mammalian DNA polymerases α and β, and human DNA 
topoisomerases I and II, exert antiproliferative effect on cancer cells (Dzubak et al. 
2006).  In one study, they have been reported to induce apoptosis in colon cancer 
cells through the apoptotic pathway dependent on caspase-8 activation (Liu et al. 
2002).  In a more recent report, acetyl-keto-β-boswellic acid is shown to induce 
apoptosis through a death receptor 5-mediated pathway in prostate cancer cells (Lu et 
al. 2008).  Collectively, these two studies suggest that activation of extrinsic 
apoptotic pathway may be the main mechanism underlying the apoptotic-inducing 
effects of boswellic acids.  In addition to their cytotoxicity on cancer cells, boswellic 
acids are found to inhibit bFGF-induced angiogenesis in an in vivo Matrigel plug 
assay and this effect is comparable with indomethacin and cyclophosphamide (Singh 
et al. 2007).   
COOH
OH
         COOH
OH
 





Oleanolic acid is a natural oleanane triterpenoid with weak anticancer 
activities including antimutagenic, antiangiogenic and differentiation-inducing effects 
(Dzubak et al. 2006).  Chemical modifications made on the structure of oleanolic 
acid have yielded two more potent synthetic oleanane triterpenoids, 
2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and its methyl ester 
(CDDO-Me).  These two synthetic triterpenoids have been demonstrated to possess 
multi-functional anticancer properties.  On one hand, they are potent inducers of 
apoptosis in a variety of cancer types in vitro and in vivo (Kim et al. 2002; Konopleva 
et al. 2002; Lapillonne et al. 2003; Hyer et al. 2008).  On the other hand, they 
regulate several key transcriptional factors that control pro-inflammatory and 
anti-inflammatory genes, and are believed to be the most potent anti-carcinogenic 
triterpenoids that have been identified so far (Liby et al. 2007).  Intensive 
experimental studies have confirmed the potential of oleanolic acid-originated agents 
as new and effective treatment for various cancer types.  Both CDDO and 
CDDO-Me are currently in phase I clinical trials for the treatment of metastatic or 
unresectable solid tumors or lymphoma (Petronelli et al. 2009).  The successful 
development of CDDO and its derivatives ascertains the importance of the rich pool 
of triterpenoids serving as valuable sources of precursors and compounds for 

















CDDO                                  CDDO-Me 
 
1.2.2 Triterpenoids from Poria cocos 
The fungal species Poria cocos, also known as Hoelen or Fuling, is one of the 
most well-known herbs used in Traditional Chinese Medicine.  Among the Chinese 
community, it has long been believed to possess highly nourishing value and is thus 
widely used as a tonic to improve the condition of internal organs (Li et al. 2005).  
In addition, it has been credited to have diuretic and sedative effects, which lead to its 
application for use in inflammatory conditions to reduce edema or phlegm.  Due to 
its gentle physiological activities with relatively mild adverse effects, Poria cocos has 
also been a health-promoting food in common Chinese tonic soups on dinner tables.  
In Traditional Chinese Medicine, Poria cocos is one of the most commonly used 
components in complex herbal prescriptions.  Scientific research has shown that 
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alcoholic extracts of Poria cocos possess multiple pharmacological activities that 
benefit human beings.  Triterpenoids are the main constituents in the alcoholic 
extracts of Poria cocos and are therefore believed to be the active components 
responsible for the biological activities of this plant (Akihisa et al. 2007).   
Most of the identified triterpenoids contained in Poria cocos belong to the 
lanostane group.  These lanostane-type triterpenoids are observed to exhibit a wide 
range of activities including anti-rejection, anti-emetic, anti-inflammatory and 
anticancer effects.  For instance, ethanol extract of Poria cocos has been reported to 
relieve the acute rejection of heart transplantation in a rat model (Zhang et al. 2004), 
indicating that triterpenoids contained in Poria cocos have the ability to regulate 
immune response.  In addition, some triterpenoids have been demonstrated to inhibit 
emetic action induced by oral administration of copper sulfate pentahydrate to 
leopard frog (Tai et al. 1995).  Though much preliminary and incomplete, these two 
findings suggest that triterpenoids from Poria cocos may play a protective role in a 
human body by relieving unfavorable responses.   
Apart from the studies mentioned above, the majority of research interests 
have been focused on investigating the anti-inflammatory activities of Poria 
cocos-originated triterpenoids.  The methanol extracts of Poria cocos are found to 
markedly inhibit the inflammatory activity provoked by 
12-O-tetradecanoylphorbol-13-acetate (TPA) in mice (Yasukawa et al. 1995).  In 
another study, triterpenoids including pachymic acid, 
3-O-acetyl-16α-hydroxytrametenolic acid, dehydropachymic acid, dehydroeburiconic 
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acid, 3β-hydroxylanosta-7,9(11),24-trien-21-oic acid, poricoic acid A and poricoic 
acid B are found capable of reducing TPA-induced mouse ear edema with 50% 
inhibitory dose of 17-44 µg/ear (Kaminaga et al. 1996).  Their anti-inflammatory 
effects have been observed to be comparable with that of hydrocortisone, the most 
widely used anti-inflammatory drug for the treatment of skin inflammation 
(Kaminaga et al. 1996).   
A different research group had reported the isolation of several new 
anti-inflammatory triterpenoids from Poria cocos methanol extracts more than a 
decade ago (Nukaya et al. 1996).  These compounds were identified as 
3β,-16α-dihydroxylanosta-7, 9(11), 24-trien-21-oic acid, 
16α-hydroxydehydropachymic acid, 16α-hydroxytrametenolic acid and 
dehydrotumulosic acid.  All these four triterpenoids have been demonstrated to be 
effective against TPA-induced mouse ear edema.  Another identified triterpenoid, 
3β-p-hydroxybenzoyldehydrotumulosic acid has also shown anti-inflammatory 
activity in a mouse model (Yasukawa et al. 1998).  It is effective against ear 
inflammation in mice induced by either TPA or arachidonic acid, being relatively 
more potent in inhibiting inflammation induced by the former (50% inhibitory dose 
for TPA and arachidonic acid is 0.27 and 1.25 mg/ear respectively).  Similarly, 
Cuellar et al. had demonstrated that alcoholic extracts from Poria cocos were 
effective against various inflammatory conditions; tropical or oral application of the 
alcoholic extracts not only reduced acute inflammation induced by carrageenan, 
arachidonic acid and TPA, but also showed inhibitory effect on TPA-induced chronic 
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inflammation and oxazolone-induced delayed hypersensitivity in mice (Cuellar et al. 
1997).   
Two isolated monomeric triterpenoids from Poria cocos, pachymic acid and 
dehydrotumulosic acid have shown efficacy against TPA-induced mouse ear 
inflammation, but exert no effects against inflammation induced by arachidonic acid 
(Giner et al. 2000).  In another study by the same research group, alcoholic extracts 
of Poria cocos have demonstrated effectiveness against phospholipase A2-induced 
mouse paw edema either application through oral or intraperitoneal route 
(Giner-Larza et al. 2000).  A more recent paper has assessed the anti-inflammatory 
effects of Poria cocos extracts on human subjects (Fuchs et al. 2006).  In this study, 
the anti-inflammatory effect of Poria cocos extracts has been evaluated in 
experimentally induced irritant contact dermatitis resulting from repeated exposure to 
sodium lauryl sulphate.  Clinical assessment and skin measurement reveal that 
tropical application of Poria cocos extracts successfully prevents sodium lauryl 
sulphate-induced dermatitis in these subjects.  In summary, these studies have 
demonstrated the anti-inflammatory potential of Poria cocos-originated triterpenoids.     
Inflammation plays an important role in the transformation of normal cells 
into cancer cells (Federico et al. 2007).  Therefore, the anti-inflammatory property 
of triterpenoids from Poria cocos indicates that these compounds may also be 
effective agents for cancer chemoprevention.  Indeed, previous studies had explored 
the chemopreventive effects of these triterpenoids.  Kaminaga et al. first 
demonstrated that several triterpenoids from Poria cocos, namely pachymic acid, 
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3-O-acetyl-16 alpha-hydroxytrametenolic acid, and poricoic acid B, inhibited the 
promoting effect of TPA on skin tumor formation following initiation with DMBA 
(Kaminaga et al. 1996); these triterpenoids are found to exert inhibitory effect at 
dosages as low as 0.2 μmol/mouse.  Subsequently, Ukiya et al. demonstrated that ten 
triterpenoids from Poria cocos potently inhibited TPA-induced Epstein-Barr virus 
early antigen (EBV-EA) activation (Ukiya et al. 2002).  These triterpenoids include 
poricoic acid A, poricoic acid B, poricoic acid G, poricoic acid H, tumulosic acid, 
dehydrotumulosic acid, 3-epidehydrotumulosic acid, polyporenic acid C, 
25-hydroxy-3-epidehydrotumulosic acid and dehydroabietic acid methyl ester.   
In a recent study, two new anti-tumor-promoting triterpenoids have been 
isolated from Poria cocos and identified as 16-deoxyporicoic acid B and poricoic 
acid C (Akihisa et al. 2007).  Tropical application of either compound inhibits skin 
tumor formation in an in vivo two-stage carcinogenesis test using DMBA as an 
initiator and TPA as a promoter (Akihisa et al. 2007).  In the same study, most of the 
other triterpenoids isolated from Poria cocos have also been found to inhibit 
EBV-EA activation induced by TPA.  Since EBV-EA activation is usually regarded 
as an early sign of tumor-promoting activity (Ito et al. 1981) and the two-stage mouse 
skin carcinogenesis test (DMBA as initiator and TPA as promoter) is a 
well-established animal model for prediction of chemopreventive ability of a 
compound (Drinkwater 1990), these abovementioned studies provide evidence that 




Besides the chemopreventive potential of these triterpenoids, several lines of 
evidence have suggested that triterpenoids from Poria cocos may have cancer 
therapeutic potential.  Li et al. investigated the cytotoxicity and DNA 
topoisomerases inhibitory activity of triterpenoids from Poria cocos and found that 
polyporenic acid C, dehydropachymic acid, pachymic acid and tumulosic acid 
exhibited moderate cytotoxicity on a human colon carcinoma cell line (Li et al. 2004).  
They further showed that these compounds effectively inhibited DNA topoisomerase 
I and II as potently as the positive control etoposide.  The inhibition of DNA 
topoisomerase by triterpenoids from Poria cocos is further substantiated by the study 
of another group in which dehydroebriconic acid, another lanostane-type triterpenoid 
from Poria cocos, was identified as a DNA topoisomerase inhibitor (Mizushina et al. 
2004).  In a different study by the same research group, dehydroeburiconic acid, and 
another Poria cocos-originated triterpenoid dehydrotrametenonic acid were shown to 
inhibit eukaryotic DNA polymerase α and β (Akihisa et al. 2004).  In the light that 
DNA topoisomerases and polymerases are important cellular targets for 
chemotherapeutic intervention in the treatment of cancer (Spadari et al. 1986), 
findings of these studies therefore provide the basis to predict the cytotoxic potencies 
of such triterpenoids found in Poria cocos.   
Moreover, a study by Kang et al. found that dehydrotrameteolic acid 
selectively inhibited the growth of H-ras transformed rat2 cells and induced apoptosis 
through the caspase-3 pathway, whereas it had no lethal effect on untransformed 
normal cells (Kang et al. 2006), indicating that triterpenoids from Poria cocos may be 
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developed as safe anticancer agents without eliciting toxicity to normal cells.   
The ability of triterpenoids from Poria cocos to induce apoptosis of cancer 
cells was also previously demonstrated by our own research group (Gapter et al. 2005) 
in which pachymic acid, a lanostane-type triterpenoid and main component of Poria 
cocos alcoholic extracts, is reported to induce apoptosis in prostate cancer cells by 
caspase activation and reducing Akt activity.  Together, these studies suggest that 
triterpenoids from Poria cocos possess beneficial biological activities that render 
them potential cancer therapeutic and/or preventive agents. 
Despite the broad studies on the biological activities of triterpenoids from 
Poria cocos, the mechanisms underlying their anti-inflammatory and anticancer 
properties have not been well studied.  Some researchers have proposed that 
triterpenoids from Poria cocos may exhibit their biological activities through 
regulation of phospholipase A2, an important enzyme involved in inflammation and 
carcinogenesis.  For example, one research group has demonstrated the inhibitory 
effects of two lanostane triterpenoids, pachymic acid and dehydrotumulosic acid, on 
phospholipase A2 derived from snake venom (Cuella et al. 1996).  Pachymic acid 
has been found to inhibit phospholipase A2 activity with the same potency as a 
positive control mepacrine, while dehydrotumulosic acid causes inhibition of 
phospholipase A2 with a potency 3-fold higher than mepacrine.  The involvement of 
phospholipase A2 in anti-inflammatory activity of triterpenoids from Poria cocos has 
been further supported by in vivo studies.  In one of these in vivo studies, Giner et al. 
testified that administration of Poria cocos alcoholic extracts effectively inhibited 
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phospholipase A2-induced mouse paw edema by either the oral or parenteral route, 
and hypothesized that the inhibition of phospholipase A2 enzyme by triterpenoids 
from Poria cocos was the main mechanism underlying their anti-inflammatory and 
anticancer activities (Giner et al. 2000).   
However, these studies may have over-concluded their findings.  Firstly, 
there are three major types of phospholipase A2 enzymes (secretary, 
calcium-independent and cytosolic) and each type is further sub-classified according 
to their structural or biological differences.  However, in the above experiments, 
only type IA secretary phospholipase A2 from snake venom was examined.  The 
effects of these triterpenoids on other PLA2 isoforms which are more biologically 
relevant to human beings have not yet been evaluated.  Secondly, the reported 
effective concentrations of tested triterpenoids are obtained from an in vitro assay 
with IC50 > 2mM, thus the biological relevance of the observed inhibitory effect in 
relation to triterpenoids’ anti-inflammatory properties is questionable.  As such, the 











1.3.1 Overview of apoptosis 
Apoptosis, also called programmed cell death, is a genetically directed 
process of cell self-destruction that is marked by the fragmentation of nuclear DNA 
(Hockenbery 1995).  The term apoptosis was first used by Kerr, Wyllie, and Currie 
in 1972 to describe a morphologically distinct form of cell death.  These authors 
described this kind of cell death to be an active and inherently programmed 
phenomenon and emphasized the significance of this cell death form in removing 
redundant cells (Kerr et al. 1972).  A large number of studies arising thereafter have 
since established that apoptosis is a normal physiological process for removing 
DNA-damaged, superfluous, or unwanted cells.   
One typical example is the formation of separated fingers during fetal life due 
to apoptosis of cells between fingers, in which failure to do so would result in the 
existence of webbed fingers.  Another example is the loss of a tadpole’s tail through 
programmed cell death during amphibian development.  In addition, apoptosis is 
also important for the maintenance of the normal functions of immune system by 
removing both ineffective and potentially damaging immature T cells (Werlen et al. 
2003).  Therefore, apoptosis is critical to cell growth regulation, development, 
immune response as well as maintaining a constant net number of cells in organs.  
Conversely, alternations that affect apoptosis can disrupt homeostasis and have 
pathological effects.  Insufficient apoptosis may cause disorders like hyperplasia or 
neoplasia, whereas excessive apoptosis can lead to abnormal cell loss, such as the loss 
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of CD4+ T cells seen in AIDS patients (Elmore 2007).   
1.3.2 Characteristics of apoptosis 
Apoptosis and necrosis are two common types of cell death.  Compared to 
necrosis, apoptosis has some distinct characteristics，which involve a defined set of 
programmed morphological and biochemical changes.  The differences between 
cells undergoing apoptosis and necrosis are summarized below in Table 1.1.  
Table 1.1 Differences between apoptosis and necrosis. 
Apoptosis Necrosis 
Morphological features  
Begins with shrinking of cytoplasm and 
condensation of nucleus 
Begins with swelling of cytoplasm and 
mitochondria 
Blebbing of plasma membrane without loss 
of integrity 
Loss of membrane integrity 
 
Aggregation of chromatin at the nuclear 
membrane  
Formation of membrane bound vesicles 
(apoptotic bodies) 
No vesicle formation, complete lysis 
 
Biochemical features  
Tightly regulated process involving 
activation and enzymatic steps 
Loss of regulation of ion homeostasis 
 
Energy (ATP)-dependent No energy requirement 
Non-random mono- and oligonucleosomal 
length fragmentation of DNA (Ladder pattern 
after agarose gel electrophoresis) 
Random digestion of DNA (smear of  
DNA after agarose gel electrophoresis) 
Activation of caspase cascade  
Physiological significance  
Induced by physiological stimuli (eg. lack of 
growth factors, changes in hormonal 
environment) 
Evoked by non-physiological  
disturbances  
 
Localized effect that destroys individual cells Affects groups of contiguous cells 




1.3.2.1 Morphological features  
Apoptosis involves a series of sequential morphological events (Elmore 
2007).  These morphological features of cells undergoing apoptosis include cell 
shrinkage, blebbing, nuclear condensation and nuclear fragmentation (Figure 1.2A).  
During the early stage of apoptosis, cell shrinkage can be observed under a light 
microscope (Hacker 2000).  Consequently, cells become smaller in size with a more 
compact cytoplasm.  The plasma membrane retains its integrity during the process 
of apoptosis.  The earliest detectable change in the nucleus is the condensation of 
nuclear chromatin along the nuclear membrane (Hacker 2000).  The condensed 
nucleus then breaks up into similarly dense, smaller particles which are packed and 
taken up.  Accompanying the progress of the cell shrinkage and nuclear 
condensation, cells start to show protrusions known as “blebs” from the plasma 
membrane.  These blebs finally form apoptotic bodies, which are membrane-bound 
vesicles that vary in size and composition (Hacker 2000).  First termed by Kerr et al., 
apoptotic bodies are one of the most striking characteristics of cells undergoing 
apoptosis.  The apoptotic bodies can contain a mixture of various parts of cells 
contents, such as cytosolic components, organelles or fragmented nuclei.  In tissues, 
apoptotic bodies are quickly engulfed and digested by neighboring macrophages or 
epithelial cells (Figure 1.2B).  During the apoptotic process, cell contents are well 
enclosed by plasma membrane.  Therefore, apoptosis of cells does not cause 
inflammation or serious damage to nearby cells since there is no leakage of cell 





Figure 1.2 Morphological features of cell death by apoptosis.  (A) Schematic 
drawings illustrating the progression of morphologic changes observed in apoptotic 
cells.  During early apoptosis, chromosome condensation occurs along the nuclear 
periphery and cell shrinkage occurs, with most organelles reaming intact.  At a later 
stage, both the nucleus and cytoplasm become fragmented to form apoptotic bodies, 
which are then phagocytosed by surrounding cells.  (Adopted from Kuby, 1997)  
(B) Disintegration of apoptotic cells into apoptotic bodies and subsequently 




In contrast to apoptosis, necrotic cell death is usually accompanied by 
development of inflammation and injury to neighboring cells (Elmore 2007).  Cells 
undergoing necrosis are characterized by irreversible swelling of cytoplasmic 
compartments and distortion of organelles.  These events lead to rupture of the 
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plasma membrane and release of cytoplasmic contents.  Consequently, these 
cytoplasmic contents cause damage to the surrounding tissues by sending chemostatic 
signals with eventual recruitment of inflammatory cells. 
 
1.3.2.2 Biochemical features  
During apoptosis, cells display a series of biochemical characteristics.  The 
typical biochemical features of apoptosis include loss of membrane asymmetry, 
caspase activation, cleavage of apoptosis-related proteins and DNA fragmentation 
(Hengartner 2000). 
 
a. Loss of membrane asymmetry 
Cells dying of apoptosis can expose ‘eat me’ signals for their recognition and 
subsequent removal by neighboring cells (Elmore 2007).  One of these signals is the 
exposure of phosphatidylserine on the outer leaflet of the cell membrane bilayer.  
Phosphatidylserine is an anionic phospholipid normally located in the inner leaflet of 
the plasma membrane.  During apoptosis, phosphatidylserine moves to the outer side 
of the membrane due to loss of membrane asymmetry (Martin et al. 1995).  The 
mechanism that underlies the loss of membrane asymmetry remains unclear.  Some 
studies suggested the involvement of downregulation of an ATP-dependent 
aminophospholipid translocase and upregulation of 'flippase' in this event (Bratton et 
al. 1997; Savill 1997).  The exposure of phosphatidylserine may also be a result of 
the opening of mitochondrial 'megachannels' by the so-called permeability transition, 
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which may release an apoptosis-inducing protease from mitochondria into the 
cytoplasm (Savill 1997).  Although the exact mechanism remains to be further 
clarified, the exposure of phosphatidylserine is a classic marker of apoptosis and this 
feature has been generally used for the detection of apoptosis.  Annexin V is a 
calcium-dependent phospholipid-binding protein that has a high affinity for 
phosphatidylserine.  Thus, annexin V labeled with a fluorophore or biotin can be 
used to identify apoptotic cells by binding to phosphatidylserine exposed on the outer 
leaflet (Aubry et al. 1999).  In addition, studies have suggested that 
phosphatidylserine exposure is an early marker of apoptosis preceding nuclear 
changes (Aubry et al. 1999).  These findings indicate the importance of the annexin 
V binding assay as a useful tool for recognition of cells undergoing early apoptosis.    
 
b. Caspases 
The process of apoptosis is characterized by the cascade of proteases that are 
the central executioners of the apoptotic program.  These proteases are a group of 
cysteine proteases that cleave after an aspartate residue in their substrates and 
therefore named “caspases” (Alnemri et al. 1996).  To date, eleven caspases have 
been identified in humans and about two-third of these caspases have been suggested 
to play important roles in apoptosis (Hengartner 2000).  The apoptotic caspases can 
be generally categorized into two types: initiator caspases and effector caspases.  
Caspase-2, -8, -9 and -10 are initiator caspases and caspase-3, -6 and -7 are effector 
caspases (Riedl and Shi 2004).  An initiator caspase usually contains one or more 
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adaptor domains in its extended N-terminal region, while an effector caspase has 
20-30 residues in its prodomain sequence (Riedl and Shi 2004).  In the apoptosis 
process, initiator caspases are activated by apoptotic stimuli that in turn activate the 
downstream effector caspases.  As the executioner proteases, effector caspases 
cleave their target proteins, leading to the morphological changes seen in apoptotic 
cells.    
All caspases are synthesized in cells as catalytically inert zymogens and need 
to be activated to exert their catalytic function in apoptosis.  Generally, there are 
three mechanisms of caspase activation (Figure 1.3): (1) processing by an upstream 
caspase,  (2) induced proximity and (3) association with a regulatory subunit 
(Hengartner 2000).  Effector caspases are activated by the upstream initiator 
caspases through proteolytic cleavage of their zymogen domains.  This mode of 
procaspase activation applies to caspase-3, -6 and -7.  Induced proximity is the 
mechanism underlying activation of caspase-8.  As a key initiator caspase in death 
receptor-mediated apoptosis, caspase-8 is cross-activated through aggregation of 
multiple procaspase-8 protein molecules into close proximity (Muzio et al. 1998).  
Since procaspase-8 has a weak intrinsic protease activity, the close proximity will 
allow cleavage and activation of adjacent procaspase-8 molecules.  Likewise, 
activation of caspase-2 is also achieved through this induced proximity (Hengartner 
2000).  Unlike caspases described above, caspase-9 is activated by the mechanism 
of association with a regulatory subunit.  The activation of procaspase-9 requires the 
assembly of the mammalian apoptosome (Cain et al. 1999).  The apoptosome is a 
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seven-subunit complex assembled by Apaf-1 and cytochrome c.  Interaction of the 
apoptosome with procaspase-9 causes the autocleavage and dimerization of this 
procaspase, which is required for caspase-9 activation (Cain et al. 1999).  Therefore, 
as depicted by Figure 1.3, it can be summarized from the above discussion that 
initiator caspases are usually activated by regulated protein-protein interactions, 




Figure 1.3 Mechanisms of caspase activation.  Caspase activation can be achieved 
through proteolytic cleavage by an upstream caspase (A), induced proximity (B) or 






c. Cleavage of apoptosis-related proteins 
The cleavage of apoptosis-related proteins causes the morphological 
characteristics of apoptosis.  These proteins are the target of executor caspases and 
they include nuclear lamins, poly-ADP ribose polymerase (PARP), p21-activated 
kinase 2 (PAK2) and inhibitor of caspase activated DNase or DNA fragmentation 
factor 45 (ICAD/DFF45) (Elmore 2007).  Nuclear lamins and PARP are among the 
earliest proteins discovered to be specifically cleaved during apoptotic cell death.  
Lamins are nuclear proteins which are located at the inner side of the nuclear 
envelope and interact with other membrane-associated proteins to form the nuclear 
lamina.  The degradation of nuclear lamins by effector caspases may contribute to 
the nuclear breakdown in apoptotic cells.  This notion was supported by the findings 
that overexpression of lamin A or lamin B can prevent or delay changes in nuclear 
morphology.  PARP is a nuclear protein that catalyses the synthesis of 
poly(ADP-ribose) from nicotinamide adenine dinucleotide (Satoh and Lindahl 1992).  
It is involved in a number of cell functions, such as DNA repair and genome integrity 
(Herceg and Wang 2001).  Thus, the maintenance of PARP function is essential for 
cell survival.  During apoptosis, PARP is cleaved by effector caspases such as 
caspase-3 from the full length (116 kDa) to a cleaved form of 89 kDa, and thereby 
loses its function to protect cells (Lazebnik et al. 1994).  Studies have consistently 
showed the coincidence of cleavage of caspase-3 and PARP with the appearance of 
other morphological and biochemical characteristics of apoptosis (Boulares et al. 
1999).  Therefore, generation of the cleaved from of PARP has been regarded as a 
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hallmark of apoptotic cells.  In addition to nuclear lamins and PARP, caspases also 
activate PAK2, which is critical for cytoskeleton reorganization and nuclear signaling 
(Rudel and Bokoch 1997).  In apoptotic cells, PAK2 is activated by caspase 
cleavage and contributes to apoptotic events leading to membrane and morphological 
changes.  ICAD/DFF45 is a specific inhibitor of CAD/DFF40.  The cleavage and 
inactivation of ICAD/DFF45 by caspase-3 unleashes the endonuclease activity of 
CAD/DFF40 (Nicholson 1999; Widlak 2000).  As a DNA fragmentation factor, 
CAD/DFF40 leads to the characteristic changes in the nucleus of apoptotic cells 
(Nicholson 1999; Widlak 2000).  In summary, these apoptosis-related proteins serve 
as targets of effector caspases and relay the apoptotic signal to result in eventual cell 
death.  
 
d. DNA fragmentation 
DNA fragmentation is a key feature of apoptotic cell death.  In apoptotic 
cells, endogenous endonucleases are activated by caspases and these enzymes 
specifically cleave genomic DNA in the linker regions between nucleosomes (Nagata 
2000).  As a result, nuclear DNA is cleaved into mutiples of 180 bp, where each 
fragment corresponds to the internucleosomal spacing.  The resulting DNA 
fragments, when separated in agarose gel electrophoresis, take the appearance of a 
unique ladder pattern that is conventionally called the “DNA ladder” (Nagata et al. 
2003).  In contrast, necrotic cell death is accompanied by random DNA degradation 
and digestion of histone (Elmore 2007).  When analyzed by agarose gel 
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electrophoresis, the degraded DNA forms a diffuse smear on gels.  Therefore, 
assessing genomic DNA laddering can be used to distinguish cell apoptosis from cell 
necrosis.         
 
1.3.3 Pathways of apoptosis 
There are two main apoptotic pathways that have been described in 
caspase-mediated cell death (MacFarlane and Williams 2004; Riedl and Shi 2004).  
One is the extrinsic apoptosis pathway and the other is the intrinsic apoptosis pathway 
(Figure 1.4).  These two pathways converge at the level of effector caspases such as 
caspase-3.  The effector caspases then induce the downstream targets which will 






Figure 1.4 Extrinsic and intrinsic apoptotic pathways.  The extrinsic pathway is 
triggered by members of the death receptor superfamily, such as CD95 and TNF 
receptor 1.  Binding of corresponding ligands to their death receptors induces 
receptor clustering and formation of a death-inducing signaling complex (DISC).  
This complex recruits multiple procaspase-8 molecules, resulting in caspase-8 
activation through induced proximity.  In the intrinsic pathway, stress signals bring 
about disruption of mitochondria and subsequently cause release of proteins such as 
cytochrome c, from the inter-mitochondrial membrane space.  Cytochrome c release 
is regulated by Bcl-2 family members (anti-apoptotic proteins such as Bcl-2 and 
Bcl-XL; pro-apoptotic proteins such as Bax, Bak and tBid).  Once released, 
cytochrome c binds to Apaf-1 and then procaspase-9, forming apoptosome complex.  
As a result, procaspase-9 is activated by holoenzyme formation.  The activated 
initiator caspases 8 and 9 then activate the effector caspase 3, 6 and 7, which are 
responsible for the cleavage of important cellular substances resulting in the classical 
biochemical and morphological changes associated with apoptosis.  (Adopted from 
MacFarlane and Williams, 2004) 
 
1.3.3.1 Extrinsic pathway 
The extrinsic pathway, also known as the death-receptor pathway, is triggered 
by the engagement of death receptors on the cell surface.  Death receptors are 
members of the tumor necrosis factor (TNF) receptor superfamily and comprise a 
subfamily that is characterized by a cytoplasmic domain of about 80 amino acids 
called the death domain (Igney and Krammer 2002).  The death receptors include 
Fas receptor (also known as CD95), tumor necrosis factor receptor 1, death receptor 3, 
death receptor 4 and death receptor 5.  
The events of death receptor-mediated apoptosis are characterized by the Fas 
ligand/Fas receptor and TNFα/ TNF receptor models (Schulze-Osthoff et al. 1998; 
Wang and El-Deiry 2003).  In these models, binding of the ligand to the 
corresponding receptor leads to clustering of receptors.  As a result, the death 
domains in the death receptor attract the intracellular adaptor protein Fas-associated 
death domain (FADD) or TNF receptor-associated death domain (TRADD) with 
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recruitment of FADD and receptor interacting protein 1 (RIP-1).  FADD then 
associates with procaspase-8 via dimerization of the death effector domain and forms 
a death-inducing signaling complex (DISC).  At the DISC level, procaspase-8 and 
procaspase-10 are cleaved through induced proximity and yield active initiator 
caspases.  The activation of caspase-8 or caspase-10 causes the activation of effector 
caspases, and leads to apoptotic cell death.   
Other death receptors such as those  that respond to TNF-related apoptosis 
inducing ligand (TRAIL) are found to convey apoptotic signals in a similar way to 
Fas ligand (Wang and El-Deiry 2003).  The induction of apoptosis by TRAIL also 
involves the DISC formation and ensuing caspase activation.  Interestingly, as 
compared to normal cells, tumor cells are seemingly more sensitive to TRAIL 
treatment.  This may be due to the decoy receptors expressed by normal cells which 
sequester the TRAIL signal (Zhang et al. 2000).  This difference between normal 
cells and cancer cells renders TRAIL a possible treatment to selectively kill cancer 
cells, which is a desired strategy in cancer treatment.   
On the other hand, several proteins can negatively regulate the death receptor 
pathways.  For instance, a homologue of procaspase-8, FADD-like IL-1β-converting 
enzyme (FLICE)-inhibitory protein [c-FLIP], can bind to FADD and caspase-8, 
rendering them biologically inactive (Kataoka et al. 1998; Scaffidi et al. 1999).  A 
protein called Toso also has been shown to block Fas-induced apoptosis in T cells via 
inhibition of caspase-8 processing (Hitoshi et al. 1998). 
It has been reported that there are two types of cells that employ a different 
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mechanism to induce apoptosis following death receptor stimulation (Figure 1.5) 
(Scaffidi et al. 1999).  In type I cells, activated caspase-8 is sufficient to directly 
activate the effector caspases and cause the following apoptotic events.  In type II 
cells, the amount of activated caspase-8 is too small to directly induce apoptosis by 
itself.  Instead, caspase-8 relays the apoptotic signal through the mediation of Bid, 
which connects the death receptor-mediated pathway with the intrinsic apoptosis 
pathway and thus amplifies the apoptotic signal (Li et al. 1998).  Bid is a member of 
the Bcl-2 family and truncation of Bid by caspase-8 leads to the translocation of Bid 
from cytosol to mitochondria (Chou et al. 1999).  As a pro-apoptotic protein, 
truncated Bid causes changes in mitochondrial proteins in a way favoring apoptosis.  
The sum of these changes leads to release of cytochrome c and subsequently drives 
activation of caspase-9.  Caspase-9 removes the prodomain of other family members 
of caspases and activates the effector caspases, which then execute the task of cell 
death by acting on their target proteins.  Therefore, in type II cells, death 
receptor-mediated apoptosis recruits the mitochondria to amplify the apoptotic signal 






Figure 1.5 Model of the two CD95 signaling pathways. (A) In type I cells CD95 
triggering leads to strong caspase-8 activation at the DISC which bypasses 
mitochondria directly leading to activation of other caspases such as caspase-3 and 
subsequently to apoptosis.  (B) In type II cells only a little DISC is formed leading 
to the activation of mitochondria, which in turn results in cleavage of caspase-8 and 
caspase-3.  Therefore, blocking activation of mitochondria by Bcl-2 or Bcl-xL 
inhibits apoptosis only in type II cells. Red box, death domain; blue box, death 
effector domain.  (Adopted from Scaffidi et al., 1999) 
 
 
1.3.3.2 Intrinsic pathway 
The intrinsic pathway is also called the mitochondria-mediated apoptotic 
pathway.  Being different from the extrinsic pathway that is triggered upon 
stimulation of death receptors, intrinsic apoptosis is induced by a wide range of 
non-death receptor-mediated stimuli which act directly on intracellular events.  The 
stimuli inducing intrinsic apoptosis may act in a positive or negative way (Elmore 
2007).  Negative signals involve the absence of certain growth factors, hormones 
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and cytokines which are important for maintaining cell growth.  The negative 
signals lead to an imbalance between cell growth and cell death by loss of cell growth 
signal, thus activation of apoptosis.  The stimuli that positively induce intrinsic 
apoptosis include a large variety of signals such as radiation, toxins, hypoxia, viral 
infection and free radicals. 
Both the negative signals and positive signals cause changes in the 
mitochondrial membrane which include the opening of mitochondrial permeability 
transition pore and loss of mitochondrial membrane potential (Elmore 2007).  These 
mitochondrial membrane changes allow release of two groups of pro-apoptotic 
proteins into the cytosol, and thereby activate the caspase cascade (Saelens et al. 
2004).  The first group of released proteins such as cytochrome c and 
Smac/DIABLO contributes to the following activation of caspase-9 (Du et al. 2000; 
Goldstein et al. 2000; Garrido et al. 2006).  In the cytosol, cytochrome c associates 
with Apaf-1 and then with procaspase-9 to form the apoptosome.  The assembly of 
the apoptosome leads to autocleavage and activation of caspase-9 (Chinnaiyan 1999; 
Hill et al. 2004).   
On the other hand, Smac/DIABLO has been demonstrated to negatively 
regulate inhibitors of apoptosis proteins (IAP), and thereby increases the sensitivity of 
cells to apoptotic signals (van Loo et al. 2002; Schimmer 2004).  The second group 
of released proteins from mitochondria to cytosol includes pro-apoptotic proteins like 
apoptosis inducing factor (AIF), endonuclease G and caspase-activated DNase (CAD) 
(Elmore 2007).  These proteins contribute to mitochondria-mediated apoptosis as a 
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late event in apoptosis.  After releasing into the cytosol, AIF can further translocate 
to the nucleus to cause DNA fragmentation as well as condensation of peripheral 
nuclear chromatin (Joza et al. 2001).  This nuclear change caused by AIF is 
considered to be a relatively early event and hence referred by Susin et al. as “stage I” 
condensation (Susin et al. 2000).  Endonuclease G is the enzyme responsible for the 
production of oligonucleosomal DNA fragments (Li et al. 2001).  As implicated in 
its name, cleavage of CAD by caspase-3 is needed for the activation of CAD.  The 
functional CAD exerts its enzyme activity and causes oligonucleosomal DNA 
fragmentation (Susin et al. 2000).  The DNA fragmentation caused by CAD 
produces more prominent and advanced nuclear condensation.  Thus, it is defined by 
Susin et al as “stage II” nuclear condensation (Susin et al. 2000).  Together, 
endonuclease G and CAD contribute to DNA fragmentation and formation of DNA 
ladder, the key feature of apoptosis.  
The mitochondrial events are largely regulated by Bcl-2 family proteins 
(Gross et al. 1999).  The Bcl-2 family proteins can either be pro-apoptotic or 
anti-apoptotic.  The pro-apoptotic Bcl-2 family members include Bcl-10, Bax, Bak, 
Bid, Bad, Bim, Bik, and Blk; while Bcl-2, Bcl-x, Bcl-XL, Bcl-XS and Bcl-w belong 
to anti-apoptotic Bcl-2 family proteins.  As mentioned earlier, Bid can cross-link the 
extrinsic apoptotic pathway and the intrinsic apoptotic pathway by relaying apoptotic 
signal from caspase-8 to the mitochondria (Li et al. 1998).   
Another pro-apoptotic protein Bad plays an important role in intrinsic 
apoptosis (Hengartner 2000).  Phosphorylated Bad is sequestered in the cytosol by 
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its inhibitor protein 14-3-3.  Pro-apoptotic proteins such as p53 can cause 
unphosphorylation of BAD and thus lead to separation of BAD and 14-3-3 (Yang et 
al. 1995; Zha et al. 1996).  Consequently, BAD translocates from cytosol to nucleus 
where it neutralizes the anti-apoptotic effects of Bcl-2 and Bcl-XL.  As a result, the 
mitochondrial membrane potential is disrupted and cytochrome c is released into the 
cytosol.  These events trigger the activation of caspase-9 and activation of effector 
caspases follows.   
On the other hand, Bcl-2 and Bcl-XL represent Bcl-2 family proteins that 
play important roles in preventing apoptotic cell death (Hengartner 2000).  Studies 
have shown that overexpression of Bcl-2 or Bcl-XL contributes to the resistance of 
cancer cells to apoptosis (Gross et al. 1999; Hengartner 2000; Elmore 2007).  Bcl-2 
and Bcl-XL prevent the formation of mitochondrial apoptosis-induced channel (MAC) 
(Dejean et al. 2006).  During the apoptotic events, anti-apoptotic Bcl-2 and Bcl-XL 
are down-regulated, while pro-apoptotic Bak and Bax are activated and associated 
together to form MAC in the outer mitochondrial membrane (Dejean et al. 2006).  
The formation of MAC mediates cytochrome c release into the cytosol, triggering the 
commitment step of the mitochondrial apoptotic cascade (Dejean et al. 2006).  
Therefore, pro-apoptotic and anti-apoptotic Bcl-2 family proteins work in 
coordination to regulate the function of mitochondria.  Apoptosis occurs when the 
balance is interrupted in a way favoring pro-apoptotic signals.   




1.3.4 Promoting apoptosis as strategy against cancer 
To maintain tissue homeostasis, cell growth and cell death have to be well 
balanced. Apoptosis plays an important role in removing unwanted or damaged cells 
by causing self-destruction.  In cancer cells, the apoptotic pathways have various 
defects which make the cells insensitive to apoptotic signals (Igney and Krammer 
2002).  Dysregulation of apoptosis causes too much cell growth and too little cell 
death, leading to the unlimited growth of cancer cells.  Indeed, as described by 
Hanahan and Weinberg, evasion of programmed cell death is one of the six essential 
characteristics of cancer (Hanahan and Weinberg 2000).  Therefore, restoration of 
the apoptosis machinery of cancer cells can be a useful strategy against cancer.  
The death receptors of the TNF superfamily can serve as potential targets for 
promoting apoptosis in cancer.  TNF-α is a cytokine intensely involved in the 
immune system and inflammation.  Apart from its role in inflammation, TNF-α has 
been shown to activate the death-receptor mediated apoptotic pathway through its 
stimulation on corresponding death receptor (Wang and El-Deiry 2003).  However, 
the apoptosis-inducing capacity of TNF-α is relatively weak, as a result of 
counteraction by its simultaneous activation of the anti-apoptotic protein NF-κB 
(Natoli et al. 1998; Rath and Aggarwal 1999).  Notably, TNF-α induces the binding 
of TRADD to the death domain located in the intracellular TNF receptor.  TRADD 
then binds to FADD, which causes the recruitment of procaspase-8 and leads to the 
cascade of apoptotic events.  On the other hand, TRADD can bind to tumor necrosis 
factor receptor associated factor 2 (TRAF2).  TRAF2 in turn activates a protein 
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kinase which is the upstream signal of NF-κB signaling pathway.  Consequently, 
NF-κB enhances the transcription of anti-apoptotic proteins such as c-FLIP, Bcl-2 and 
cIAP1/cIAP2, which interfere with the death receptor-mediated apoptosis.   
Combined treatments with TNF-α and inhibitors of NF-κB have been shown 
to increase the apoptosis-inducing effect of TNF-α in cancer cells (Nakanishi and Toi 
2005).  The clinically used anticancer drug 5-fluorouracil induces apoptosis through 
stimulation on death receptor CD95 (Eichhorst et al. 2001).  Studies have shown that 
5-fluorouracil increases CD95 expression through p53-dependent transcriptional 
regulation (Muller et al. 1998).  Simultaneously, it leads to upregulation of CD95 
ligand through SAPK/JNK pathway (Eichhorst et al. 2000; Eichhorst et al. 2001).   
Another death receptor ligand TRAIL has attracted much attention due to its 
selective induction of apoptosis in cancer cells (Gura 1997; Sadarangani et al. 2007).  
Many cancer cell lines are sensitive to TRAIL treatment.  In addition, TRAIL has 
been shown to induce apoptosis and cause tumor regression in animal models without 
causing significant adverse effects (Mishier et al. 1975).  Combination of TRAIL 
with other anticancer agents such as irinotecan or paclitaxel has shown synergistic 
effects against cancer growth in mouse model (Singh et al. 2003; Ravi et al. 2004).  
Although the development of TRAIL is still in trial phases, its potential providing a 
more effective and safe anticancer treatment has earned itself continuous attention 
from scientists and clinicians.    
The overexpression of anti-apoptotic Bcl-2 family proteins is a common 
approach employed by cancer cells to evade apoptosis (Igney and Krammer 2002).  
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An abnormal chromosomal translocation t(14;18) has been found in over 60% of 
human follicular B-cell lymphomas.  This chromosomal translocation leads to 
overexpression of Bcl-2 protein, which largely contributes to the lymphoma 
development.  In addition, Bcl-2 protein is found to be overexpressed in other cancer 
types such as lung, breast, pancreatic and colorectal cancers (Thomadaki and Scorilas 
2006).  Approaches targeting anti-apoptotic Bcl-2 proteins have been developed.  
These approaches include using small molecules that inhibit Bcl-2, developing 
antisense oligonucleotide against Bcl-2 and synthesizing peptides which interact with 
and inhibit Bcl-2 (Fesik 2005).  For instance, the antisense oligonucleotide 
Genasense has been developed to inactivate the mRNA of Bcl-2 gene, thereby 
reducing Bcl-2 protein expression (Frantz 2004).  Having been shown to be effective 
for treatment of lymphoma in vitro, Genasense had entered clinical trials.  It failed to 
receive FDA approval due to disappointing results from phase III trial in malignant 
melanoma and multiple myeloma (Bedikian et al. 2006).  More recently, a phase III 
trial in refractory chronic lymphocytic leukemia (CLL) was conducted to seek 
approval of Genasense (O'Brien et al. 2007).  Unfortunately, FDA did not approve 
this new drug application.  A five-year follow-up study of the CLL trial showed a 
significant increase in patient survival by using Genasense (Rai et al. 2008), and 
therefore an amended new drug application has been submitted and currently under 
review by FDA.  Other agents to inhibit Bcl-2 family proteins such as Gossypol, 




The phosphatidylinositol 3-kinase (PI3K)-Akt pathway plays an important 
role in cell growth and survival (Vivanco and Sawyers 2002).  In many cancers, 
PI3K-Akt pathway is deregulated in a way that results in overgrowth of cancer cells.  
The activation of PI3K-Akt pathway not only renders tumor cells more competencies 
for growth, but also provides a mechanism for cancer cells to evade apoptosis 
(Hennessy et al. 2005).  The function of Akt signaling is achieved by its regulation 
of downstream signals (Vivanco and Sawyers 2002).  On one hand, Akt signaling 
brings about activation of anti-apoptotic proteins.  For instance, Akt activates the 
NF-κB signaling pathway, which in turn activates the transcription of pro-survival 
proteins.  It can also promote cell growth through activating its downstream signal, 
mammalian target of rapamycin (mTOR), which is a protein kinase regulating 
stimulation of cell proliferation.  On the other hand, Akt signaling inactivates 
pro-apoptotic proteins.  One such protein is the Bcl-2 family member protein, BAD.  
The unphosphorylated form of BAD can function to antagonize the anti-apoptotic 
Bcl-2 and Bcl-XL, thereby disrupting the mitochondria potential and initiating 
caspase cascade.  Once phosphorylated by Akt, BAD loses its function and gets 
sequestered by its inhibitor 14-3-3 protein (Datta et al. 1997).   
Another class of protein inactivated by Akt is the forkhead family 
transcription factors.  These factors can induce transcriptional activation of CD95L 
and contribute to death receptor-mediated apoptosis (Suhara et al. 2002).  Akt 
inhibition of these factors leads to reduced CD95L, therefore reversing the 
apoptosis-inducing effects of these factors.  In addition, Akt can inhibit the function 
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of the tumor suppressor p53 by activating MDM2, which is the inhibitor of p53 
protein (Mayo and Donner 2001).  The evasion of cancer cell from apoptosis 
through enhanced Akt activity thus provides the basis that this pathway be targeted to 
restore tumor apoptosis.   
Inhibitors of the PI3K family have been developed and tested for their 
apoptosis-inducing effects in cancer cells (Hennessy et al. 2005).  Two PI3K 
inhibitors, wortmannin and LY294002 have been demonstrated to exert anticancer 
activity in vitro and in vivo (Schultz et al. 1995; Hu et al. 2000).  In addition, these 
two compounds have been shown to sensitize tumors to other chemotherapeutic 
treatments (Hu et al. 2002).  Unfortunately, these compounds are not suitable to be 
developed into anticancer agents since they lack selectivity against PI3K isoforms 
(Stein 2001).  Instead, they have been widely used as pharmacological tools in the 
study of PI3K-Akt pathway.   
Another target of this pathway for restoring tumor cell apoptosis is the 
downstream effector protein mTOR.  Inhibitors of mTOR include macrolide 
rapamycin, CCI-779 and RAD001 (Eng et al. 1984; Shi et al. 1995; Dudkin et al. 
2001).  These compounds have shown inhibitory effects on tumor growth both in 
vitro and in vivo.  They also synergize with other chemotherapeutic agents such as 
tamoxifen (deGraffenried et al. 2004).  Because of its effectiveness against cancer, 
CCI-779 has been under clinical evaluation for treatment of patients with renal cell 
carcinoma and glioblastoma (Hennessy et al. 2005).  Furthermore, the combination 
of CCI-779 with aromatase inhibitor letrozole is under a phase III clinical trial for 
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treatment of metastatic breast cancer (Hennessy et al. 2005).  However, more 
detailed understanding of the mTOR pathway is warranted to validate the treatments 
aimed to target mTOR.  Advances in research to elucidate this signaling pathway 
will also help to develop more specific mTOR inhibitors with higher therapeutic 
efficacy and less adverse effects.   
Tumor suppressor p53 plays a critical role in inducing cell cycle arrest and 
cell death in response to DNA damage (Ljungman 2000).  As a result, p53 has been 
called the “the guardian of the genome” because of its protective role in genome 
mutation and maintenance of gene stability.  Mutation of p53, which results in 
circumvention of apoptosis, occurs in around 50% of human cancers (Bullock and 
Fersht 2001).  The loss of p53 function accelerates cancer tumorigenesis in many 
ways (Bullock and Fersht 2001).  Firstly, mutated p53 is not able to repair DNA 
damage, and the consequent accumulation of DNA damage forms the genetic basis 
for cancer development.  Secondly, p53 can induce cell cycle arrest and prevent the 
continuous growth of cells suffering from DNA damage through transcriptional 
activation of the p21 cyclin kinase inhibitor gene.  This allows DNA repair to set in 
before cells are released out of cell cycle arrest.  In cancer cells with p53 mutation, 
non-functioning p53 is not able to hold damaged cells for damage repair.  Thirdly, 
p53 can induce apoptosis if DNA damage is beyond repair, thereby eliminating the 
chance of existence of cells with instable genome.  Cancer cells have a defective 
p53-mediated apoptotic pathway, thereby leading to excessive cell growth but 
diminished cell death (Bullock and Fersht 2001).  The inactivation of p53 can either 
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be caused by the mutation of p53 or be a result of overexpression of its negative 
regulator, MDM2.  Therefore, the strategies restoring the function of p53 as tumor 
suppressor include (1) delivery of the p53 gene into cells with inactive p53 proteins 
and, (2) reducing the binding of p53 to overpressed MDM2 (Fesik 2005).  The p53 
gene therapy drugs such as INGN201and INGN201 have been under clinical trials for 
their effectiveness against a variety of cancer types (Zhang 2002).  Being a negative 
regulator of p53, MDM2 binds to p53 protein and leads to the proteasomal 
degradation of p53 (Shieh et al. 1997).  Several types of human cancers have been 
reported to overexpress MDM2 (Bueso-Ramos et al. 1993; Bueso-Ramos et al. 1996; 
Watanabe et al. 1996).  Blocking p53-MDM2 interaction is one way to prevent p53 
degradation and re-establish p53 function.  Using p53 analogues to prevent the 
binding of MDM2 to p53 has been shown to effectively sensitize cancer cells to 
apoptosis, especially in cells expressing wild-type p53 (Vassilev et al. 2004).  Nutlin 
is a small-molecule MDM2 inhibitor developed based on this strategy (Vassilev et al. 
2004).  It causes accumulation and activation of p53 in cancer cells, and 
consequently induces cell cycle arrest in G1 and G2 phase.  Most importantly, it 
inhibits tumor growth in xenograft nude mouse models without causing significant 
damage to normal organs (Vassilev et al. 2004).  These findings highlight the 
importance of p53 in suppressing tumor formation and regulating apoptosis in cancer 
cells.   
In addition to the targets discussed above, there are many other pathways that 
can be targeted for the induction of apoptosis in cancer cells.  Promoting apoptosis 
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has been one of the most potent defenses against cancer.  Indeed, the conventionally 
used chemotherapeutic agents exert their anticancer effects largely through the 
induction of apoptosis in tumor cells (Kaufmann and Earnshaw 2000).  With the 
expansion of knowledge on apoptosis and its underlying mechanisms, more effective 




















1.4 Prostaglandins in cancer development 
1.4.1 Overview of prostaglandins 
Prostaglandins are 20-carbon atom fatty acid derivatives, which are 
structurally composed of hydroxylated fatty acids and a five-member carbon ring.  
The prostaglandins are classified into several types (A to I) according to their 
structural differences in the carbon ring.  A number is added after the type 
designation to indicate the number of double bonds in the fatty acid side chains 
(Karmali 1983)  All prostaglandins in the body are derived from polyunsaturated 
fatty acids (as depicted in Figure 1.6).  Specifically, arachidonic acid is the precursor 
of prostaglandins with two double bonds in the side chain (Karmali 1983).  
Therefore, the production of these prostaglandins depends on the availability of 
arachidonic acid.  There are two kinds of key enzymes involved in the production of 
prostaglandins.  One is phospholipase A2 (PLA2) family of enzymes, which is 
responsible for release of arachidonic acid from membrane phospholipids; the other 
one is the cyclooxygenase (COX) family of enzymes, controlling the rate-limiting 





Figure 1.6 Prostaglandin biosynthesis cascade.  Membrane phospholipids can be 
cleaved by PLA2 family enzymes at the sn-2 position to release arachidonic acid.  
Arachidonic acid is subsequently converted by COX enzymes (COX-1 and -2) to 
prostaglandin G2 and then prostaglandin H2.  Prostaglandin H2 is further converted 
to series-2 tissue specific prostaglandins.  PG, prostaglandin; TX, thromboxane. 
 
1.4.1.1 PLA2 family enzymes 
As a substrate for further conversion to prostaglandins, arachidonic acid plays 
a critical role in the formation of prostaglandins.  In the cells, the basal levels of 
arachidonic acid are usually low, and thus limit the synthesis of arachidonic acid 
metabolites.  The formation of arachidonic acid is tightly controlled by PLA2 family 
enzymes (Murakami et al. 1997).  The PLA2 family comprises a group of enzymes 
that cleave membrane phospholipids from the sn-2 position and subsequently release 
fatty acids, the predominant form being arachidonic acid (Murakami et al. 1997).   
The PLA2 family enzymes can be generally categorized into three classes: 
secretary PLA2 (sPLA2), calcium-dependent cytosolic PLA2 (cPLA2) and 
calcium-independent PLA2 (iPLA2) (Six and Dennis 2000).  The class of sPLA2 
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enzymes can be further classified into ten groups (I-III, V and IX-XIV) based on their 
genetic sequence (Six and Dennis 2000).  The sPLA2 enzymes share several 
characteristics.  Firstly, they are all between 14-19 kDa. Secondly, their enzymatic 
activation requires millimolar concentrations of calcium.  Thirdly, as their names 
describe, they are secreted from cells and generally found in the extracellular space.   
According to the classification system based on gene sequences, cPLA2 
family enzymes include mainly group IV PLA2 enzymes which are further 
subclassified into type IVA, IVB AND IVC.  These enzymes have a high molecular 
mass of 85, 114 and 61 kDa respectively.  They are found in the cytosolic fraction of 
almost all the cell types studied.  In response to increase in intracellular calcium 
levels, cPLA2 enzymes translocate to membranes and subsequently hydrolyze the 
phospholipids on the cell membrane for the release of arachidonic acid (Durstin et al. 
1994).  Thus, one unique characteristic of cPLA2 family enzymes is their expression 
in the membrane.  The preference for phospholipid precursor of arachidonic acid is 
another unique characteristic of cPLA2 enzymes (Clark et al. 1991).  Additionally, 
cPLA2 enzymes have been suggested to be involved in receptor-activated 
mitogen-activated signaling cascade (Lin et al. 1993).  The phosphorylation of 
cPLA2 enzymes by kinases of the mitogen-activated protein kinase cascade results in 
an enhancement of their enzymatic activity (Lin et al. 1993).   
iPLA2 enzymes are represented by group VI enzymes, which tend to share 
some similarities with both sPLA2 and cPLA2 (Balsinde and Dennis 1997).  Similar 
to sPLA2, iPLA2 enzymes have no substrate specificity for phospholipid precursors of 
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arachidonic acid.  The similarities between iPLA2 and cPLA2 include their 
comparable molecular mass, cellular location and some catalytic elements.  A 
unique feature of iPLA2 enzymes is that their activation does not require the 
involvement of calcium (Balsinde and Dennis 1997).   
The hydrolysis of membrane phospholipids by PLA2 family enzymes 
represents a critical primary step in the arachidonic acid signaling cascade and the 
formation of lysophospholipids.  As rate-limiting enzymes controlling the release of 
arachidonic acid, PLA2 enzymes provide the essential substrate for COX enzymes to 
convert into prostaglandins.       
 
1.4.1.2 COX enzymes 
Conversion of arachidonic acid to prostaglandins is essentially the main 
arachidonic acid metabolic pathway (Rosenfeld 1988).  COX enzymes are the key 
enzymes responsible for the production of prostaglandins from arachidonic acid.  
Under the catalysis of COX enzymes, prostaglandins are formed by the cyclization of 
the central five carbons in the 20-carbon polyunsaturated chain of arachidonic acid 
(Karmali 1983).  There are two steps involved in the formation of prostaglandins.  
The fatty acid is first oxidized to prostaglandin G2 and prostaglandin H2; 
prostaglandin H2 is subsequently converted to one of the series-2 products, including 
structurally related prostaglandins such as prostaglandin E2, D2, F2 and I2 (Karmali 
1983).   
To date, two isoforms of COX have been identified (FitzGerald 2003).  
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COX-1 is constitutively expressed in most tissues in the body, and is generally 
regarded as a housekeeping enzyme responsible for synthesis of physiologically 
relevant prostaglandins.  Through the synthesis of prostaglandins, COX-1 executes 
functions such as protection of gastric mucosa, regulation of renal blood flow and 
platelet aggregation.  On the other hand, COX-2 is undetectable in most tissues; 
expression of COX-2 is usually induced by a large variety of pro-inflammatory 
factors such as growth factors and cytokines.  Being highly inducible, COX-2 is 
perceived to be the main enzyme responsible for prostaglandin formation in 
inflammation and cancer (FitzGerald 2003).    
   
1.4.2 Prostaglandins and cancer 
Prostaglandins have a wide range of physiological functions such as control 
of cell growth and differentiation (Wang and Dubois 2006).  They act through their 
widely distributed and diverse receptors on various cell types (Wang and Dubois 
2006).  These receptors that are recognized by prostaglandins belong to the family 
of cell surface seven-transmembrane G protein-coupled receptors.  The binding of 
receptors by the corresponding prostaglandins activates a complex series of 
downstream signals which subsequently exert the cellular effects.   
In addition to the maintenance of normal physiological function, 
prostaglandins also play important roles in pathological conditions such as pain, fever, 
inflammation and cancer development (Wang and Dubois 2006).  Among the 
prostaglandins, prostaglandin E2 (PGE2) plays a predominant role in promoting 
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cancer progression (Wang and Dubois 2006).  The central role of PGE2 in 
tumorigenesis has been supported by experiments involving animals with deleted EP1 
and EP4 receptors, which show findings that the occurrence of aberrant crypt foci 
induced by colon carcinogen is reduced (Watanabe et al. 1999; Mutoh et al. 2002).  
Disruption of another PGE2 receptor, EP2, effectively reduces the number and size of 
intestinal polyps in a mouse carcinogenesis model (Sonoshita et al. 2001).  
Furthermore, PGE2 has been shown to induce cancer cell growth and proliferation in 
vitro (Sheng et al. 2001).   
These studies indicate that PGE2 may serve as a target for cancer prevention.  
Indeed, inhibition of PGE2 production has been demonstrated to be an effective 
strategy to prevent cancer occurrence and development.  Clinical trials have shown 
that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) over 10-15 years 
reduces the risk of developing colorectal cancer by 40-50% (Smalley and DuBois 
1997).  In addition, use of NSAIDs leads to regression of pre-existing adenomas in 
patients with family adenomatous polyposis (Gupta and Dubois 2001).  Together 
with other experiments showing the effectiveness of NSAIDs against cancer (Watson 
1998; Gupta and Dubois 2001; Harris et al. 2003), these results suggest that inhibition 
of PGE2 is a useful strategy for cancer prevention. 
In addition, prostaglandins are found to be overexpressed in many human 
cancer types.  The overexpression of prostaglandins in cancer further validates the 
prevention strategy involving reduction of prostaglandin production (Wang and 
Dubois 2006).  These findings provide a rationale for the development of anticancer 
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agents that exert inhibitory effects on prostaglandin formation.  As key enzymes 
involved in prostaglandin formation, PLA2 and COX-2 have been suggested to be 
highly involved in carcinogenesis and cancer development (Wang and Dubois 2006).     
 
1.4.2.1 PLA2 enzymes and cancer 
a. sPLA2 and cancer 
All three classes of PLA2 enzymes have been reported to be associated with 
cancer development.  The role of sPLA2 in cancer promotion remains controversial.  
sPLA2 IIA has been suggested by some research groups to have a role in tumor 
development and progression (Kennedy et al. 1998; Graff et al. 2001; Jiang et al. 
2002).  The expressions of sPLA2 IIA protein and its gene have been found to be 
elevated in human colorectal adenomas from patients with familial adenomatous 
polyposis (Kennedy et al. 1998).  In addition, significantly higher expression of 
sPLA2 IIA has been observed in prostate cancer patients, as compared to benign 
prostatic glands (Jiang et al. 2002).  Furthermore, prostatic sPLA2 IIA expression 
increases with progression to androgen independence, and is inversely related to 
5-year patient survival (Graff et al. 2001).   
These findings therefore lead to the hypothesis that sPLA2 IIA enzyme may 
be a prognostic indicator of cancer development and progress.  However, other 
groups of researchers have reported contradictory findings suggesting that sPLA2 may 
act as a tumor suppressor.  This notion is supported by hemizygous deletion of 
sPLA2 IIA gene observed in human neuroblastoma and colorectal carcinomas 
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(Riggins et al. 1995; Kawamata et al. 1997).  Another line of evidence supporting 
the suppressive role of sPLA2 in cancer development is the establishment of a 
positive correlation between sPLA2 IIA expression and prolonged patient survival and 
decreased metastatic frequency in human gastric adenocarcinoma (Leung et al. 2002).  
In addition, sPLA2 IIA gene has been identified as a negative regulator of intestinal 
adenoma formation in the condition of multiple intestinal neoplasia (MacPhee et al. 
1995; Cormier et al. 1997).  Given the contradictory results obtained so far, the role 
of sPLA2 in tumor development thus remains to be further clarified.   
 
b. cPLA2 and cancer 
Elevated expression and functional activity of cPLA2 have been observed in a 
range of human tumor types such as colorectal, intestinal and lung cancers, which 
result in high levels of arachidonic acid and prostaglandins (Kawamoto et al. 1995; 
Wendum et al. 2003).  The expression of oncogenic Ras mutation is a common 
genetic characteristic of several human tumor types such as colon, prostate and lung 
cancers (Bos 1989).  In non-small cell lung cancer, cPLA2 expression is found to be 
correlated with the occurrence of Ras mutation (Heasley et al. 1997).  Interestingly, 
constitutively active Ras was able to increase the expression of both cPLA2 and 
COX-2 in normal lung epithelial cells (Heasley et al. 1997; Blaine et al. 2001).  On 
the other hand, studies have shown that Ras inhibition results in decreased cPLA2 
expression and activity, and thereby a reduction in prostaglandin synthesis (Heasley 
et al. 1997).  The regulation of cPLA2 activity by Ras may be mediated by the 
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mitogen-activated protein kinase (MAPK) signaling pathway, which induces the 
phosphorylation and activation of cPLA2 (Lin et al. 1993; Blaine et al. 2001).  
Considering the frequent mutation of Ras gene in non-small cell lung cancer, these 
studies provide a possible mechanism for the high expression of PGE2 frequently 
observed in this type of lung cancer.   
The role of cPLA2 in lung cancer development was further established by a 
knock-out animal study (Meyer et al. 2004).  In this study, as compared to wild-type 
control group, deletion of the cPLA2 gene significantly reduced tumor formation by 
43%.  The levels of prostaglandins are also lower in tumors of cPLA2-null mice than 
those in wide-type mice.  These studies suggest that cPLA2 promotes pathogenesis 
of lung tumors through the production of prostaglandins.   
cPLA2 also plays an essential role in the development of intestinal tumors.  
In an animal model of human family adenomatous polyposis, knockout of cPLA2 
gene reduced the size of small intestinal polyps by approximately 11-fold, but had 
little effect on decreasing the number of polyps (Takaku et al. 2000).  In another 
similar study, knockout of cPLA2 not only reduced the size of tumors, but also 
significantly reduced the number of tumors by 80% (Hong et al. 2001).  In another 
study using COX-2 knockout mice, a similar inhibitory effect on intestinal tumor 
formation is observed (Oshima et al. 1996).  Altogether, these studies show a critical 
role of cPLA2 in cancer pathogenesis, and accordingly the inhibition of cPLA2 
expression and activation may be a useful strategy for prevention of cancer 
development.    
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c. iPLA2 and cancer 
iPLA2 enzymes are the most recently identified PLA2 family members.  
Studies suggest that these enzymes do not appear to be directly involved in 
stimulating arachidonic acid release (Balsinde and Dennis 1997).  Instead, they are 
important for phospholipid fatty acid remodeling (Balsinde et al. 1995; Balsinde and 
Dennis 1997).  Therefore, iPLA2 enzymes are generally regarded as “housekeepers” 
within cells by controlling phospholipid levels and maintaining homeostasis.  
Compared to sPLA2 and cPLA2, the role of iPLA2 in human cancers is not well 
investigated.  Two members of the iPLA2 enzymes, Group VIA and VIB PLA2, have 
been shown to be expressed in cultured cell lines including pancreatic, kidney and 
brain cancer cells (Ma et al. 1998; Zhang et al. 2005; Bao et al. 2006).  iPLA2 
enzymes have also been shown to mediate cell growth in cancer cell models (Bao et 
al. 2006; Saavedra et al. 2006).  Although these studies may indicate the 
involvement of iPLA2 in cancer, the exact role of iPLA2 in cancer development 
remains largely unknown because of the lack of in vivo studies on iPLA2. 
  
1.4.2.2 COX enzymes and cancer     
COX enzymes include COX-1 and COX-2.  As a housekeeping enzyme, 
COX-1 is constitutively expressed in tissue cells (FitzGerald 2003).  Under the 
pathological conditions, COX-2 is the main enzyme that can be induced by a wide 
range of stimuli to produce prostaglandins (FitzGerald 2003).  The importance of 
COX-2 in tumorigenesis was first noted by the efficacy of aspirin and other NSAIDs 
Chapter 1 
 60 
to reduce the risk of colon cancer (Gupta and Dubois 2001).  These inhibitors of 
COX-2 also promote tumor regression in experimental animal models of colon cancer 
as well as colon cancer patients (Gupta and Dubois 2001).  COX-2 has been found 
to be overexpressed in a wide range of cancer types such as colorectal, lung, breast, 
prostate, bladder, stomach and pancreas cancers (Gupta and Dubois 2001; FitzGerald 
2003).  Several studies have suggested that COX-2 has an important role in 
promoting cancer development.  In one study, knockout of COX-2 gene significantly 
reduces the number of intestinal polyps in mice (FitzGerald 2003).  In other studies, 
overexpression of COX-2 is found to induce carcinogenesis of breast and skin in 
animal models (Liu et al. 2001; Muller-Decker et al. 2002).  The tumor promotion 
effect of COX-2 has also been demonstrated in human cancer cell lines in which 
inhibition of COX-2 activity effectively suppresses cancer cell proliferation (Hsu et al. 
2000).  Therefore, COX-2 can serve as a valid target for cancer prevention.  
Additionally, since COX-2 is highly inducible by pro-inflammatory factors, agents 
that can inhibit the induction of COX-2 may be as effective in preventing tumor 
formation as COX-2 inhibitors. 
 
1.4.3 Prostaglandins as target for cancer prevention 
Because of the important role of prostaglandins in cancer development, a 
variety of approaches have been explored for the control of prostaglandin formation.  
The inhibition of prostaglandin formation can be achieved by reducing arachidonic 
acid release or by suppressing the conversion of arachidonic acid to prostaglandins.       
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1.4.3.1 Inhibition of arachidonic acid release 
The release of arachidonic acid is tightly controlled by the PLA2 family 
enzymes (Laye and Gill 2003).  Among these enzymes, cPLA2 may become a target 
for cancer chemoprevention because of its close association with cancer development 
(Nakanishi and Rosenberg 2006).  Downregulation of cPLA2 expression or its 
activity would decrease the release of arachidonic acid, thereby inhibiting cancer 
development.  In many cancer types, dysregulation of cPLA2 is often observed 
(Laye and Gill 2003; Nakanishi and Rosenberg 2006).  The high expression and 
activity of cPLA2 has been illustrated by the transcriptional activation of cPLA2 by 
oncogenic Ras in non-small cell lung cancer (Heasley et al. 1997).  Ras can activate 
MAPK signaling pathway, which subsequently leads to the activation of 
transcriptional factors such as SP1 and c-Jun (Blaine et al. 2001).  These 
transcriptional factors can bind to the promoter region of cPLA2 gene, thus initiate the 
transcription of cPLA2 gene (Blaine et al. 2001).  In addition, a downstream signal of 
c-Jun, epidermal growth factor receptor, can lead to translocation and 
phosphorylation of cPLA2, thus increases its enzymatic activity (Sato et al. 1997).  
Therefore, it can be postulated that the inhibition of these pathways leading to cPLA2 
expression and activation may reduce cPLA2-catalyzed release of arachidonic acid.  
Similarly, specific enzyme inhibitors of PLA2 enzymes can also result in a reduction 
in arachidonic acid release.   For instance, a cPLA2 inhibitor Wyeth-1 was found to 
effectively inhibit tumor growth in a xenograft prostate cancer model (Patel et al. 
2008).  A small interfering RNA against cPLA2 was also found to be effective in 
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reducing prostate cancer growth (Patel et al. 2008).  To date, although there are no 
clinical trials investigating the effectiveness of cPLA2 inhibitors as cancer preventive 
agents, inhibition of cPLA2 is certainly a promising strategy to be employed for 
cancer prevention. 
 
1.4.3.2 Inhibition of arachidonic acid conversion to prostaglandins 
The cancer prevention strategy targeting prostaglandins initiates from the 
findings that NSAIDs effectively reduce cancer occurrence (Gupta and Dubois 2001).  
NSAIDs, as inhibitors of COX enzymes, have been used to treat inflammation, fever 
and pain for over a century.  Unexpectedly, a combined use of two common 
NSAIDs (indomethacin and sulindac) for the purpose of pain relief was reported to 
have cured a patient with rectal polyps (Waddell and Loughry 1983).  Subsequent 
studies have found that neoplasic lesions contain elevated levels of prostaglandins, 
suggesting a role of prostaglandins in tumorigenesis (Rolland et al. 1980; Rigas et al. 
1993; Uefuji et al. 2000).  It is thus hypothesized that reducing prostaglandins by 
COX inhibition may underlie the cancer preventive mechanism of NSAIDs, which to 
date, has been supported by multiple lines of evidence obtained from in vitro and in 
vivo work, as well as from clinical trials (Gupta and Dubois 2001).  However, 
traditional nonselective COX inhibitors cause damage to the gastric mucosa that thus 
pose safety issues regarding the use of NSAIDs as chemopreventive agents; this side 
effect is found to be related to inhibition of COX-1 (Gupta and Dubois 2001).  
Therefore, efforts have been made to develop selective COX-2 inhibitors that retain 
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the anti-inflammatory and chemopreventive activity but exert less toxicity to the 
gastrointestinal system.   
Specific COX-2 inhibitors such as celecoxib and rofecoxib have been 
developed.  They are very effective agents in relieving inflammation and pain.  In 
addition, celecoxib has been shown to be very effective in preventing colorectal 
carcinogenesis in high-risk patients (Williams et al. 2000; Phillips et al. 2002; Huls et 
al. 2003).  However, COX-2 selective inhibitors are found to increase the risk for 
heart attack and stroke (Gupta and Dubois 2001; Bresalier et al. 2005; Solomon et al. 
2005).  As such, rofecoxib was withdrawn from the market in 2004.  The 
mechanism underlying this possible cardiovascular side effect of COX-2 specific 
inhibitors is still unknown and further elucidation is required.  Nevertheless, the 
inhibition of COX-2 has been demonstrated to be an effective strategy for cancer 
chemoprevention.  Compounds that are able to reduce prostaglandin formation 
either through inhibition of COX-2 expression or COX-2 enzyme may possess 










1.5 Matrix metalloproteinases and tumor invasion 
1.5.1 Overview of tumor invasion 
Tumor invasion and metastasis is one of the six essential characteristics of 
cancer and metastasis is responsible for 90% of human cancer deaths (Hanahan and 
Weinberg 2000).   Tumor metastasis causes the spread of cancer from its primary 
site to distant organs, and ultimately makes surgical resection impossible.  The 
high mortality rate of cancer is largely associated with cancer invasion and 
metastasis (Bogenrieder and Herlyn 2003).  The occurrence of tumor metastasis 
comprises a complex series of sequential and interrelated events (Chambers et al. 
2002; Steeg 2006).  These events include invasion of adjacent tissues, intravasion, 
transport through the circulatory system, arrest at a distant vascular bed, 
extravasation and growth as a secondary colony and angiogenesis.  Disruption of 
the basement membrane and subsequent tumor invasion represent critical early steps 
required for tumor metastasis; changes in tumor cell-cell adherence and on the 
extracellular matrix allow the tumor cells to detach from their original sites and 
invade into adjacent tissues or blood vessels (Steeg 2006).   
The cell-cell adhesion is regulated by a class of transmembrane proteins 
called cadherins through protein-protein interaction involving their extracellular 
domains (Cavallaro and Christofori 2004).  In addition, they can interact with 
catenins and the actin cytoskeleton using their intracellular domain (Cavallaro and 
Christofori 2004).  The members of cadherin proteins have distinct functions.  For 
instance, E-cadherin is often expressed in epithelial tissues.  It plays an essential 
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role in maintaining cell-cell adhesion and thereby blocks invasion.  On the contrary, 
N-cadherin is normally expressed on mesenchymal cells and its function is to 
facilitate cell binding to stroma, thus to assist tumor invasion.  Tumor invasion is 
often accompanied by the loss of E-cadherin expression or function and increased 
expression of N-cadherin (Cavallaro and Christofori 2004).   
In addition to the cell-cell adhesion changes, successful tumor invasion 
requires remodeling of extracellular matrix which will facilitate cell migration 
through tissues (Steeg 2006).  The remodeling of tumor microenvironment is 
usually achieved by proteolytic degradation of extracellular matrix.  Matrix 
metalloproteinases (MMPs) are prime candidates for the remodeling of tumor 
microenvironment since they are able to digest the various structural components of 
the extracellular matrix (Coussens et al. 2002).   
 
1.5.2 Matrix metalloproteinases 
1.5.2.1 The MMP family 
MMPs are a family of zinc-dependent proteinases capable of degrading 
extracellular matrix proteins; more than 20 human MMPs have been identified and 
the number of MMP members is still increasing (Nelson et al. 2000).  Based on their 
preferred substrate, these MMPs can be classified into collagenases, gelatinases, 
stromelysins and matrilysins.  Alternatively, these MMPs are named by a sequential 
numbering system according to their structures.  All MMPs share common structural 
domains, such as a pre-region, a pro-region and an active catalytic region (Overall 
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and Lopez-Otin 2002).  These domains have different function: the pre-region is to 
target for enzyme secretion; the pro-region is to maintain the enzyme in a latent state; 
the active region contains a zinc-binding site for catalytic activation. 
Apart from these basic domains, many MMPs have other structural 
components such as the hemopexin region, fibronectin-like region and 
transmembrane domain (Overall and Lopez-Otin 2002).  The functions of these 
regions include recognition of substrate, binding to inhibitors and attaching to cell 
surface.  For instance, gelatinases A and B (MMP-2 and MMP-9, respectively) have 
a unique insertion of three head-to-tail cysteine-rich repeats in the catalytic region 
(Sternlicht and Werb 2001).  Having similar structures with collagen-binding type II 
repeats of fibronectin, these inserts allow MMP-2 and MMP-9 to digest collagen and 
elastin (Murphy et al. 1994; Shipley et al. 1996).   
The MMPs with transmembrane domain are called membrane-type MMPs 
(MT-MMPs).  One function of MT-MMPs is to allow anchorage of secreted MMPs 
and trigger the activation of these MMPs (Nelson et al. 2000).  The secreted MMPs 
that are known to be activated by MT-MMPs include MMP-2 and MMP-13 (Strongin 
et al. 1995; Kinoh et al. 1996; Knauper et al. 1996).    
 
1.5.2.2 Regulation of MMP activity 
To create an extracellular environment favoring cancer invasion, the 
proteolytic activity of MMP family enzymes must be activated to degrade the 
extracellular matrix components.  The activation of MMPs is controlled at three 
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different levels: transcription, proenzyme activation and inhibition by endogenous 
MMP inhibitors (Sternlicht and Werb 2001).  
 
a. Transcriptional regulation 
The biological function of MMPs is largely controlled at the transcriptional 
level (Sternlicht and Werb 2001).  Because of differences in their gene structures, 
MMP family members are regulated differently by transcriptional stimuli, which 
results in different expression patterns for each individual MMP member.  The 
majority of MMP genes are usually expressed at low levels under normal quiescent 
conditions, but in pathological conditions such as inflammation, wound healing and 
cancer, copies of MMP transcripts can increase rapidly (Overall and Lopez-Otin 
2002).  In cancer pathogenesis, MMP genes are transcriptionally activated by 
various stimulatory factors such as phorbol esters, cytokines, growth factors and 
oncogene products (Sternlicht and Werb 2001).  These stimulatory factors are 
usually originated from stroma, inflammatory cells or tumor cells (Sternlicht and 
Werb 2001).   
Several signaling pathways have been proposed to mediate the induction of 
MMP gene transcription by these stimulatory factors.  MAPK signaling pathways 
are highly involved in the regulation of MMP gene transcription (Sternlicht and Werb 
2001).  The MAPK family enzymes such as extracellular signal-regulated kinase 
(ERK), c-Jun NH2-terminal kinase (JNK) and p38 MAPK have all been shown to 
stimulate gene transcription of MMP family enzymes, and thereby lead to increased 
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protein expression of their protein levels (Gum et al. 1997; Simon et al. 1998; 
Johansson et al. 2000; Lakka et al. 2002).  These MAPK signal transduction 
pathways converge at the transcription factor activator protein-1 (AP-1), which binds 
to the promoter region of most MMP genes and activate the transcriptional process 
(Overall and Lopez-Otin 2002).  AP-1 is a heterodimer composed of the two 
oncoproteins, c-Jun and c-Fos.  Studies have suggested that c-Fos is mainly 
activated by ERK signaling, while c-Jun is the downstream signal of JNK and p38 
MAPK (Shaulian and Karin 2002).  Several other signaling pathways are also found 
to be associated with MMP gene transcription.  NF-κB signaling is one of the most 
important regulators for MMP gene transcription.  It has been found to induce gene 
expression of MMP-1, 3, 9, 13 and 14 (Bond et al. 1999; Han et al. 2001).  Other 
transcriptional regulators leading to MMP gene expression include signal transducers 
and activators of transcription (STATs), ETS family of oncoproteins, T-cell factor 4 
and CAS-associated zinc-finger protein (Overall and Lopez-Otin 2002).  STATs is 
known to mediate interferons-induced MMP gene expression; ETS oncoproteins bind 
to PEA3 sites located in MMP gene promoter region and consequently activate gene 
transcription; T-cell factor 4 and CAS-associated zinc-finger protein activates gene 
expression of MMP-1, 3 and 7 (Overall and Lopez-Otin 2002).     
 
b. Proenzyme activation 
MMP proteins are synthesized as the inactive zymogens or proenzymes 
(Nelson et al. 2000).  Therefore, the conversion of MMP proenzymes into their 
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active forms represents a critical step in regulating MMP function.  The latency of 
MMP proenzymes is maintained by MMP prodomain which covers and prevents 
hydration of the zinc-containing active site (Sternlicht and Werb 2001).  The 
protection on the active site is achieved by an unpaired cysteine residue near the 
C-terminal end of the propeptide domain.  To activate proenzymes of MMP, the 
cysteine-zinc interaction has to be destroyed or the propeptide domain has to be 
removed (Sternlicht and Werb 2001).  The concept of cysteine-switch mechanism of 
MMP activation has been demonstrated by structural analysis of pro-MMP-2 and 
pro-MMP-3 (Becker et al. 1995; Morgunova et al. 1999).  Most MMP proteins are 
secreted to the extracellular environment as inactive proenzymes.  However, several 
MMP members such as MMP-27, MMP-11 and MT-MMPs are secreted as active 
forms (Sternlicht and Werb 2001).  These enzymes have a furin-like enzyme 
recognition motif located between the propeptide and catalytic domains.  This motif 
makes it possible that these enzymes be activated by intracellular furin-like 
proprotein convertase before they are secreted (Pei and Weiss 1995).  For those 
MMP enzymes without the furin-like motif, the activation of proenzymes usually 
occurs after they are secreted to the extracellular space.  In the extracellular space, 
they are activated by other MMP members or by serine proteinases that have the 
ability to remove the prodomains (Sternlicht and Werb 2001).  MMP-2 is activated 
at the cell surface by MT-MMPs with the involvement of TIMP-2 in a multi-step 
process (Sternlicht and Werb 2001).  The N-terminal domain of TIMP-2 can bind to 
MT-MMP, which is located on the membrane.  The C-terminal domain of TIMP-2, 
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on the other hand, can bind to pro-MMP-2 and thus anchor MMP-2 enzymes on the 
cell surface.  As a result, the adjacent MT-MMP is able to cleave and activate 
pro-MMP-2.  A residual portion of the MMP2 prodomain is subsequently removed 
by another MMP-2 molecule to allow for fully activation of MMP-2 (Deryugina et al. 
2001).    
 
c. Inhibition by endogenous inhibitors 
The blocking of MMP enzyme activity by endogenous inhibitors is another 
mechanism to regulate MMP function.  The MMP inhibitors include 
α2-macroglobulin and tissue inhibitors of metalloproteinases (TIMPs) (Overall and 
Lopez-Otin 2002).  α2-Macroglobulin is present in the plasma and tissue fluids, thus 
representing a major inhibitor of MMPs in tissue fluids.  Comparatively, TIMPs are 
more specific inhibitors of MMPs and may perform their inhibitory effects locally.  
Another difference between these two kinds of inhibitors is that α2-macroglobulin 
often results in irreversible clearance of MMPs, while the inhibition of MMPs by 
TIMPs is reversible (Sottrup-Jensen and Birkedal-Hansen 1989; Sternlicht and Werb 
2001).  The TIMP family comprises four members, namely TIMP-1, -2, -3 and -4, 
where each inhibits different MMP members.  They can bind MMPs tightly through 
non-covalent force to form a 1:1 MMP-inhibitor complex (Brew et al. 2000).  As a 
result, the MMP-inhibitor complex is unable to bind to substrate of MMP and MMP 
proteolytic activity is inhibited.  TIMP expression levels have been suggested to 
negatively correlate with tumorigenesis (Khokha et al. 1989).  However, many 
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studies have reported an increase in TIMP expression during tumor development 
(Jiang et al. 2002; Overall and Lopez-Otin 2002).  These findings may indicate a 
host-protective response during tumor progression or they may indicate that TIMPs 
have more functions other than inhibition of MMPs.  Indeed, in the case of MMP-2, 
TIMP binding seems to be necessary for the conversion of pro-MMP-2 to its active 
form (Overall and Lopez-Otin 2002).  
 
1.5.3 MMP-2 and MMP-9 
1.5.3.1 The role of MMP-2 and MMP-9 in tumor invasion 
Among the MMPs identified so far, MMP-2 and MMP-9 are believed to be 
the most relevant enzymes involved in tumor invasion (Brinckerhoff and Matrisian 
2002).  According to their substrate specificity, MMP-2 and MMP-9 are also 
referred as gelatinase A and gelatinase B, respectively.  They play a key role in the 
degradation of type IV collagen and gelatin, which are the main components of 
extracellular matrix (Brinckerhoff and Matrisian 2002).  Therefore, they are the 
enzymes most responsible for the remodeling of extracellular matrix and subsequent 
tumor invasion.   
Increased expression of MMP-2 and MMP-9 has been observed in many 
human cancer types such as ovarian, prostate and breast cancers (Duffy et al. 2000; 
Egeblad and Werb 2002).  In addition, expression levels of MMP-2 and MMP-9 are 
generally correlated with the stage of tumor progression (Egeblad and Werb 2002).  
For instance, MMP-2 expression is found to be associated with tumor grade in 
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melanomas (Vaisanen et al. 1996).  In the same kind of tumor type, conversion from 
radial growth phase to vertical growth phase and subsequent invasion occurs with an 
increased expression of MMP-9 (MacDougall et al. 1995).  The ratio of activated 
form and inactive form also seems to correlate with cancer malignancy.  For 
example, although MMP-2 is widely expressed in breast cancers, metastatic cancers 
seem to have higher levels of activated MMP-2 (Brown et al. 1993).  A series of in 
vivo studies has established the role of MMP-2 and MMP-9 in promoting metastatic 
spread of tumor cells to the lung after intravenous injection of bladder, fibrosarcoma 
and lung cancer cells (Bernhard et al. 1994; Kawamata et al. 1995; Tsunezuka et al. 
1996).  Observations from experiments investigating tumor metastasis have also 
ascertained the involvement of MMP-2 and MMP-9 in tumor invasion and metastasis 
(Bernhard et al. 1994; Kawamata et al. 1995; Hasegawa et al. 1998).  On the 
contrary, treatment of mice with TIMP-1 has been shown to reduce the number of 
metastatic lung nodules after intravenous injection of melanoma cells (Khokha 1994).  
In vitro, the negative regulation of TIMPs on tumor invasion has been demonstrated 
in a Matrigel basement membrane model, which mimics the tumor extracellular 
environment (Albini et al. 1991).  In an in vivo tumor intravasation model using 
chick chorioallantoic membrane that has been developed to quantify tumor cells 
invading the bloodstream and circulating to other sites, MMP-9 expression is found to 
be indispensable for intravasation of human epidermal carcinoma (Koop et al. 1994).   
These studies together suggest that MMP-2 and MMP-9 alter the 
extracellular environment in a way that favors tumor invasion and subsequent 
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metastatic spread to distant locations.  Additionally, it has been reported that 
MMP-2 and MMP-9 not only facilitate tumor invasion by degradation of extracellular 
components, but also contribute to the process of angiogenesis (Handsley and 
Edwards 2005).  For instance, decreased and delayed angiogenesis has been 
observed respectively in MMP-2-null and MMP-9-null mice as compared to their 
wild-type counterparts (Itoh et al. 1998).  Since angiogenesis is a fundamental step 
in the metastatic spread and growth of tumors, the involvement of MMP-2 and 
MMP-9 in angiogenesis further highlights their importance in tumor invasion.     
   
1.5.3.2 Regulation of MMP-2 and MMP-9 
Although MMP-2 and MMP-9 share functional similarities as gelatinases, 
large differences exist between their structures (Overall and Lopez-Otin 2002).  
These structural differences underlie the different mechanisms regulating MMP-2 and 
MMP-9 activity.  MMP-9 activity is controlled by gene transcription, proenzyme 
activation and inhibition by endogenous inhibitors, whereas MMP-2 activity is 
regulated by the two latter factors and lacks regulation at the transcriptional level 
(Overall and Lopez-Otin 2002).   
MMP-2 is usually constitutively expressed with only modest regulation at the 
transcriptional level under certain conditions.  The insensitivity of MMP-2 to 
transcriptional regulation is largely due to its gene promoter structures.  It has been 
identified that regulatory elements located in the MMP-2 promoter region include 
AP2, p53, SP-1, CREB and PEA3 (Overall and Lopez-Otin 2002).  These regulatory 
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elements do not respond to a large variety of stimulatory signals such as growth 
factors and cytokines, and it is only under selective conditions that can stimulate 
these regulatory elements, will MMP-2 gene expression be possibly induced.   
Conversely, MMP-9 is highly inducible by a wide range of stimuli.  The 
promoter region of MMP-9 contains multiple DNA-binding sites which recognize 
AP-1, NF-κB, SP-1, TIE, KRE, RCE and PEA3 (Overall and Lopez-Otin 2002).  
The regulatory units such as AP-1 and NF-κB binding sites can be activated by 
various inflammatory stimuli which can trigger MAPK and NF-κB signaling 
pathways.  For instance, protein kinase C (PKC) activator phorbol ester is a strong 
inducer of MMP-9 expression through activating MAPK and NF-κB signaling 
pathways (Van den Steen et al. 2002).  Cytokines such as TNF-α and IL-1β can 
cause similar transcriptional activation of MMP-9 through the regulatory elements 
located on MMP-9 promoter region.  Using β-galactosidase activity as an indicator, 
MMP-9 promoter activity has been detected in animal models carrying a 
β-galactosidase reporter gene (Kupferman et al. 2000).   
Both MMP-2 and MMP-9 are synthesized and secreted as proenzymes 
without proteolytic activity.  To perform their functions, both of them need the 
conversion from proenzymes to active forms.  As described in Section 1.5.2.2, the 
mechanism for pro-MMP-2 activation involves MT-MMP and TIMP-2 (Sternlicht 
and Werb 2001).  However, the activation of pro-MMP-9 is currently not clear 
(Fridman et al. 2003).  Several mechanisms underlying the activation of pro-MMP-9 
have been proposed.  It has been hypothesized that MMP-9 is activated by 
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interaction with cell surface components (Fridman et al. 2003).  For instance, some 
studies suggest that MMP-9 is activated by multi-step process with the involvement 
of plasminogen/MMP-3 and urokinase plasminogen activator (uPA).  Plasminogen 
is firstly cleaved by uPA to produce plasmin, and plasmin in turn activates 
pro-MMP-3, followed by activation of pro-MMP-9 by MMP-3.   
Since uPA is bound to its cell surface receptor uPAR, the complex activation 
of pro-MMP-9 has been indicated to occur at the cell surface.  Interestingly, 
knockout of uPA gene, but not MMP-3 gene, reduced MMP-9 activation in mouse 
models (Fridman et al. 2003).  This may indicate that while plasmin is indispensible 
for MMP-9 activation, MMP-3 may not be the only partner mediating signaling from 
plasmin to MMP-9 activation.   
Other mechanisms in play include the activation of pro-MMP-9 by human 
tumor-associated trypsin-2 or by chymotrypsin-like proteinase (Fridman et al. 2003).  
In addition, several purified MMPs including MMP-2, -3, -7, -10 and -13 are found to 
cleave the 92-kDa pro-MMP-9 protein to the 82-kDa active MMP-9 enzyme in vitro 
(Fridman et al. 2003).  More intriguingly, pro-MMP-9 has been reported to have 
proteolytic activity without removal of its propeptide (Okamoto et al. 2001; Bannikov 
et al. 2002; Gu et al. 2002).  Indeed, the presumed 82-kDa active MMP-9 has been 
commonly reported to be undetectable in cultured cells and cancer tissues (Fridman et 
al. 2003).  Conversely, high expression of 92-kDa pro-MMP-9 is frequently found in 




These findings thus suggest that the activation of pro-MMP-9 may not be 
necessarily associated with a significant change in molecular size.  To date, despite 
its clear involvement in tumor invasion, how the pro-MMP-9 is actually converted to 
the active form remains elusive.  In addition to transcriptional regulation and 
zymogen activation as also mentioned in Section 1.5.2.2, MMP-2 and MMP-9 can be 
further regulated by endogenous inhibitors such as TIMPs and α2-macroglobulin 
(Overall and Lopez-Otin 2002).  For instance, MMP-2 is regulated by TIMP-2, 
while MMP-9 can form a noncovalent complex with TIMP-1 (Fridman et al. 2003).   
 
1.5.3.3 MMP-2 and MMP-9 as targets for control of tumor invasion 
Given the importance of MMP-2 and MMP-9 in tumor invasion, strategies 
intended to exert control over metastatic spread of cancer cells have been undertaken 
to modulate MMP-2 and MMP-9 activity.  One most-explored strategy is to reverse 
the invasion-promoting effects of these MMPs by direct inhibition of their activities 
(Coussens et al. 2002).  The direct inhibition of enzyme activity is especially 
suitable for MMP-2, as the gelatinase is largely regulated at the posttranscriptional 
level.  The endogenous MMP inhibitors have been initially considered as potential 
therapeutics for cancer malignancies.  However, the development of TIMPs into 
useful drugs has been hampered by technical difficulties (Coussens et al. 2002).  
Efforts have been focused on development of small molecule inhibitors of MMPs.  
One of the successful small molecule inhibitors is MPI SC-44463, a broad MMP 
inhibitor.  It has exhibited inhibitory effect on tumor metastasis in mouse models 
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(Reich et al. 1988).  Batimastat, a broad-spectrum hydroxamate inhibitor, is found to 
reduce breast cancer metastasis in a mouse xenograft model (Sledge et al. 1995).  
However, despite the effectiveness of these MMP inhibitors in animal models, results 
of clinical trials evaluating these MMP inhibitors have been disappointing (Coussens 
et al. 2002).  One of the problems is that many MMP inhibitors in clinical trials are 
broad-spectrum MMP inhibitors.  Different MMP family members have distinct 
roles in tumor development and some may even have anti-tumor activity (Coussens et 
al. 2002); broad-spectrum inhibition of MMPs may not show beneficial effects to 
cancer patients.  A better understanding of the molecular function of each MMP and 
development of more specific MMP inhibitors may improve the therapeutic value of 
MMP inhibitors.   
Tumors are frequently found to grow in an inflammatory environment that is 
characterized by increased expression of cytokines, growth factors and other 
proinflammatory factors (Federico et al. 2007).  Many of these inflammatory factors 
can increase MMP expression through transcriptional regulation.  Due to the highly 
inducible nature of MMP-9, an increased expression of MMP-9 has been frequently 
found in invasive cancers.  Therefore, downregulation of MMP-9 expression can be 
a plausible approach to inhibit cancer invasiveness.  The effectiveness of targeting 
MMP-9 to inhibit tumor invasion has been demonstrated by various in vitro and in 
vivo studies.  For instance, a hairpin RNA-triggered interference of MMP-9 
synthesis not only significantly inhibits invasiveness of glioblastoma cell line in vitro, 
but also decreases the metastasis of gliomas in vivo (Lakka et al. 2004).  A naturally 
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occurring active compound, curcumin, has been shown to reduce the number of 
metastases in an animal prostate cancer model through downregulation of MMP-9 
expression and activity (Hong et al. 2006).  Natural flavonoids have also been 
shown to inhibit metastasis of gliomas in vitro and in vivo, with their anti-invasive 




















1.6. Aims of study 
Alcoholic extracts of Poria cocos have shown anti-inflammatory and cancer 
chemopreventive activities.  However, the exact compounds responsible for these 
activities and the underlying mechanisms are largely undefined.  Previous studies 
carried out in our laboratory had demonstrated that the alcoholic extracts of Poria 
cocos, with triterpenoids as the main constituents, exhibited growth inhibitory effects 
against a variety of cancer cells.  On the basis that alcoholic extracts of Poria cocos 
potentially served as a rich source of triterpenoids with promising therapeutic benefits, 
this PhD project was undertaken to extend the currently limited research and 
understanding of triterpenoids with anticancer properties.  Studies were carried out 














Aim 1: To isolate and identify triterpenoids contained in alcoholic extracts of Poria 
cocos; and to evaluate the antiproliferative effects of the isolated triterpenoids against 
human-derived cancer cells 
 
Aim 2: To investigate the apoptosis-inducing effects of triterpenoid(s) that had 
demonstrated effective antiproliferative activities 
 
Aim 3: To investigate the cancer chemopreventive mechanism of PA with focus on 
its possible effect on prostaglandin production 
 
Aim 4: To evaluate the in vitro anti-invasive effects of triterpenoids on breast cancer 
migration 
 
Experimental approaches to achieve the above aims and corresponding 










Chapter 2: Isolation and identification of triterpenoids from Poria cocos 
 
Summary 
In this chapter, the procedures used to isolate triterpenoids from Poria cocos are described.  
Isolated compounds were subjected to physical and spectroscopic analyses for elucidation of 
their chemical structures.  In total, eight compounds were obtained and identified as (1) 
pachymic acid, (2) dehydropachymic acid, (3) 3-acetyloxy-16α-hydroxytrametenolic acid, (4) 
polyporenic acid C, (5) 3-epi-dehydropachymic acid, (6) 3-epi-dehydrotumulosic acid, (7) 
tumulosic acid, and (8) 29-hydroxypolyporenic acid.  Among these identified lanostane-type 
triterpenoids, compound 8 was novel, whereas the other compounds were known triterpenoids.  
Cell viability assays were conducted on these compounds, of which most of them showed 
moderate cytotoxicity on human non-small cell lung cancer A549 cells.   
 
2.1 Introduction 
Poria cocos has been widely used in Traditional Chinese Medicine for its diuretic, 
sedative and tonic effects (Yuan and Lin 2000).  As a famous herb with a long history of use, 
Poria cocos has been acclaimed for its mild yet effective biological functions.  To 
understand the underlying mechanisms responsible for its health-promoting effects, various 
studies have been carried out in an attempt to identify the main active components contained 
in Poria cocos.  In the aqueous extracts of Poria cocos, polysaccharides are identified as the 
main active compounds (Lee et al. 2004; Zhang et al. 2006).  The biological activities of 
polysaccharides include modulation of immune system and anticancer activity (Kanayama et 
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al. 1986; Lee et al. 2004).  Polysaccharides are shown to inhibit proliferation, as well as 
induce differentiation of leukemic cells (Chen and Chang 2004).  They are also reported to 
cause cell cycle arrest and induce apoptosis in breast cancer cells (Zhang et al. 2006).  On 
the other hand, the alcoholic extracts of Poria cocos are found to have anti-inflammatory and 
anticancer activities.  Chemical analyses have identified that triterpenoids are the main 
components in the alcoholic extracts (Zhong and Liu 2002; Setzer and Setzer 2003; Akihisa 
et al. 2007).  A complex mixture of triterpenoids or a single purified triterpenoid from Poria 
cocos have both been shown to possess certain anticancer properties, including inhibition of 
DNA polymerases, inhibition of tumor cell growth induced by TPA and inhibition of DNA 
topoisomerase II (Kaminaga et al. 1996; Kaminaga et al. 1996; Ukiya et al. 2002; Akihisa et 
al. 2004; Li et al. 2004; Mizushina et al. 2004).   
Earlier efforts in our laboratory had demonstrated the antiproliferative effect of 
alcoholic extracts of Poria cocos on a wide range of cultured human cancer cells.  Pachymic 
acid, a lanostane-type triterpenoid largely contained in Poria cocos, was also isolated on 
earlier occasions in the laboratory, and subsequent study yielded a novel finding that it was 
able to prevent the growth of both androgen-responsive and -insensitive prostate cancer cells 
by inducing apoptosis in a dose- and time-dependent manner (Gapter et al. 2005).  
Encouraged by these preliminary findings, we sought to conduct further research on Poria 
cocos with the objective to uncover and evaluate other pachymic acid-like compounds with 
possible anticancer activities.  The approach employed began with the isolation and 
purification of potential anticancer compounds from Poria cocos using bioassay-guided 
fractionation.  The purified compounds were then subjected to structural identification, after 
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which their possible antiproliferative effects against cancer cells were evaluated in vitro.   
 
2.2 Materials and methods 
Materials 
Dried sclerotia of Poria cocos were purchased from Tai Shan Medicinal Hall in 
Singapore, with origins from An Hui Province, China.  All sorbents for chromatographic 
isolation, such as Silica gel (60-200 µm), Silica gel 60 (40-63 µm), LiChroprep® RP-18 
(40-63 µm), and pre-coated silica gel 60 TLC plates, were purchased form Merck KGaA 
(Darmstadt, Germany).  MTT was purchased from Sigma (St. Louis, MO). 
 
Thin Layer Chromatography 
Thin Layer Chromatography (TLC) was used to facilitate column chromatographic 
separation from several aspects.  Firstly, TLC was used to select and determine suitable 
mobile phase and stationary phase before each separation using column chromatography.  
The crude extracts or fractions to be separated were tested on both silica gel (normal phase) 
and C18 (reverse phase) TLC plates as well as on different solvent systems.  The conditions 
that gave the best separation on the TLC plates were adopted as the separating condition in 
column chromatography.  Secondly, TLC was performed to assess polarities of compounds 
contained in collected fractions.  Fractions with similar retention factor values were 
combined and subjected to the next separation step.  Thirdly, TLC was used to determine if 
pure compounds were obtained.  The compounds were tested on both normal phase and 
reverse phase TLC plates using at least three different solvent systems.  The TLC plate was 
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inspected under UV light before using 6% sulphuric acid as a visualization agent to develop 
the spots.  If all the plates showed the presence of one single spot, it would indicate that a 
pure compound was successfully isolated.   
 
Column chromatography 
Column chromatography was used for the separation and isolation procedures.  
Based on the TLC results, normal phase or reverse column chromatography was chosen for 
the specific separation steps.  For normal phase column chromatography, silica gel with 
particle size of 40-63µm was used as the stationary phase in the column.  The elution 
solvent system was used to suspend silica gel, and then the mixture of silica gel and solvent 
was poured into the column.  After continuously flushing the silica gel with solvent, a 
homogeneous and compact silica gel bed was finally formed.  The fractions to be separated 
was dissolved in the minimum amount of solvent and added drop by drop onto silica gel 
(particle size: 63-200 µm) so as to form an even coating of compounds on the silica gel.  
The silica gel coated with compounds was then loaded onto the top of the compact silica gel 
bed in the column.   
For reverse phase column chromatography, LiChroprep® RP-18 (40-63 µm) was used 
as the stationary phase in the column.  LiChroprep® RP-18 was suspended in methanol and 
poured into the column.  The stationary phase was made compact by  the continuous flow 
of solvent.  The fractions to be separated was dissolved in a small amount of solvent and 
added directly onto the compact stationary phase.   
For both methods, compounds were eluted by gradient elution.  Solvent was added 
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continuously and the polarity of solvent system was changed gradually to allow for best 
separation of compounds.  The fractions were collected in different volumes depending on 
the size of the column.  The collected fractions were then evaporated under reduced pressure 
using a rotary evaporator to remove excess solvent.  Guided by TLC results, fractions 
containing similar compounds were combined together for next round of separation.       
 
Cell culture 
A549 human non-small cell lung cancer cells were obtained from American Type 
Culture Collection (Rockville, MD) and cultured in F12 Ham Kaighn’s modification (F12K) 
medium supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT), 
10 mM HEPES (AppliChem, Darmstadt, Germany) and antibiotics (100 U/ml penicillin G 
and 100 µg/ml streptomycin; Invitrogen, Carlsbad, CA).  The cells were maintained at 37 °C 
in a 5% CO2 humidified incubator.   
 
Cell proliferation assay 
The effects of collected fractions or isolated compounds on the proliferation of A549 
cells were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay.  MTT is a tetrazolium salt which can be converted by mitochondrial 
dehydrogenases in living, metabolically active cells to dark blue formazan crystals (Denizot 
and Lang 1986; Carmichael et al. 1987).  These formazan crystals can be solubilized by 
isopropanol or other solvents.  The absorbance of the dissolved formazan is proportional to 
the number of viable cells over a wide range (Denizot and Lang 1986; Carmichael et al. 1987).  
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Generally, the more viable cells present, the more formazan crystals are formed, and thus the 
higher absorbance reading is measured (Denizot and Lang 1986; Carmichael et al. 1987).  
Therefore, the MTT assay offers a convenient method for quantitatively measuring cell 
viability.   
The MTT assay was performed in 96-well microplate.  5 × 103 A549 cells 
suspended in 100 µl of culture medium were seeded into each well and the plate was left to 
incubate overnight.  Dried fractions or pure compounds were reconstituted in DMSO at a 
stock concentration of 20 mg/ml and further diluted to the working concentrations for the 
experimental procedures.  DMSO was employed as a negative control in all experiments.  
After overnight incubation, the cells were treated with fresh medium containing the desired 
concentrations of fractions or pure compounds.  The plates were left to incubate for the 
indicated period of time, after which 11 µl of 5 mg/ml MTT dissolved in PBS was added into 
each well.  The plate was left to incubate for 4 hours to develop the dark blue formazan 
crystals.  The developed formazan crystals were then dissolved in 111 µl of solubilizing 
solution (stock composition: 125ml anhydrous isopropanol containing 10% Triton X-100 and 
0.1N HCl).  Absorbance was measured immediately at 590 nm using an automatic 
microplate reader (Tecan GENios, Salzburg, Austria).  The effect of various treatments on 
cell proliferation was expressed as percent cell viability compared with DMSO treated control 
cells set at 100%. 
MTT assays were also performed on pure compounds to determine the IC50 values.  
IC50 was obtained by plotting the percent cell viability values against a dose response curve 




2.3.1 Separation of alcoholic extracts into four fractions 
Sclerotia of Poria cocos (4 kg) were crushed and then extracted three times with 95% 
ethanol (12 liter) under reflux for 3 h.  The ethanol solution was combined and evaporated in 
vacuum to give a crude extract (18 g).  The crude extract was mixed with silica gel (particle 
size: 63-200 µm), and fractionated on silica (particle size: 40-63 µm) column chromatography 
[600 × 80mm internal diameter (i.d.)] by gradient elution using CHCl3 and CH3OH (100:0 → 
95:5 → 80:20, with methanol added at 1% gradient).  Fractions were collected, combined 
and subjected to further chromatography on a silica gel 60 column (600 × 80 mm i.d.) by step 
gradients of CHCl3–CH3OH (100:0 → 85:15).  The collected fractions were combined on 
the basis of their TLC characteristics to give four pooled fractions: A (1 g), B (3.6 g), C (4.12 
g), and D (1.85 g), listed in increasing order of polarity.  
The effects of these four fractions on proliferation of non-small cell lung cancer A549 
cells were evaluated using the MTT assay.  As shown in Figure 2.1, fraction B and C 
showed stronger inhibitory effects on A549 cell proliferation.  With a concentration of 30 
µg/ml, fraction B brought about a 50% decrease on cell viability of A549 cells after 72 h 
treatment.  Fraction C inhibited A549 cell proliferation to a similar extent at the 
concentration of 30 µg/ml.  In contract, fraction A and D exhibited weak cytotoxicity.  At 
30 µg/ml, fraction A only slightly reduced A549 cell viability to 80%.  Fraction D did not 
exert apparent cytotoxicity on A549 cells at all three concentrations tested.  Based on these 
observations, it was concluded that fractions B and C might contain potential anticancer 
compounds.  Therefore, fractions B and C were subjected to repeated column 
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Figure 2.1 Effects of four pooled fractions obtained from crude extract of Poria cocos against 
A549 cell proliferation.  A549 cells were treated with different concentrations (10, 30 and 100 
µg/ml) of fraction A-D for 72 h, respectively.  After treatment, MTT assay was performed to 
determine cytotoxicity of these fractions on A549 cells as detailed in Materials and methods.  
Columns, means of three experimental readings; bars, standard deviation.  
 
2.3.2 Isolation of pure compounds 
Fraction B (3.6 g) was subjected to reverse column chromatography on an Octadecyl 
Silane (ODS) column (500 g) with step gradient elution conducted with CH3OH–H2O (60:40 
→ 85:15), which gave rise to two subfractions: fraction B-a and B-b.  Both sub-fractions 
were taken into the next phase for further separation and isolation of active pure compounds.  
Fraction B-a was subjected to an ODS column chromatography with step gradient elution 
conducted with CH3OH–H2O (70:30 → 85:15) to give a pure compound (compound 1: 1.5 g) 
and a mixture of compounds.  The mixture was further fractionated on silica gel 60 column 
chromatography (500 × 40 mm i.d.) to give compounds 2 (43 mg) and 3 (7 mg), using 
isocratic elution with hexane-ethyl acetate-CH3OH (70:30:5).  Fraction B-b was subjected to 
chromatography on a silica gel 60 column (500 × 40mm i.d.), from which two pure 
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compounds, 4 (230 mg) and 5 (24 mg), were isolated with step gradient elution of 
CHCl3–CH3OH (98:2 → 93:7).  Fraction C (4.12 g) was subjected to chromatography on a 
silica gel 60 column (600 × 80 mm i.d.).  Step gradient elution was conducted with 
CHCl3–CH3OH (97:3 →85:15) to give 2 sub-fractions, fraction C-a and C-b.  Fraction C-a 
was subjected to an ODS column chromatography with step gradient elution conducted with 
CH3OH–H2O (55:45 → 70:30) to isolate compound 7 (80 mg).  Fraction C-b was 
fractionated on silica gel 60 column chromatography (500 × 40 mm i.d.) with isocratic elution 
of CHCl3–CH3OH (93:7) to give compounds 6 (110 mg) and 8 (28 mg).  A scheme was 




Figure 2.2 Schematic diagram illustrating the extraction schemes leading to isolation of 









































2.3.3 Identification of purified compounds 
The identification work was performed by Dr. Zhou Liang, Department of Pharmacy, 
NUS.  The chemical structures were determined using physical and spectroscopic tools 
including melting point (mp) measurement, nuclear magnetic resonance (NMR), mass 
spectrometry (MS) and infrared spectroscopy.  The eight purified compounds were 
identified as (1) pachymic acid, (2) dehydropachymic acid, (3) 
3-acetyloxy-16α-hydroxytrametenolic acid, (4) polyporenic acid C, (5) 
3-epi-dehydropachymic acid, (6) 3-epi-dehydrotumulosic acid, (7) tumulosic acid, and (8) 
29-hydroxypolyporenic acid.  The chemical structures of compounds 1-8 were presented in 
Figure 2.3.  The identification of compounds 1-7 was conducted by comparison of their 
physical and spectroscopic data (1H-, 13C-NMR and MS) with the corresponding compounds 
reported in the literature (Tai et al. 1995; Tai et al. 1995; Ukiya et al. 2002; Mizushina et al. 
2004).  A detailed discussion on steps undertaken leading to the identification of novel 
compound 8was published in the publication entitled “Cytotoxic and anti-oxidant activities of 
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(7) tumulosic acid                      (8) 29-hydroxypolyporenic acid 
 
 
Figure 2.3 Chemical structures of compounds 1-8 
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The physical and spectroscopic features of compounds 1-8 were listed below.  A 
summary of 13C-NMR spectral data was presented in Table 2.1.  The original 13C-NMR 
spectral of compounds 1-8 were provided in the Appendices.   
 
Pachymic Acid (1): White powder, mp 293-294 °C. ESI-MS m/z: 529 [M + H]+; 1H-NMR 
(300 MHz, Pyridine-d5) δ: 0.92 (3H, s, H-28), 0.94 (3H, s, H-29), 0.97 (3H, s, H-19), 0.99, 
1.01 (ea. 3H, d, J_6.5 Hz, H-26, H-27), 1.13 (3H, s, H-18), 1.49 (3H, s, H-30), 2.07 (3H, s, 
CH3CO), 2.27 (1H, m, H-25), 2.84 (1H, dd, J = 11, 5.5 Hz, H-17), 2.94 (1H, m, H-20), 4.54 
(1H, t, J = 6 Hz, H-16), 4.68 (1H, dd, J = 11, 4 Hz, H-3), 4.86, 4.99 (ea. 1H, s, H-31); 
13CNMR (75 MHz, Pyridine-d5); Table 2.1. 
 
Dehydropachymic Acid (2): White powder, mp 265-267 °C. ESI-MS m/z: 527 [M + H]+; 
1H-NMR (300 MHz, Pyr-d5) δ: 0.90 (3H, s, H-28), 0.99 (3H, s, H-29), 1.01 (3H, s, H-19), 
0.99, 1.01 (ea. 3H, d, J_6.5 Hz, H-26, H-27), 1.05 (3H, s, H-18), 1.50 (3H, s, H-30), 2.05 (3H, 
s, CH3CO), 2.30 (1H, m, H-25), 2.88 (1H, dd, J = 11, 5.5 Hz, H-17), 2.94 (1H, m, H-20), 
4.54 (1H, t, J = 6 Hz, H-16), 4.70 (1H, dd, J = 11, 4 Hz, H-3), 4.86, 4.99 (ea. 1H, s, H-31), 
5.34 (1H, d, J = 6 Hz, H-11), 5.59 (1H, br s, H-7); 13C-NMR (75 MHz, Pyr-d5); Table 2.1. 
 
3-Acetyloxy-16α-hydroxytrametenolic acid (3): White powder, mp > 300 °C. ESI-MS m/z: 
515 [M + H] +; 1H-NMR (300 MHz, Pyr-d5) δ: 0.90 (3H, s, H-28), 0.93 (3H, s, H-29), 0.96 
(3H, s, H-19), 1.13 (3H, s, H-18), 1.48 (3H, s, H-30), 1.60, 1.62 (ea. 3H, s, H-26, H-27), 2.05 
(3H, s, CH3CO), 2.80 (1H, dd, J = 11, 6 Hz, H-17), 2.94 (1H, m, H-20), 4.53 (1H, t, J = 6 Hz, 
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H-16), 4.70 (1H, dd, J = 11, 4 Hz, H-3), 5.35 (1H, br s, H-24); 13C-NMR (75 MHz, Pyr-d5); 
Table 2.1. 
 
Polyporenic Acid C (4): White needles, mp 261-263 °C. ESI-MS m/z: 483 [M + H] +; 
1H-NMR (300 MHz, Pyr-d5) δ: 1.06 (3H, s, H-28), 1.14 (3H, s, H-29), 1.14 (3H, s, H-19), 
0.99, 1.01 (ea. 3H, d, J = 6.5 Hz, H-26, H-27), 1.07 (3H, s, H-18), 1.46 (3H, s, H-30), 1.64 
(1H, m, H-5), 2.88 (1H, m, H-17), 2.94 (1H, m, H-20), 4.55 (1H, t, J_6Hz, H-16), 4.86, 4.99 
(ea. 1H, s, H-31), 5.37 (1H, d, J = 6 Hz, H-11), 5.60 (1H, d, J = 6 Hz, H-7); 13C-NMR (75 
MHz, Pyr-d5); Table 2.1. 
 
3-epi-Dehydropachymic Acid (5): White powder, mp 276-278 °C. ESIMS m/z: 527 [M + H] 
+; 1H-NMR (300 MHz, Pyr-d5) δ: 0.90 (3H, s, H-28), 0.93 (3H, s, H-29), 1.03 (3H, s, H-19), 
0.99, 1.01 (ea. 3H, d, J = 6.5 Hz, H-26, H-27), 1.07 (3H, s, H-18), 1.44 (3H, s, H-30), 1.75 
(1H, m, H-5), 2.86 (1H, dd, J = 11, 6 Hz, H-17), 2.94 (1H, m, H-20), 4.54 (1H, t, J = 6 Hz, 
H-16), 4.85 (1H, br s, H-3), 4.86, 4.99 (ea. 1H, s, H-31), 5.37 (1H, d, J = 6 Hz, H-11), 5.60 
(1H, br s, H-7); 13C-NMR (75 MHz, Pyr-d5); Table 2.1. 
 
3-epi-Dehydrotumulosic Acid (6): White powder, mp 236-239 °C. ESIMS m/z: 485 [M + H] 
+; 1H-NMR (300 MHz, Pyr-d5) δ: 1.19 (3H, s, H-28), 0.98 (3H, s, H-29), 1.11 (3H, s, H-19), 
0.99, 1.01 (ea. 3H, d, J = 6.5 Hz, H-26, H-27), 1.08 (3H, s, H-18), 1.43 (3H, s, H-30), 2.30 
(1H, m, H-25), 2.88 (1H, m, H-17), 2.94 (1H, m, H-20), 4.52 (1H, t, J = 6 Hz, H-16), 3.63 
(1H, br s, H-3), 4.85, 4.98 (ea. 1H, s, H-31), 5.47 (1H, d, J = 6 Hz, H-11), 5.64 (1H, br s, H-7); 
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13C-NMR (75 MHz, Pyr-d5); Table 2.1. 
 
Tumulosic Acid (7): White powder, mp 253-256 °C. ESI-MS m/z: 487 [M + H] +; 1H-NMR 
(300 MHz, Pyr-d5) δ: 1.01 (3H, s, H-28), 1.06 (3H, s, H-29), 1.14 (3H, s, H-19), 0.96, 0.98 
(ea. 3H, d, J = 6.5 Hz, H-26, H-27), 1.23 (3H, s, H-18), 1.47 (3H, s, H-30), 2.27 (1H, m, 
H-25), 2.84 (1H, dd, J = 11, 5.5 Hz, H-17), 2.94 (1H, m, H-20), 4.52 (1H, t, J = 6 Hz, H-16), 
3.43 (1H, t, J = 7 Hz, H-3), 4.86, 4.99 (ea. 1H, s, H-31); 13C-NMR (75 MHz, Pyr-d5); Table 
2.1. 
 
29-Hydroxypolyporenic Acid C (8): White powder, mp 255-258 °C. UV (MeOH) λmax nm: 
236, 244, 252; IR (KBr) νmax cm -1: 3400, 2960, 1710, 1675, 1642, 1380, 1100, 900; 
HR-ESI-MS m/z: 497.3265 [M + H] +; 1H-NMR (300 MHz, Pyr-d5) δ: 0.99, 1.01 (ea. 3H, d, J 
= 6.5 Hz, H-26, H-27), 1.07 (6H, s, H-18, H-28), 1.14 (3H, s, H-19), 1.42 (3H, s, H-30), 1.64 
(1H, m, H-5), 2.25 (1H, m, H-25), 2.86 (1H, m, H-17), 2.92 (1H, m, H-20), 3.59, 4.17 (each 
1H, d, J = 10.5 Hz, H-29), 4.53 (1H, t, J = 6 Hz, H-16), 4.86, 4.99 (ea. 1H, s, H-31), 5.44 (1H, 





Table 2.1 13C-NMR spectral data for compound 1-8 (75 MHz in C5D5N; δ in ppm) 
 
 
2.3.4 Cytotoxicity test 
The effects of the eight isolated compounds on A549 cell growth were evaluated 
using MTT assay.  As shown in Figure 2.4, all these compounds exhibited cytotoxicity on 
A549 cells after treatment for 72 h.  However, the cytotoxicity of dehydropachymic acid 
was relatively weak.  Although dehydropachymic acid at 20 µM caused reduction in cell 
viability to about 70%, further elevation of concentration did not manifest stronger 
cytotoxicity on A549 cells.  Even a high dose of 400 µM failed to reduce the viability of 
A549 cells below 50%.  As compared to dydropachymic acid, other seven compounds 
showed stronger antiproliferative effects, in particular polyporenic acid C exhibited the 
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greatest growth inhibitory effect.  These compounds generally inhibited A549 cell growth in 










































































































































Figure 2.4 Effects of compounds 1-8 on A549 cell proliferation.  In a 96-well plate, A549 
cells were exposed to compounds 1-8 with indicated concentrations for 72 h.  Relative cell 
viability was then determined by MTT assay as detailed in materials and methods.  Columns, 
means of two independent experiments repeated in triplicate; bars, standard deviation. 
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From the MTT data illustrated in Figure 2.4, IC50 values of these compounds were 
calculated using GraphPad software.  Table 2.2 lists the IC50 values of the eight isolated 
triterpenoids.   
 
Compound IC50 (µM) ± S.D. 
1  Pachymic acid 30.5 ± 9.7 
2  Dehydropachymic acid 194.3 ± 247.3 
3  3-Acetyloxy-16α-hydroxytrametenolic acid 44.3 ± 39.1 
4  Polyporenic Acid C 19.8 ± 5.2 
5  3-epi-Dehydropachymic Acid 24.0 ± 12.8 
6  3-epi-Dehydrotumulosic Acid 25.3 ± 9.2 
7  Tumulosic acid 
8  29-Hydroxypolyporenic acid C 
44.0 ± 1.2 
38.1 ± 19.9 
 
Table 2.2 IC50 values of compounds 1-8 against A549 cell growth.  IC50 values were 
calculated from 72 h-drug exposure MTT assays and expressed as mean ± standard deviation 
from two independent experiments repeated in triplicate.   
 
2.4 Discussion 
Previous studies on Poria cocos-originated triterpenoids had encouraged us to search 
for potential anticancer agents among these triterpenoids.  Since triterpenoids are mainly 
contained in the alcoholic extracts of Poria cocos, the sclerotia of Poria cocos was extracted 
with ethanol to obtain a mixture of triterpenoids.  The alcoholic extracts were subsequently 
separated into four fractions based on their TLC characteristics.  Fraction A and D did not 
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possess considerable cytotoxic effects on lung cancer A549 cells, which implied that these 
fractions might not be good sources for isolation of active anticancer agents.  Moreover, 
these two fractions also lacked cytotoxic effects on prostate cancer DU145 cells [as 
previously determined by Dr. Leslie Gapter, Department of Pharmacy, NUS; (Zhou et al. 
2008)].  By contrast, fraction B and C display stronger cytotoxic effects on A549 cells.  
Similar effects were also observed on DU145 cells in experiments performed by Dr. Gapter 
(Zhou et al. 2008).  These results suggested that fractions B and C might contain compounds 
with active anticancer properties.  Isolation work performed on fractions B and C resulted in 
the purification of a total of eight compounds, among which 29-dehydroxypolyporenic acid C 
was a novel lanostane-type triterpenoid.  Among these compounds, pachymic acid had the 
highest yield (1.5 g) and 3-acetyloxy-16α-hydroxytrametenolic acid had the lowest yield (7 
mg).  Considering the significantly higher yield of pachymic acid, it was deduced that it is 
the main triterpenoid present in Poria cocos.  The eight compounds isolated belonged to the 
lanostane type of triterpenoids and therefore shared structural resemblance to one another.  
These findings further supported the notion that lanostane-type triterpenoids are the main 
triterpenoid type in Poria cocos (Tai et al. 1995; Kaminaga et al. 1996; Zheng and Yang 2008; 
Zheng and Yang 2008).  Based on previous reports, the number of triterpenoids identified to 
be present in Poria cocos was more than eight.  However, due to limited time and resources, 
our isolation work had only focused on the compounds with relatively high abundance.  
Some minor spots did appear on TLC during the isolation process, but due to low abundance, 
were not further purified and identified.  As such, the possibility of discovering novel 
triterpenoids responsible for the minor spots might be missed.  In addition, some compounds 
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might possess highly similar polarity which would not allow them to be easily differentiated 
on TLC.  Therefore, the efficiency of separation and purification of these compounds with 
the use of column chromatography would be compromised.  With the advance in 
chromatographic techniques, it is reasonable to expect that more novel triterpenoids will be 
separated and identified from Poria cocos.  
With the exception of dehydropachymic acid, all the isolated compounds display 
moderate cytotoxic effects on A549 cells with IC50 values ranging from 20 to 45 µM.  The 
equipotencies in cytotoxicity registered by these compounds would indicate that the basic 
lanostane-type structure possibly contributed mainly to the anticancer activity of these 
compounds.  However, it remained unexplained for the much weaker antiproliferative 
activity of dehydropachymic acid.  Interestingly, the weak anticancer activity of 
dehydropachymic acid was also observed by Dr. Gapter on prostate cancer DU145 cells 
(Zhou et al. 2008).  Although much is still unknown about the structural-activity relationship 
of these lanostane-type triterpenoids, results demonstrating that these triterpenoids possess 
moderate cytotoxicity on human cancer cells had indeed suggested the anticancer potential of 
these triterpenoids.  The following chapters in this PhD thesis therefore focused on 








Chapter 3: Polyporenic acid C induces caspase-8-mediated apoptosis in human lung 
cancer A549 cells 
 
Summary 
In this chapter, we examined the apoptosis-inducing effect of polyporenic acid C (PPAC), one 
of the eight triterpenoids isolated from Poria cocos, on lung cancer cells.  PPAC was found 
to inhibit proliferation of small cell lung cancer H82 and H187 cells.  In addition, PPAC 
inhibited anchorage-dependent and –independent growth of non-small cell lung cancer A549 
cells, which was associated with increase in sub-G1 cell population, positive annexin V 
staining, and increase in cleavage of procaspase-8, -3 and PARP.  Apoptosis induced by 
PPAC was not accompanied by disruption of mitochondrial membrane potential nor an 
increase in procaspase-9 cleavage.  Moreover, PPAC-induced apoptosis was inhibited by 
specific caspase-8 inhibitor z-IETD-fmk and pan caspase inhibitor z-VAD-fmk, and not by 
specific caspase-9 inhibitor z-LEHD-fmk.  Taken together, the obtained results suggested 
that PPAC induced apoptosis through the death receptor-mediated apoptotic pathway where 
the activation of caspase-8 by PPAC had led to the direct cleavage of execution caspases 
without the involvement of mitochondria.  Furthermore, PPAC was shown to suppress 
PI3-kinase/AKT signal pathway and enhance p53 activation, implying the involvement of an 







Lung cancer is one of the most frequent and malignant cancers in the world.  In the 
United States, it has been estimated that there will be 219,440 new cases and 159,390 deaths 
from lung cancer in 2009 (Jemal et al. 2009).  Lung cancer is ranked as the second most 
common cancer among both men (15%) and women (14%) in the United States (Jemal et al. 
2009).  It is also the leading cause of cancer mortality for both men (30%) and women (26%) 
(Jemal et al. 2009).  According to histological characteristics, lung cancer can be classified 
into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).  NSCLC, 
which represents the vast majority of lung cancers, accounts for 80% of all lung cancer cases 
(Travis et al. 1995; Felip et al. 2007).  The prognosis for both types of lung carcinoma is 
poor, with overall 5 year survival rates varying from 8.9% in developing countries to 15% in 
the United States (Parkin et al. 2005).  The prevailing morbidity and poor prognosis of lung 
cancer highlight the importance of searching for new and effective agents against lung cancer.   
In the previous chapter, the isolation and identification of eight lanostane-type 
triterpenoids from Poria cocos was reported.  The anti-cancer activity of these compounds 
was tested on NSCLC A549 cells using MTT assay.  Among these compounds, PPAC 
showed the greatest cytotoxicity on A549 cells with an IC50 of 20 µM, thus indicating the 
potential of PPAC as an anticancer agent.  Although PPAC has been previously shown to 
possess anti-bacterial activity (Marcus 1952; Keller et al. 1996) and inhibit EBV-EA 
activation by TPA (Ukiya et al. 2002), its cytotoxic effects against cancer cells has not been 
well studied.  One study has suggested that PPAC inhibits DNA topoisomerases (Li et al. 
2004), however, its anticancer potency and mechanism of antitumor action remain elusive.  
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Therefore, in this chapter, the apoptosis-inducing effect of PPAC on A549 cells was 
determined.  Further studies conducted to achieve understanding of the mechanisms 
involved revealed the effect of PPAC on PI3-Kinase/AKT pathway and p53 protein.   
 
3.2 Materials and methods 
Reagents 
Vybrant Apoptosis Assay Kit and 3,3'-dihexyloxacarbocyanine iodide [DiOC6(3)] 
were purchased from Molecular Probes (Eugene, OR).  Antibody for actin (I-19) was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  Antibodies specific for 
phospho-p53 (Ser15), phospho-AKT (Ser473), cleaved caspase-3 (Asp175), cleaved 
caspase-8 (Asp374), caspase-9, cleaved PARP, phospho-JNK (Thr183/Tyr185), goat 
anti-rabbit IgG-conjugated to horseradish peroxidase (HRP), and goat anti-mouse 
IgG-conjugated to HRP were purchased from Cell Signaling Technology (Beverly, MA).  
Pan caspase inhibitor (z-VAD-fmk), caspase-8 inhibitor (z-IETD-fmk) and caspase-9 inhibitor 
(z-LEHD-fmk) were purchased from R&D Systems (Minneapolis, MN).  JNK-specific 
inhibitor, SP600125, was purchased from Biomol International LP (Plymouth Meeting, PA).   
 
Cell culture and treatment 
A549 human NSCLC cells were obtained from American Type Culture Collection 
(Rockville, MD) and cultured in F12 Ham Kaighn’s modification (F12K) medium 
supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT), 10 mM 
HEPES (AppliChem, Darmstadt, Germany) and antibiotics (100 U/ml penicillin G and 100 
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µg/ml streptomycin; Invitrogen, Carlsbad, CA).  Human SCLC cell lines H82 and H187 
were purchased from American Type Culture Collection and were maintained in RPMI-1640 
Medium from Sigma Aldrich supplemented with 10% fetal bovine serum, 10mM HEPES and 
antibiotics.  The cells were maintained at 37°C in a 5% CO2 humidified incubator.  PPAC 
was reconstituted in DMSO at a stock concentration of 20 mg/ml and further diluted with 
DMSO to the working concentrations for the experimental procedures.  DMSO was 
employed as a negative control at a final concentration ≤ 0.5% in all experiments.  
 
Cell proliferation assay 
The effect of PPAC on the proliferation of lung cancer cells (H82, H187 and A549 
cells) was determined using MTT assay as described in the “Materials and methods” section 
of chapter 2.  Briefly, 1 × 104 (for H82 and H187) or 5 × 103 (for A549) cells per well were 
plated in 96-well culture plates.  After overnight incubation, the cells were treated for 
different time points with fresh medium containing the desired concentrations of PPAC.  
Absorbance was measured at 590 nm using a microplate reader (Tecan GENios, Salzburg, 
Austria).  The effect of PPAC on cell viability was expressed as percent cell viability 
compared with vehicle treated control cells set at 100%.  
 
Soft agar assay 
The soft agar assay was performed to evaluate the ability of cells to grow in an 
anchorage-independent environment.  Agarose (ultra pure or low-melt) was autoclaved as a 
1.25% stock solution.  For the base layer, 0.5% agarose medium (Ham’s F12K medium 
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containing 10% FCS and 0.5% ultra pure agarose) was dispensed into each well of a 6-well 
plate and allowed to solidify.  The function of the base layer of agar medium was to prevent 
the attachment of cells to the culture plate.  To make the cell layer, A549 cells (1.5 × 104) 
were suspended in 0.33% agarose medium (Ham’s F12K medium containing 10% FCS and 
0.33% low-melt agarose) and mixed with DMSO or PPAC.  This mixture was then added 
over the base layer in each well.  The plates were incubated at 37°C under an atmosphere of 
5% CO2 for 3 weeks without further medium feeding.  To limit evaporative loss of water, 
the plates were wrapped loosely with parafilm.  Colonies ≥ 0.1 mm were enumerated under 
a light microscope at 20 x objective (Olympus CKX41, Tokyo, Japan).  Images were 
obtained using the Nikon Eclipse TE2000-U microscope (Nikon Corp., Tokyo, Japan). 
 
Propidium iodide staining assay 
To quantify PPAC-induced apoptosis, A549 cells were stained with propidium iodide 
(PI) and subjected to flow cytometric analysis.  The cells were treated with various 
concentrations of PPAC for the indicated time periods.  The floating and trypsinized 
adherent cells were pooled and the collected cell pellet was washed twice with PBS.  The 
cells were then fixed using ice-cold ethanol at -20°C for at least 30 min, followed by 
incubation with 0.5 mL of PI staining solution [0.1% (v/v) Triton X-100 in PBS containing 
200 µg/ml of RNase and 20 µg/ml of PI] at room temperature for 30 min.  Cell cycle 
distribution was analyzed by a CYAN-LX flow cytometer (DakoCytomation, Fort Collins, 
CO) equipped with Summit v4.3 software (DakoCytomation).  Cells with sub-G1 DNA (as 




A549 cells were analyzed for presence of apoptosis by annexin V-FITC labeling 
according to the manufacturer’s instructions (Vybrant Apoptosis Assay Kit [Molecular 
Probes]).  1.5 × 105 A549 cells in 2 ml media were seeded in each well of 6-well plates and 
maintained at 37°C in 5% CO2 humidified incubator.  Upon adherence, cells were incubated 
in fresh media with different concentrations of PPAC for the indicated time periods.  The 
floating and trypsinized adherent cells were pooled, pelleted and washed twice with PBS.  
The cell pellets were suspended in 100 µl of Annexin Binding Buffer provided by the 
manufacturer, and stained with 5 µl of Alexa Fluor® 488 annexin V and 1 µl of 100 µg/ml PI.  
After incubation at room temperature for 15 min, the cells were gently mixed with 400 µl of 
Annexin Binding Buffer and analyzed immediately by flow cytometry as described above in 
“Propidium iodide staining assay”.  The early apoptotic cells, which bind to annexin V-FITC 
and give a green fluorescence, are represented in the lower right quadrant of the histogram.  
The late apoptotic cells, which bind to both FITC and PI, give a red-green fluorescence and 
are represented in the upper right quadrant of the histogram.  For experiments involving 
caspase inhibitors, A549 cells were pretreated with the desired inhibitor for 1 h prior to 
treatment with PPAC. 
 
Analysis of mitochondrial membrane potential 
The mitochondrial membrane potential (ΔΨm) was analyzed by labeling A549 cells 
with DiOC6(3).  DiOC6(3) is a cationic lipophilic dye that can diffuse through the plasma 
membrane, enter the cytoplasm and finally accumulate inside the mitochondria matrix 
Chapter 3 
 106
(Korchak et al. 1982).  The accumulation of DiOC6(3) is driven by the ΔΨm and loss of this 
potential will lead to decreased retention of DiOC6(3) in the mitochondria (Korchak et al. 
1982).  Therefore, cells can be stained with DiOC6(3) to monitor the change in ΔΨm.  In 
our study, A549 cells were grown to semi-confluence in cell culture flasks and treated with 
DMSO or PPAC in fresh medium for the indicated time periods.  During the final 30 min of 
treatment, 40 nM of DiOC6(3) was added into the culture medium.  Cells were then washed 
twice in PBS containing 0.1% BSA (w/v), spun to a pellet, suspended in 500 µl of PBS/0.1% 
BSA, and analyzed by flow cytometry (DakoCytomation).  
 
Preparation of cell lysates 
Following desired treatment, medium containing detached cells was collected.  
Attached cells were collected by scraping using a rubber policeman.  Both attached and 
floating cells were pooled and pelleted by centrifugation.  The pellet was washed twice with 
cold PBS, and resuspended in an appropriate volume (0.1-0.5 ml, depending on size of cell 
pellet) of ice-cold lysis buffer (Cell Signaling Technology) containing freshly added protease 
inhibitors.  The lysis buffer was composed of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 
mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM 
beta-glycerophosphate, 1 mM Na3VO4 and 1 µg/ml leupeptin.  The protease inhibitors added 
were 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin and 5 µg/ml pepstatin A.  
After brief sonication on ice, cell lysates were centrifuged at 14, 000 × g for 15 min at 4°C to 
remove cell debris.  The supernatant was collected and protein content was quantified using 
a bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL) according to the 
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manufacturer’s instructions.  This protein assay was conducted using a 96-well plate.  200 
µl of BCA reaction solution was added to each well containing 20 µl of protein samples or 
different concentrations of BSA.  After incubation of the plate in 37°C for 30 min, 
absorbance values at 562 nm were measured using a microplate reader.  Protein 
concentration of cell lysates was calculated against BSA standard calibration curve. 
 
Western blot analysis 
Protein mixture in cell lysates was separated using SDS-PAGE based on their 
molecular size.  10% Resolving gel (solution formula for two gels: 9.6 ml distilled water, 5 
ml 40% acrylamide, 5 ml 1.5 M Tris pH 8.8, 200 µl 10% SDS, 200 µl 10% ammonium 
persulfate and 8 µl TEMED) and 5% stacking gel (solution formula for two gels: 7.25 ml 
distilled water, 1.25 ml 40% acrylamide, 1.25 ml 1 M Tris pH 6.3, 100 µl 10% SDS, 100 µl 
10% ammonium persulfate and 8 µl TEMED) were used to cast gels for the separation 
process.  A 10 or 15-well comb was used to create wells for sample loading.  Cell lysates 
containing equal amount of proteins were diluted with 1:1 Laemmli sample buffer [62.5 mM 
Tris HCl (pH 6.8), 2% SDS, 25% glycerol, 0.01% (w/v) bromophenol blue, 5% 
2-mercaptoethanol], and boiled at 100°C for 10 min.  The samples were then loaded into 
wells in the stacking gel.  The proteins were separated by 10% resolving gel under constant 
current of 40 mA using running buffer containing 25 mM Tris, 192 mM glycine and 0.1% 
SDS.   
After separation of proteins by SDS-PAGE, the proteins were transferred to a 
polyvinylidene fluoride membrane (Millipore, Bedford, MA) under constant voltage of 25 V 
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at 4°C for overnight using blotting buffer containing 25 mM Tris, 192 mM glycine, 0.1% 
SDS and 20% methanol.  The transblotted membrane was blocked with 5% (w/v) non-fat 
milk in TBS-T (113 mM NaCl, 25 mM Tris HCl with 0.05% Tween 20) at room temperature 
for 1 h, and then incubated with the primary antibody for 2 h at room temperature.  After 
washing the membrane with TBS-T for three times, appropriate secondary antibody was 
added onto the membrane to incubate at room temperature for 1 h.  Prior to antibody 
visualization using the enhanced chemiluminescence system, the membrane was rinsed in 
TBS-T for three times to remove excess secondary antibody.  The antibody/protein 
complexes were visualized by enhanced chemiluminescence (Perkin-Elmer, Boston, MA) and 
digital images were obtained by scanning X-ray film (Eastman Kodak, Rochester, NY) or 
were captured directly using the FluorChem™ 9900 (Alpha Innotech, San Leandro, CA). 
 
Statistical analysis 
Statistical significance between treatment and control groups were analyzed using a 











3.3.1 Inhibitory effect of PPAC on the proliferation of lung cancer cells 
In the previous chapter, PPAC was shown to inhibit A549 cell growth after 72 h 
treatment.  To further evaluate the antiproliferative effect of PPAC, MTT assay was 
conducted to determine the viability of A549 cells at three different time points of PPAC 
treatment (24, 48 and 72 h).  As shown in Figure 3.1, treatment of A549 cells with 0-200 µM 
of PPAC resulted in dose-dependent inhibition of cell growth at all three time points.  
Significant inhibition was observed with 20 µM PPAC treatment, and at 60 µM, relative cell 
viability had decreased to below 40% at all time points (Figure 3.1).  These data thus 
indicated that PPAC effectively inhibited NSCLC A549 cell proliferation. 
  
Figure 3.1 PPAC decreased the cell viability of human NSCLC A549 cells in a 
dose-dependent manner.  Following PPAC treatment, A549 cell viability was determined 
by MTT assay as detailed in Materials and Methods.  Columns, means of three independent 
experiments repeated in triplicate; bars, standard deviation.  * p < 0.05; ** p < 0.01 
 
To examine whether the growth inhibitory effect of PPAC was selective to a specific 
cell line, its possible antiproliferative effect was tested on two other lung cancer cell lines.  
H82 and H187 SCLC cells were selected for investigation.  As shown in Figure 3.2, 
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treatment of H82 with PPAC for 72 h resulted in decrease in cell viability at high 
concentrations of ≥ 60 µM, whereas viability of H187 cells began to decrease 
dose-dependently at a PPAC concentration of 6 µM.  These results indicated that H187 cells 
were more sensitive to PPAC treatment than H82 cells.  In addition, the growth inhibitory 
effect on H187 cells by PPAC was observed to be comparable to that exerted on A549 cells.  
These results therefore showed that PPAC was not only effective in inhibiting NSCLC A549 













































Figure 3.2 Effect of PPAC on the proliferation of SCLC H82 and H187 cells.   
Following treatment of H82 or H187 cells with PPAC for 72 h, cell viability was determined 
using MTT assay as detailed in Materials and Methods.  Columns, means of two 
independent experiments repeated in triplicate; bars, standard deviation.  * p < 0.05 
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3.3.2 Inhibitory effect of PPAC on colony formation of A549 cells 
Cancer cells have a unique ability to form colony in anchorage-independent 
conditions (Hanahan and Weinberg 2000).  Comparing with monolayer cell growth studies 
such as MTT assay, the three-dimensional anchorage-independent growth of cancer cells 
mimics more closely the in vivo growth of tumor cells in a solid tumor (Agre and Williams 
1983).  Soft agar assay, which can be used to study anchorage-independent cell growth, 
therefore provides a more biologically relevant method to assess the anticancer activity of a 
compound (Agre and Williams 1983).  The possible effect of PPAC against colony 
formation was investigated using soft agar assay.  As shown in Figure 3.3A, 6 and 20 µM of 
PPAC significantly reduced the number of colonies formed by A549 cells from 70 (untreated) 
to 43 and 16 respectively.  In the soft agar plates treated with higher doses of 60 or 200 µM 
PPAC, no colonies larger than 0.1 mm could be observed, suggesting that PPAC completely 
inhibited A549 colony formation in these concentrations.  Notably, PPAC treatment not only 
effectively decreased the number of formed colonies, but also reduced the colony size.  The 
colonies formed in PPAC-treated plates were generally smaller than those in control plates.  
Figure 3.3B shows a typical image obtained from plates treated with PPAC or DMSO control.  
The remarkable inhibitory effect of PPAC on A549 colony formation further affirmed the 


































Figure 3.3 PPAC reduced colony formation of A549 cells.  (A) Colony formation ability 
of A549 cells was determined using soft agar assay as described in Materials and methods.       
Columns, means of number of colonies ≥ 0.1 mm from two independent experiments; bars, 
standard deviation.  (B) Representative image of colony formation of A549 cells to illustrate 
the reduction in colony size by PPAC.   
 
3.3.3 Induction of apoptosis in A549 cells by PPAC 
To determine if PPAC suppressed A549 cell proliferation through induction of 
apoptosis, PPAC-treated cells were examined using two approaches.  In the first approach, 
PPAC-treated cells were incubated with PI and analyzed for sub-G1 staining.  For cells 
undergoing apoptosis, the DNA content is low due to loss of small fragmented DNA 
(Darzynkiewicz et al. 1992).  By labeling DNA with PI, the low DNA content can be 
detected using flow cytometric analysis.  Sub-G1 population represents cells with decreased 
PI staining and thus represents apoptotic cells.  As shown in Figure 3.4A, the cell population 
in sub-G1 (R1) increased time-dependently from 2% to 47% within 48 h following 60 µM 
DMSO PPAC 6 µM PPAC 20 µM PPAC 60 µM PPAC 200 µM 
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PPAC treatment.  PPAC also induced apoptosis after 48 h treatment in a dose-dependent 
manner, as shown by the increased fraction of sub-G1 cells from 5% to 51% when cells were 






Figure 3.4 PPAC induced apoptosis in A549 cells as evaluated by sub-G1 analysis.  
A549 cells were stained with PI and analyzed by flow cytometry after treatment with 60 µM 
of PPAC for 0, 10, 24 or 48 h (A) or with 0, 20, 60 or 80 µM of PPAC for 48 h (B).  Sub-G1 
values in (A) and (B) were represented by the percentage of cells in R1 region.  Data is 
representative of a single experiment repeated on three different occasions with similar 
results. 
 
To ascertain that PPAC indeed induced apoptosis, an alternative approach was 
adopted whereby A549 cells were stained with annexin V-FITC and PI using an apoptosis 
assay kit.  In apoptotic cells, the phospholipid asymmetry of the plasma membrane is lost 
and phosphatidylserine (PS) is translocated from the inner to the outer cell membrane 
(Bratton et al. 1997).  The exposed PS is recognized and bound by FITC-conjugated annexin 
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V.  Apoptotic cells were counted as early and late apoptotic cells, which are detected 
respectively in the lower right (R5) and upper right region (R3) of the histograms (Figure 
3.5A and 3.5B).  As depicted in Figure 3.5A, 24 h treatment with PPAC resulted in a 
dose-dependent increase in the number of apoptotic cells in both the early and late stages of 
apoptosis: vehicle control (5.6%), 60 µM (20.8%), 100 µM (33.8%).  Prolonged treatment 
involving 48 h treatment with 60 and 100 µM PPAC increased apoptotic fractions to 30.9% 
and 93.9% respectively (Figure 3.5B).  Taken together, the obtained results suggested that 











Figure 3.5 PPAC induced apoptosis in A549 cells as evaluated by annexin V labeling 
assay.  A549 cells were exposed to 0, 60 or 100 µM of PPAC for 24 h (A) or 48 h (B) and 
stained with the reagents in the Vybrant Apoptosis Assay Kit, followed by flow cytometric 
analysis.  The percentage of early apoptotic or late apoptotic cells is designated by the value 
at the lower right or upper right quadrant.  Data is representative of a single experiment 
repeated on three different occasions with similar results. 
 
3.3.4 Activation of the caspase-8-mediated apoptotic pathway by PPAC 
To investigate the involvement of caspases in PPAC-induced apoptosis, experiments 
were carried out to assess whether PPAC treatment could activate initiator caspase-8 and -9, 
and the executioner, caspase-3.  As shown in Figure 3.6, treatment of A549 cells with 60 µM 
of PPAC resulted in caspase-8 and caspase-3 cleavage, but not that of caspase-9.  Cleavage 
of the caspase-3 substrate, PARP, also correlated with caspase-3 activation (Figure 3.6).  
These results implied that PPAC was likely to induce apoptosis in A549 cells through 
activation of caspase-8. 
 
 
Figure 3.6 PA induced cleavage of caspase-8, caspase-3 and PARP.  Following 24 h 
treatment of A549 cells with 60 µM PPAC or vehicle control, total cell protein was extracted, 
resolved using SDS-PAGE, and immunoblotted with the indicated antibodies.  The analysis 
was repeated three times with similar results and a representative immunoblot is shown.   
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To further confirm the essential role of caspase activation in PPAC-induced apoptosis, 
caspase inhibitors were used to determine whether cells could be protected from apoptosis.  
The results presented in Figure 3.7 lent support to a caspase-8-dependent apoptotic signaling 
pathway: the apoptotic fractions (including early and late apoptosis) were 4.3% and 25.5% in 
the control and PPAC-treated cells respectively, as compared to an apoptotic cell population 
of 5.1% and 6.4% in the group of cells coincubated with PPAC and pan caspase inhibitor 
z-VAD-fmk, or PPAC and caspase-8 inhibitor z-IETD-fmk.  In contrast, the caspase-9 
inhibitor, z-LEHD-fmk, failed to block PPAC-induced apoptosis, where the apoptotic cell 
population of 28.9% was comparable to that of PPAC only-treated cells (Figure 3.7). 
Consistent with the flow cytometry data, pretreatment with the caspase-8 inhibitor 
z-IETD-fmk, but not the caspase-9 inhibitor z-LEHD-fmk, prevented the cleavage of PARP 
by PPAC as determined using immunoblot analysis (Figure 3.8).  Collectively, these 






Figure 3.7 Effect of caspase inhibitors on PPAC-induced apoptosis.  A549 cells were 
treated with vehicle control, 60 µM of PPAC for 24 h, or pretreated with 50 µM of pan 
caspase inhibitor z-VAD-fmk, 50 µM of caspase-8 inhibitor z-IETD-fmk or 50 µM of 
caspase-9 inhibitor z-LEHD-fmk for 1 h prior to treatment with 60 µM PPAC for 24 h.   
Treated cells were stained with the reagents in the Vybrant Apoptosis Assay Kit, followed by 
flow cytometric analysis.  The percentage of early apoptotic and late apoptotic cells is 
designated by the value at the lower right and upper right quadrant respectively.  The 
analysis was repeated in three times with similar results and a representative flow cytometric 


















Figure 3.8 Effect of caspase inhibitors or JNK inhibitor on PPAC-induced PARP 
cleavage.  A549 cells were pretreated with 50 µM of caspase-8 inhibitor z-IETD-fmk, 50 
µM of caspase-9 inhibitor z-LEHD-fmk or 20 µM of JNK inhibitor SP600125 for 1 h, 
followed by treatment with 60 µM PPAC for another 24 h.  Total cellular protein was 
extracted, resolved using SDS-PAGE, and immunoblotted with the indicated antibodies.  
The analysis was repeated three times with similar results and a representative immunoblot is 
shown. 
 
3.3.5 Mitochondrial membrane potential (ΔΨm) was not disrupted by PPAC 
Caspase-8 has been demonstrated to activate caspase-3 either directly or indirectly 
through a mitochondria-mediated pathway.  In the latter case, Bid is truncated by caspase-8, 
leading to the translocation of Bid from the cytosol to the mitochondria where it disrupts the 
ΔΨm via binding to other Bcl-2 family members and triggers cytochrome c, Apaf-1 and 
procaspase-9 (Li et al. 1998).  Therefore, to determine whether PPAC induced apoptosis in a 
mitochondrial-dependent or independent manner following caspase-8 activation, the effect of 
PPAC on the ΔΨm was evaluated.  In the experiment, A549 cells were labeled with the 
cationic lipophilic dye DiOC6(3), which accumulates within mitochondria in a 
potential-dependent manner (Korchak et al. 1982).  Upon disruption of the ΔΨm, the 
intracellular DiOC6(3) fluorescence signal would decrease due to the impaired function of 
cells to retain DiOC6(3).  Treatment of A549 cells with PPAC for both 24 h and 48 h (20, 60 
and 100 µM) did not result in any decrease in the ΔΨm (Figure 3.9).  Interestingly, pachymic 
Chapter 3 
 119
acid, a structurally related lanostane-type triterpenoid from Poria cocos that was among the 
eight purified and isolated triterpenoids, caused a dose- and time-dependent decrease in 
DiOC6(3) fluorescence intensity in A549 cells (Figure 3.9).  The results concluded that 
unlike pachymic acid, PPAC induced apoptosis via a mechanism independent of the 
mitochondria and therefore did not bring about a disruption of the ΔΨm.  This finding was 
consistent with the observations that PPAC did not activate caspase-9 and inhibition of 
caspase-9 using caspase-9 inhibitor z-LEHD-fmk failed to protect A549 cells from 
PPAC-induced apoptosis (Figure 3.6, 3.7 and 3.8).  Taken together, the data indicated that 
PPAC induced apoptosis in NSCLC cells through caspase-8-driven proteolysis and direct 





Figure 3.9 PPAC failed to affect ΔΨm while pachymic acid caused disruption of ΔΨm in a 
dose- and time-dependent manner.  A549 cells were stained with DiOC6(3) and subjected 
to flow cytometric analysis after exposure to 0, 20, 60 or 100 µM of PPAC or pachymic acid, 
respectively for 24 h and 48 h as detailed in Materials and Methods.  Measured relative 
DiOC6(3) dye intensity in A549 cells after treatment with PPAC or pachymic acid for 24 h 
and 48 h was presented in the corresponding bar chart.  Columns, means of three 
independent experiments; bars, standard deviation. * p < 0.05, versus vehicle-treated control 
group 
 
3.3.6 PPAC-induced apoptosis was not blocked by JNK inhibitor SP600125  
Recent studies suggest that activation of JNK may lead to caspase-8 activation (Deng 
et al. 2003; Zou et al. 2004).  To investigate the involvement of JNK in PPAC-induced 
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apoptosis, protein expression of the active form of JNK (phosphorylated JNK) was analyzed 
by western blot.  Sustained activation of JNK in A549 cells following PPAC treatment was 
observed (Figure 3.10).  To investigate whether JNK activation is necessary for 
PPAC-induced apoptosis, the effect of PPAC on PARP cleavage in presence of the 
JNK-specific inhibitor SP600125 was examined.  As shown in Figure 3.8, SP600125 did not 
inhibit PPAC-induced cleavage of PARP.  The results therefore indicated that inhibition of 




Figure 3.10 Effect of PPAC on JNK activation.  A549 cells were treated with 60 µM 
PPAC for 0, 3, 6 and 24 h and immunoblotted with antibody specific for phosphorylated JNK. 
   
 
3.3.7 Inhibition of Akt activation by PPAC 
The PI3-kinase/Akt signal pathway plays a critical role in controlling cell survival 
and apoptosis.  Activation of Akt may promote cancer cell survival by inhibiting apoptosis 
through its phosphorylation on multiple downstream targets (Vivanco and Sawyers 2002).  
The tumor suppressor, PTEN, has been shown to negatively regulate the PI3-kinase/Akt 
signal pathway (Maehama and Dixon 1998; Vivanco and Sawyers 2002).  To determine the 
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potential involvement of the Akt pathway in PPAC-induced apoptosis, the phosphorylation 
status of Akt in PPAC-treated A549 cells was analyzed by western blot.  As shown in Figure 
3.11, Akt phosphorylation level was dramatically reduced by PPAC treatment, whereas total 
Akt protein expression remained unchanged.  Furthermore, PPAC treatment enhanced the 
phosphorylation of PTEN (Figure 3.11), which is believed to stabilize PTEN and increase its 
biological activity (Torres and Pulido 2001).  These results indicated that PPAC might 
induce apoptosis in A549 cells through downregulation of Akt activity. 
 
3.3.8 Modulation of p53 activation by PPAC 
Tumor suppressor protein p53 is activated by cellular stress induced by a variety of 
stimuli including chemotherapeutic drugs (Ljungman 2000).  A549 cells are known to 
express wide-type p53 (Lehman et al. 1991).  To determine whether exposure of A549 
NSCLC cells to PPAC triggered p53 activation, we analyzed the phosphorylation status of 
this protein at serine 15.  As shown in Figure 3.11, PPAC enhanced p53 activation in A549 
cells as evident from the observed increase in band intensity of phosphorylated p53.  These 
results therefore indicated that PPAC treatment brought about activation of the p53 stress 








Figure 3.11 PPAC treatment suppressed Akt activation and increased the activation of 
p53.  A549 cells were treated with 60 µM PPAC for 24 h and immunoblotted with 
antibodies specific for phosphorylated PTEN, total Akt, phosphorylated Akt and 
phosphorylated p53, respectively.  The analysis was repeated three times with similar results, 




In this chapter, PPAC was demonstrated to be a potent inhibitor of human lung cancer 
proliferation.  PPAC not only reduced the viability of NSCLC A549 cells, but also inhibited 
SCLC cell proliferation of H82 cells and H187 cells.  The results had thus indicated that 
PPAC possessed antiproliferative activity on both NSCLC and SCLC types of lung cancer.  
More importantly, a decrease in the colony-forming ability of A549 cells was observed 
following PPAC treatment in the soft agar assay, implying that PPAC inhibited 
anchorage-independent growth of A549 cells over a long period of time (three weeks).  The 
three dimensional growth and relatively long period of culture spanning over weeks allow the 
soft agar assay to mimic more closely the in vivo growth of cancer cells in a solid tumor as 
compared to cell viability MTT assay that is employed to assess growth of monolayer of 
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cancer cells (Agre and Williams 1983).  Indeed, the sensitivities of the colony formation 
assay to certain anticancer drugs have been found to agree with the drug sensitivities of the 
same tumors in vivo (Agre and Williams 1983).  Therefore, based on the results obtained 
from the soft agar assay, it would be reasonable to postulate that PPAC might be effective for 
lung cancers in vivo.   
Resistance to apoptosis is implicated in the etiology of many cancer types, including 
lung cancer (Shivapurkar et al. 2003).  Drugs which promote apoptosis in cancer cells may 
be effective for cancer treatment (Fesik 2005).  PPAC treatment was observed to cause cell 
shrinkage and rounding under the microscope, indicating occurrence of apoptosis in A549 
cells.  Moreover, PPAC treatment increased the fraction of sub-G1 cells and binding of 
annexin V to treated cells, which strongly implied that PPAC-induced growth inhibition of 
A549 cells was mainly due to enhanced apoptosis. 
The activation of the caspase family of proteolytic enzymes plays an important role in 
apoptosis triggered by pro-apoptotic stimuli (Thornberry and Lazebnik 1998).  To 
investigate if the caspase cascade was indeed involved in PPAC-induced apoptosis, the 
activation of caspases was examined by monitoring their cleavage using immunoblotting 
analysis.  Results showed that PPAC treatment cleaved caspase-3 into the active enzyme 
fragments (19 kDa and 17 kDa).  As a critical executioner of apoptosis, capsase-3 is either 
partially or totally responsible for the proteolytic cleavage of many key proteins such as the 
nuclear enzyme PARP (Fernandes-Alnemri et al. 1994; Affar et al. 2001).  The 
accompanying appearance of a typical 89 kDa PARP cleavage product, a hallmark of 
apoptosis (Lazebnik et al. 1994), further confirmed the proteolytic activity of caspase-3.  To 
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further confirm the dependence of caspase activation in PPAC-induced apoptosis, cells 
coincubated with a pan-caspase inhibitor and PPAC were assessed for degree of apoptosis.  
Results obtained had indeed demonstrated the effective suppression of PPAC-induced 
apoptosis by z-VAD-fmk (pan-caspase inhibitor), thus ascertaining the induction of apoptosis 
in A549 cells via caspase activation by PPAC.    
As discussed in Chapter 1, the induction of apoptosis can be mediated through two 
different pathways: the death receptor-mediated extrinsic pathway and the 
mitochondria-meditated intrinsic pathway (Hengartner 2000).  Results obtained from flow 
cytometric and western blot analysis showed that PPAC induced apoptosis through activation 
of caspase-8, indicating the involvement of death receptor-mediated extrinsic apoptotic 
pathway.  Activation of the death receptor-mediated apoptotic signaling pathway by 
triterpenoids is not uncommon.  The naturally occurring triterpenoid, 
acetyl-keto-β-boswellic acid (Lu et al. 2008), and the synthetic triterpenoid CDDO-Me (Zou 
et al. 2004) have been previously reported to induce apoptosis through the extrinsic apoptotic 
pathway.  
Apoptosis can be promoted by caspase-8 through direct proteolytic cleavage of 
execution caspases or indirect mediation of mitochondrial damage (Schulze-Osthoff et al. 
1998).  Based on the previous finding that pachymic acid, also a lanostane-type triterpenoid 
from Poria cocos, had induced apoptosis in prostate cancer cells through the 
mitochondria-mediated pathway (Gapter et al. 2005), it was hypothesized that mitochondrial 
damage might be involved following activation of caspase-8 by PPAC in A549 cells.  
Surprisingly, in contrast to pachymic acid, PPAC did not bring about disruption of the 
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mitochondrial membrane potential.  Therefore, our results indicated that PPAC-induced 
activation of caspase-8 had directly led to the activation of effector caspase caspase-3 without 
the relay of the mitochondria.  The findings clearly showed that PPAC and pachymic acid 
prevented cell growth and induced apoptosis by distinct mechanisms despite their similar 
chemical structures.  Due to the current limited understanding of structure-activity 
relationship involving this class of triterpenoids, it remained unclear how PPAC, which 
differs from pachymic acid by having an extra double bond in the planar ring system and an 
oxo instead of an acetyloxy group at the C3 position, could elicit such a different mechanism 
of induction of apoptosis.   
The JNK cascade is activated in response to a variety of cellular stresses including 
ultraviolet radiation, cytotoxic drugs and pro-inflammatory cytokines (Deng et al. 2003).  
The role of JNK in apoptosis remains controversial.  Several reports indicate that activation 
of JNK contributes to death receptor-mediated apoptosis (Deng et al. 2003; Zou et al. 2004; 
Lu et al. 2008), whereas other studies suggest that JNK is dispensable (Tournier et al. 2000; 
Stadheim et al. 2002).  Given that some triterpenoids might induce apoptosis in human 
cancer cells through JNK-mediated up-regulation of death receptors (Stadheim et al. 2002; 
Zou et al. 2004), it was questioned whether JNK was activated by PPAC and contributed to 
apoptosis.  Although JNK was activated following PPAC treatment, the specific JNK 
inhibitor, SP600125, did not prevent PPAC-induced apoptosis.  It therefore appeared that 
JNK activation was not required for PPAC-induced apoptosis in A549 cells. 
Apoptosis is tightly controlled by anti-apoptotic and pro-apoptotic molecules. 
PI3-kinase/Akt signaling is one of the most important pathways in regulating cancer cell 
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survival (Vivanco and Sawyers 2002).  Activated Akt signaling in cancer cells inhibits 
apoptosis by phosphorylation of downstream substrates, such as BAD and Bcl-2, which are 
involved in the regulation of the intrinsic apoptotic pathway (Vivanco and Sawyers 2002).  
Furthermore, Akt also inhibits the death receptor-mediated apoptosis pathway through 
up-regulation of c-FLIP expression (Panka et al. 2001).  As an anti-apoptotic protein, c-FLIP 
blocks apoptosis induced by the oligomerization of the adapter protein and therefore 
functions as a caspase-8 dominant negative (Panka et al. 2001).  Targeting the 
PI3-kinase/Akt signaling pathway has been reported to be an effective strategy for the 
treatment of lung cancer (Crowell and Steele 2003).  In the experiments, PPAC treatment 
decreased activation of Akt and increased the stability of PTEN in A549 cells.  Based on 
these results, it was therefore postulated that the down-regulation of Akt activity might 
decrease c-FLIP expression, which would in turn cause the activation of caspase-8.  The 
suppression of Akt activity by PPAC might be one of the essential mechanisms of 
PPAC-induced apoptosis.  However, it remains to be elucidated whether Akt inhibition 
would solely or in combination with other factors contribute towards PPAC-induced 
apoptosis.   
Apart from the down-regulation of pro-survival Akt, an up-regulation of 
pro-apoptotic p53 by PPAC was also observed.  The p53 tumor suppressor protein mediates 
the response to various stress signals to suppress cell growth, either through cell cycle arrest 
or induction of apoptosis (Ljungman 2000).  An increase in phosphorylated p53 (ser 15) 
protein by PPAC treatment in A549 cells was detected.  Phosphorylation of p53 at serine 15 
is known to up-regulate the level of p53 by reducing the interaction between p53 and its 
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negative regulator, MDM2 (Shieh et al. 1997).  Therefore, increased phosphorylation of p53 
might favor cellular apoptosis.  However, further studies would be needed to clarify the 
precise contribution of p53 in PPAC-induced apoptosis. 
In conclusion, PPAC was demonstrated to suppress lung cancer cell proliferation and 
reduce colony formation of A549 cells.  In addition, PPAC induced apoptosis in A549 cells 
via activation of caspase-8.  The involvement of PPAC-induced inhibition of Akt activation 


















Chapter 4 Inhibition of A549 cell growth and modulation of arachidonic acid 
metabolism by pachymic acid 
 
Summary 
In this chapter, the anticancer activity of pachymic acid (PA) against lung cancer was 
evaluated by examining its antiproliferative and apoptosis-inducing effect on NSCLC A549 
cells.  The effects of non-toxic doses of PA on arachidonic acid metabolism in A549 cells 
were also investigated.  Results showed that PA (1) inhibited anchorage-dependent and 
-independent A549 cell growth in a concentration-dependent manner, (2) induced apoptosis 
and disrupted mitochondrial membrane potential in A549 cells, and at non-lethal levels (3) 
decreased IL-1β-induced activation of cPLA2 and COX-2, (4) suppressed IL-1β-induced 
activation of MAPKs, as well as (5) inhibited IL-1β-stimulated NF-κB signaling pathways.  
Based on the obtained results, it was postulated that inhibition of arachidonic acid metabolism 
by PA was mediated in part by its inhibition of MAPKs and NF-κB signaling pathways.  The 
findings revealed a multi-factorial anticancer property of PA toward lung cancers: at high 
concentrations, PA exerted cytotoxicity on cancer cells by inducing apoptosis through 
mitochondria-mediated pathway; whereas at nontoxic concentrations, it reduced 
prostaglandin formation by inhibiting both arachidonic acid release and its subsequent 
conversion to prostaglandin E2.  In view that arachidonic acid metabolism plays an 
important role in promoting cancer development, these findings highlighted the 





As described in Chapter 2, among the triterpenoids isolated from Poria cocos, 
pachymic acid (PA) was purified with the greatest yield of 1.5 g.  Thus, it was concluded 
that PA could be the main triterpenoid contained in Poria cocos.  Previous work from the 
laboratory has shown that PA is an effective inducer of apoptosis in prostate cancer cells 
(Gapter et al. 2005).  Together with the finding that PA also prevents skin cancer formation 
in a two-stage carcinogenesis mouse model (Kaminaga et al. 1996), it was hypothesized that 
PA might exhibit anticancer effects against other cancer types.  Therefore, our study on PA 
was extended to examination of its effect against human lung cancer.   
Several enzymes involved in eicosanoid production including COX-2 and some PLA2 
have been linked to the carcinogenesis of lung and other cancers (Marks et al. 2000; Meyer et 
al. 2004; Mao et al. 2005).  There are three major classes of PLA2, including sPLA2, iPLA2 
and cPLA2.  PLA2 family of enzymes catalyze the rate-limiting hydrolysis of arachidonic 
acid, and released arachidonic acid is subsequently converted by COX enzymes (COX-1 and 
COX-2) to prostaglandins (Balsinde et al. 2002).  In human and animal studies, several lines 
of evidence indicate that cPLA2 and COX-2 could be involved in lung tumor development.  
Firstly, production of arachidonic acid metabolites is higher in cancerous lung tissue relative 
to normal tissue (Hida et al. 1998; Hosomi et al. 2000).  Secondly, decreased lung 
tumorigenesis is observed in mice genetically deficient in cPLA2.  Thirdly, high expression 
levels of COX-2 are frequently associated with lung cancer development (Hosomi et al. 2000; 
Campa et al. 2004).  Fourthly, treatment with COX-2 inhibitors (NSAIDs such as aspirin and 
indomethacin), which inhibit prostaglandin E2 (PGE2) synthesis by COX-2, has been shown 
Chapter 4 
 131
to inhibit lung carcinogenesis in animal lung tumor models (Campa et al. 2004).  Taken 
together, these findings suggest that modulation of AA metabolism by inhibiting cPLA2 and 
COX-2 enzymes may be an effective strategy for chemoprevention and/or chemotherapy of 
lung and other cancers. 
PA has been shown to inhibit TPA-induced tumor promotion in a two-stage 
carcinogenesis model in mouse skin (Kaminaga et al. 1996).  However, the mechanism 
underlying this observed chemopreventive effect of PA is not known.  PA has also been 
demonstrated to possess anti-inflammatory effects by several independent studies (Giner et al. 
2000; Akihisa et al. 2007).  In particular, Cuella et al had demonstrated the inhibitory effect 
of PA against PLA2 (Cuella et al. 1996).  However, a shortcoming of this study is that the 
data was obtained from a cell-free assay using snake venom-originated PLA2, and the 
inhibition was only observed at high PA doses.  As such, the effect of PA on human PLA2 
(that is cPLA2) at biologically relevant levels has not been evaluated.  Furthermore, how PA 
modulates downstream signals of arachidonic acid release also remains largely unknown.  In 
this chapter, the efficacy of PA against lung cancer and its associated anticancer mechanism(s) 
was investigated using human-derived NSCLC A549 cells.  Most importantly, the possible 
effects and mechanism of action of PA on arachidonic acid metabolism was evaluated in a 







4.2 Materials and methods 
Reagents  
The cPLA2 assay kit, general PLA2 inhibitor (7,7-dimethyl-5,8-eicosadienoic acid), 
sPLA2 inhibitor (thioetheramide phosphatidylcholine) and PGE2 EIA kit were obtained from 
Cayman Chemical Co. (Ann Arbor, MI).  SP600125, a JNK-specific inhibitor, was 
purchased from Biomol International LP (Plymouth Meeting, PA).  Bay 11-7082, a NF-κB 
inhibitor, was purchased from Calbiochem (San Diego, CA).  Antibodies for actin and 
COX-2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  MEK1/2 
inhibitor (U0126) and antibodies specific for cleaved PARP, cPLA2, phospho-cPLA2 (Ser505), 
phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-JNK (Thr183/Tyr185), phospho-p38 
MAPK (Thr180/Tyr182), NF-κB p65, IκBα, phospho-NF-κB p65 (Ser536), phospho-IKKα/β 
(Ser176/180), goat anti-rabbit IgG-conjugated to horseradish peroxidase and horse 
anti-mouse IgG-conjugated to horseradish peroxidase were purchased from Cell Signaling 
Technology (Beverly, MA).  Unless otherwise stated, all chemicals that were not specifically 
indicated were purchased from Sigma (St. Louis, MO). 
 
Cell culture and treatment 
Culturing and maintenance of A549 cells was described in Chapter 2.  PA was 
reconstituted in DMSO at a stock concentration of 20 mM and subsequently diluted to the 
working concentrations for experimental procedures.  For experiments using IL-1β, A549 




Trypan blue exclusion assay 
Trypan blue exclusion assay was performed in 6-well culture plates.  1.5 x 105 A549 
cells were seeded into each well and incubated overnight.  The cells were then incubated in 
fresh medium containing either DMSO or different concentrations of PA for 24 h.  Both 
floating and adherent cells were pooled, and a 20 µl aliquot was removed from the cell 
suspension and mixed with an equal volume of 0.2% trypan blue dye solution.  Cell counting 
was performed using a hemocytometer.  Clear cells that were not trypan blue-stained were 
counted as viable cells and the number of viable cells from each well was calculated 
accordingly.  Results are expressed as percent cell viability compared with DMSO control 
set at 100 %. 
 
Cell proliferation assay 
The effect of PA on cell viability of A549 cells was determined by two methods: 
MTT assay and an assay using a cell counting kit-8 (CCK-8, Dojindo Laboratories, 
Kumamoto, Japan).  MTT assay was carried out as described in Chapter 2.   
The CCK-8 employs the use of a water-soluble tetrazolium salt 
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt (WST-8), which can be reduced by dehydrogenases in cells to produce a 
yellow color formazan.  This yellow color formazan is water soluble and absorbance can be 
measured directly using a microplate reader.  The amount of the formazan dye generated by 
the activity of dehydrogeneases in cells is directly proportional to the number of living cells.    
Briefly, A549 cells were seeded in 96-well culture plates (5 x 103 cells / well) and 
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grown overnight.  PA was diluted in fresh medium to the desired concentration and added to 
cells in each well.  Following drug treatment for a designated period (24 or 48 h), 10 µl of 
CCK-8 solution was added into the culture medium of each well.  The 96-well plate was 
incubated for 4 h in the cell culture incubator to allow metabolic conversion.   Absorbance 
was subsequently measured at 450 nm using a microplate reader (Tecan GENios, Salzburg, 
Austria).  The effect of PA on cell viability was expressed as percent cell viability compared 
with vehicle treated control cells set at 100%. 
  
LDH release assay 
Lactate dehydrogenase (LDH) is a soluble cytosolic enzyme that is released into the 
culture medium following loss of membrane integrity resulting from either apoptosis or 
necrosis (Cuella et al. 1996).  As an additional method to determine the extent of cell death, 
A549 cells were seeded in 6-well culture plates, allowed to adhere overnight, then treated 
with the desired concentration of PA, and the LDH activity in the culture media was measured 
using a commercially prepared kit (LDH assay kit, Nanjing Jiancheng Bioengineering 
Institute, China) according to the manufacturer's instructions.  The detection of LDH activity 
is based on the ability of LDH to catalyze the synthesis of pyruvic acid.  Pyruvic acid can 
react with 2,4-dinitrophenyl hydrazine to form a derivative of phenylhydrazone, which has a 
brownish red color in basic solution.  By measuring absorbance of the reaction product at 440 
nm, LDH activity in the media sample can be determined.  The activity of LDH was expressed 
in U/L where 1 U is defined as the activity that produces 1 µmol pyruvic acid from lactic acid 
in the assay system. 
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Soft agar assay 
The soft agar assay was performed as described in Chapter 3.  Briefly, after making 
the medium-containing agar base layer, cell layer containing A549 cells (1.5 × 104) and 
DMSO or PA was added over the base layer.  The plates were incubated in the cell culture 
incubator for 3 weeks without further feeding.  Colonies ≥ 0.1 mm were enumerated under a 
light microscope. 
 
Propidium iodide staining assay 
To quantify PA-induced apoptosis, cells were stained with propidium iodide (PI) and 
subjected to flow cytometric analysis as described previously in Chapter 3.  Cells with 
sub-G1 DNA were considered as apoptotic cells. 
 
Analysis of mitochondrial membrane potential 
The mitochondrial membrane potential (ΔΨm) was analyzed by staining A549 cells 
with DiOC6(3) as described previously in Chapter 3.  
 
Measurement of cPLA2 activity 
cPLA2 activity in A549 cells was measured using a commercially available assay kit 
(cPLA2 assay kit, Cayman Chemical Co.) following the manufacturer’s instructions.  The 
cells were seeded in tissue culture plates and incubated overnight for attachment.  The cells 
were then incubaed in serum-free medium for 24 h before PA and IL-1β treatment.  After 
desired treatment, the cells were harvested and prepared in homogenization buffer (50 mM 
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Hepes pH 7.4, 1 mM EDTA).  Following brief sonication, the lysed cells were centrifuged at 
14,000 x g for 15 min at 4°C.  The supernatant was collected and the protein content was 
quantified by the BCA colorimetric detection method according to the manufacturer’s 
protocol (Pierce, Rockford, IL).  The samples were then incubated with arachidonoyl 
thio-phosphatidylcholine, a synthetic substrate of cPLA2.  Release of free thiol due to 
hydrolysis of arachidonoyl thio-phosphatidylcholine by cPLA2 would in turn reduce DTNB to 
NTB.  The NTB concentration was determined by spectrophotometric analysis at 405 nm 
(Tecan Infinite M200, Grodig, Austria).  To ensure that only cPLA2 activity was measured 
by the assay, lysate samples were pre-treated with iPLA2-specific inhibitor (bromoenol 
lactone, 5 µM) and sPLA2-specific inhibitor (thioetheramide-PC, 5 µM) for 20 min at 25°C as 
recommended by the manufacturer.  cPLA2 activity was calculated and expressed in 
nmol/min/ml. 
 
Analysis of PGE2 
A549 cells were seeded and cultured in 6-well plates till 80% confluent.  The cells 
were then maintained in serum-free medium for 24 h before PA and IL-1β treatment.  After 
the indicated treatment, the conditioned medium was collected and processed for PGE2 
quantification using a specific enzyme immunoassay kit (PGE2 EIA kit – Monoclonal, 
Cayman Chemical Co.) following the manufacturer’s instructions.  
This assay is based on the competition between PGE2 and a PGE2 tracer for a limited 
amount of PGE2 monoclonal antibody.  The PGE2 assay plate was precoated with a 
secondary antibody recognizing the PGE2 monoclonal antibody.  A mixture of conditioned 
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medium sample (or PGE2 standard), PGE2 tracer and PGE2 monoclonal antibody was loaded 
into the PGE2 assay plate.  Due to their competitive binding to PGE2 antibody, the amount of 
PGE2 tracer binding to the well is inversely related to PGE2 amount containing in the medium 
sample.  The amount of PGE2 tracer can be determined by adding its substrate to produce a 
yellow color product, whose absorbance is to be measured at 412 nm.  The PGE2 
concentration of the medium sample can be determined against a PGE2 standard curve.  
 
RNA extraction and reverse transcription - PCR (RT-PCR) 
A549 cells were seeded and cultured in 6-well plates to 80% confluency.  The cells 
were then maintained in serum-free medium for 24 h before PA and IL-1β treatment.  After 
the indicated treatment, total RNA from each sample was isolated using an RNeasy® Mini 
Kit (Qiagen, Hilden, Germany).  Following the manufacturer’s instructions, cells were 
scraped in lysis buffer provided in this kit, and homogenized with a QIAshredder 
homogenizer.  Ethanol (70%) was mixed with homogenized lysate, and the mixture was 
applied on an RNeasy spin column to remove ethanol.  After washing RNeasy spin column 
with wash buffers, RNA was finally eluted in RNase-free water.  The concentration of 
extracted RNA was determined by measurement of absorbance at 260 nm on an UV 
spectrophotometer.   
Single-stranded cDNA was synthesized from 2 µg of RNA by reverse transcription 
using a RevertAidTM First Strand cDNA Synthesis Kit (Fermentas, Hanover, MD).  An 
appropriate volume containing 2 µg of total RNA was mixed with 1µl Oligo(dT)18 primer and 
made up finally to 12 µl with nuclease-free water.  The mixture was incubated in 70 °C for 5 
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min, and then mixed with reaction buffer, RiboLockTM Ribonuclease inhibitor and dNTP for 5 
min at 37 °C.  Afterward, ReverAidTM M-MuLV Reverse Transcriptase was next added to 
the above mixture and incubated at 42 °C for 60 min for reverse transcription to occur.  The 
reverse transcription was stopped by heating at 70 °C for 10 min.  The resulting cDNA was 
stored at -20 °C until use.   
Fragments specific to examined genes were amplified in reaction solution (20 µl) 
containing 2 µl generated cDNA, 2 µl deoxyribonucleotide triphosphate (2 mM), 0.2 µl Taq 
DNA Polymerase (New England Biolabs) and 1 µl of each specific sense and anti-sense 
primers (5 nM).  PCR was run for 30 cycles of 94 °C for 15 s (denaturation), 55 °C for 15 s 
(annealing) and 72 °C for 30 s (extension).  The primer sequences used for COX-2 and 
cPLA2 and their product sizes were as followed - COX-2 (561 bp): forward 
5'-GAATGGGGTGATGAGCAGTT -3', reverse 5'-CAGAAGGGCAGGATACAGC-3' (Lister 
et al. 1989); cPLA2 (430 bp): forward 5'-GGATTCTCTGGTGTGATGAAGG-3', reverse 
5'-CCCAATCTGCAAACATCAGC-3' (Khanapure et al. 2007).  Samples of each 
single-stranded cDNA were also treated with primers that amplify a 452 bp fragment of the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) house keeping gene (forward 
5'-ACCACAGTCCATGCCATCAC-3, reverse 5'-TCCACCACCCTGTTGCTGTA-3' (Favata 
et al. 1998; Yang et al. 2002)) to allow for quantitative comparison of loading.  The PCR 
products were subjected to electrophoresis on 1.2% agarose gels containing ethidium bromide 





Preparation of cell lysates, cytosolic and nuclear fractions 
Whole cell lysates were prepared as previously described in chapter 3.  For the 
separation of cytosolic and nuclear fractions, cells were collected, washed twice with cold 
PBS twice and then re-suspended in ice-cold Buffer A (10 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF, 1 mg/ml leupeptin and 1 mg/ml aprotinin).  
After incubation on ice for 15 min, igepal (final concentration 0.5%) was added to the cell 
suspension and mixed gently.  The cytosolic extracts were collected after cells were 
centrifuged at 14,000 x g for 30 sec at 4°C.  The remaining nuclear pellets were then 
re-suspended in Buffer B (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 450 mM NaCl, 25% 
glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml 
aprotinin), and incubated on ice for 30 min with gentle mixing once every 5 min.  The final 
nuclear extracts were collected as supernatants after centrifugation (14,000 x g for 15 min, 
4°C) and the protein concentration was quantified by the BCA colorimetric detection method 
as detailed in Chapter 3. 
 
Western blot analysis 
The detailed procedures on western blot analysis were described in Chapter 3.  
 
Statistical analysis 






4.3.1 Incompatibility of PA with MTT assay 
In Chapter 2, purified and isolated triterpenoids were screened for antiproliferative 
activities using MTT assay.  After 72 h, PA had been observed to inhibit A549 cell growth in 
a dose-dependent manner.  As shown in Figure 4.1, treatment of A549 cells with PA for 24 h 
resulted in a similar trend of decrease in cell viability.  According to the 24 h MTT data, 5 
µM of PA brought about an apparent decrease in A549 cell viability.  At 20 µM, PA has 
significantly reduced the viability to 50%.  However, under the microscope, no difference in 
cell density could be observed between DMSO control and PA treatment (≤ 30 µM).  To 
determine whether PA truly reduced cell viability at the tested concentrations, A549 cells 
were exposed to similar PA doses and their viability was measured using the trypan blue 
exclusion assay.  Interestingly, as shown in Figure 4.1, PA did not reduce cell viability at 
concentrations of 0.2, 5, 10 and 20 µM, and only a dose of 30 µM PA was able to cause a 
significant reduction in viable cells (86% relative to control).  The trypan blue assay data 
therefore indicated that only a PA concentration higher than 20 µM could affect A549 cell 
viability.  Given that trypan blue exclusion assay was a more direct method to quantify 
viable cells, it was deduced that the detected decrease in absorbance in a MTT assay might 













































Figure 4.1 Discrepancy between cell viability results obtained from the MTT assay and 
Trypan blue exclusion assay.  Following treatment of A549 cells with indicated 
concentrations of PA for 24 h, cell viability was determined using MTT assay or trypan blue 
exclusion assay as described in Materials and methods.  Columns, means of three 
independent experiments; bars, standard deviation.  * p < 0.05 
 
It seemed that PA decreased the conversion of MTT to insoluble purple formazan 
without decreasing the number of viable cells.  After adding MTT into culture medium, 
plates were observed under microscope every 30 min.  It was noticed that in control wells, 
grainy formazan crystals were formed around cell nuclei with an intense dark blue color 
(Figure 4.2).  In contrast, in PA-treated cells, long needle-like formazan crystals were 
formed, with a less intense color (Figure 4.2).  This difference in formazan formation, but 
not cell numbers, would likely be the reason accounting for absorbance differences between 
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the control and PA treatment groups.  Indeed, cholesterol has been reported to cause a 
similar phenomenon in A549 cells; in a MTT assay, A549 cells treated with non-toxic 
cholesterol register a significant lower absorbance value (Ahmad et al. 2006).  PA has a 
similar chemical structure with cholesterol, and it was proposed that the unique chemical 
structure of PA might interfere with MTT metabolism.  However, in A549 cells treated with 
PPAC, such an interference phenomenon was not observed.  The exact mechanism 
underlying this phenomenon was not fully understood.  Nevertheless, this finding indicated 
that at least in A549 cells, the MTT assay would not be a suitable method to evaluate PA’s 
antiproliferative effect.   
  
 
     
 
Figure 4.2 Differences in formazan formation in a MTT assay between cells treated or 
untreated with PA.  After treatment of A549 cells with DMSO (left) or 10 µM PA (right) 
for 24 h, 11 µl of MTT was added into culture medium.  Pictures were taken 2 h after MTT 
addition using a Nikon Eclipse TE2000-U microscope (Nikon Corp., Tokyo, Japan).  
 
4.3.2 Inhibition of anchorage-dependent and anchorage-independent growth of NSCLC 
A549 cells by PA 
CCK-8 was next used instead of MTT assay to assess PA’s inhibitory effect on A549 
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cell growth.  As CCK-8 involved the production of a water-soluble product, the source of 
intereference due to differeneces in the formation of insoluble formazan would likely be 
absent.  Between CCK-8 assay and trypan blue exclusion assay, PA’s antiproliferative effects 
on A549 cells were shown to be comparatively similar (Figure 4.3, Figure 4.1).  In the 
CCK-8 assay, 20 and 30 µM PA was observed to reduce A549 cell viability to 94% and 83% 
respectively, and in the trypan blue assay, similar doses of PA diminished viability to 96% and 
86% respectively.  Therefore, it could be concluded based on the obtained results that 






























Figure 4.3 Effect of PA on A549 cell viability as evaluated by CCK-8.  After treatment of 
A549 cells with indicated concentrations of PA for 24 or 48 h, cell viability was determined 
using CCK-8 assay as described in Materials and methods.  Columns, means of three 
independent experiments; bars, standard deviation. * p < 0.05. 
 
As evaluated by the CCK-8 assay, PA caused a dose-dependent decrease in 
proliferation of A549 cells.  As early as 24 h of drug treatment, PA ≥ 30 µM caused a 
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significant cytotoxic effect (Figure 4.3).  These observations were confirmed using an 
alternative method that measured LDH release by A549 cells following PA treatment (Figure 
4.4).  A decrease in cell viability is usually accompanied by a damaged cell membrane, 
which causes the release of large molecules such as LDH from the cell into the medium 
(Bonfoco et al. 1995).  In corroboration with the CCK-8 results, PA was found to exert 




Figure 4.4 Effect of PA treatment on LDH release of A549 cells into culture medium.  
After 24 h treatment of A549 cells with different concentrations of PA, LDH activity in 
culture medium was measured using a LDH assay kit as detailed in Materials and methods.  
Columns, means of three independent experiments; bars, standard deviation. * p < 0.05. 
 
A phenotypic hallmark of cancer cells is their ability to survive and grow under 
non-adhesive or anchorage-independent conditions (Hanahan and Weinberg 2000).  We next 
determined if PA could reduce the efficiency of colony initiation and anchorage-independent 
growth of A549 cells.  As presented in Figure 4.5, PA treatment caused a decrease in A549 
colony formation in a dose-dependent manner.  The effective dose to inhibit colony 
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formation was as low as 10 µM to 20 µM (Figure 4.5).  This result suggested that PA 





Figure 4.5 PA inhibited anchorage-independent growth of A549 cells.  The effect of PA 
on anchorage-independent growth of A549 cells was determined by soft agar assay as detailed 
in Materials and methods.  Columns, mean number of colonies ≥ 0.1 mm from three 
independent experiments; bars, standard deviation. * p < 0.05. 
 
4.3.3 Induction of apoptosis and disruption of mitochondrial membrane potential by PA 
To determine if PA suppressed A549 cell proliferation through the induction of 
apoptosis, PA-treated cells were incubated with PI and analyzed for sub-G1 staining.  PA 
treatment increased the percentage of apoptotic cells in a concentration- and time-dependent 
manner (Figure 4.6A and B).  PA-induced apoptosis was further substantiated by the 












Figure 4.6 PA induced apoptosis in A549 cells.  (A) Dose and time-dependent increase of 
sub-G1 cells by PA treatment.  After 24 h or 48 h treatment with either DMSO or different 
concentrations of PA, A549 cells were stained with PI and analyzed by flow cytometry.  
Sub-G1 value corresponds to the percentage of cells in R1 region.  Flow cytometric graph is 
representative of three independent experiments with similar results.  (B) Quantification of 
sub-G1 cells after 24 h or 48 h PA treatment.  Columns, means of three independent 




Figure 4.7 PA induced cleavage of PARP in A549 cells.  Following designated treatment 
of A549 cells with PA, cell lysates were pooled and subjected to western blot analysis using 
antibodies against cleaved PARP or actin.  Image presented is representative of three 
independent experiments with similar results.   
 
A previous study had shown that PA induced apoptosis in prostate cancer cells 
through the intrinsic mitochondria-mediated pathway (Gapter et al. 2005).  To determine 
whether the mitochondria were involved in PA-induced apoptosis of NSCLC cells, A549 cells 
were labeled with DiOC6(3), which would accumulate within the mitochondria in a 
potential-dependent manner.  It was found that PA caused a dose- and time-dependent 
diminution of ΔΨm in A549 cells as evident from the decreased ability of cells to retain 
DiOC6(3) following PA treatment (Figure 4.8).  Given that loss of ΔΨm would precede the 
pre-apoptotic process, results obtained therefore implied that mitochondrial membrane 






Figure 4.8 Dose and time-dependent disruption of ΔΨm by PA treatment.  PA-treated 
A549 cells were labeled with DiOC6(3) during the final 30 min of PA treatment and analyzed 
using flow cytometry.  The number in the figure corresponds to the percentage of cells in R2 
region.  Flow cytometric graph is representative of three independent experiments with 
similar results. 
 
4.3.4 Inhibition of IL-1β-induced cPLA2 activation by PA at non-lethal concentrations  
Aberrant PLA2 activity and arachidonic acid metabolism is known to correlate with 
carcinogenesis of lung and other cancers.  We first investigated whether the inhibitory 
effects of PA on snake venom PLA2 reported previously (Cuella et al. 1996) could be 
replicated using human PLA2 isoforms at non-lethal PA concentrations as determined by 
CCK-8 and LDH assay (i.e., ≤ 20 µM).  To test the hypothesis in a biologically relevant 
setting, we pre-treated A549 cells with IL-1β, a critical signal known to initiate inflammation, 
induce activation of cPLA2, and stimulate arachidonic acid release in a cellular system 
(Croxtal et al. 1996; Choudhury et al. 2000).  Consistent with previous studies, IL-1β 
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increased the protein expression of cPLA2 (both total cPLA2 and its activated phosphorylated 
form) in a time-dependent manner, with the maximum induction occurring after 8 h of 
exposure to IL-1β (Figure 4.9A).  In contrast, 10 µM PA significantly suppressed the total 







Figure 4.9 PA inhibited IL-1β-induced cPLA2 protein activation in A549 cells.              
(A) Time-dependent increase of total cPLA2 and phosphorylated cPLA2 protein expression by 
IL-1β treatment.  A549 cells were incubated in serum-free medium for 24 h and then treated 
with IL-1β (1 ng/ml) for different time periods.  (B) Suppression of PA on IL-1β-induced 
cPLA2 phosphorylation and total cPLA2 protein expression.  A549 cells were pretreated with 
DMSO or 10 µM PA for 1 h, and then challenged with IL-1β (1 ng/ml) for 8 h.  Cell lysates 
were immunoblotted using anbibodies against total cPLA2 or phosphorylated cPLA2.  
Images are representative of three independent experiments with similar results. 
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To determine if inhibition of cPLA2 expression by PA occurred at the transcriptional 
level, RT-PCR analysis was performed.  Pretreatment of A549 cells with 10 µM PA was able 
to suppress the IL-1β-induced cPLA2 mRNA expression (Figure 4.10).  Furthermore, PA 
pretreatment also decreased cPLA2 enzyme activity in A549 cells (Figure 4.11).  In contrast 
to control cells treated with IL-1β alone, the cPLA2 enzyme activity in cells treated with both 
IL-1β and 10 µM PA possessed less enzyme activity (Figure 4.11).  Compared to a general 
PLA2 inhibitor, 7,7-dimethyl-5,8-eicosadienoic acid (DEDA) (Lister et al. 1989), PA 
decreased cPLA2 activity to a lesser extent (Figure 4.11).  Taken together, these results 
indicated that PA modulated IL-1β-induced cPLA2 activation in A549 cells via suppression of 
cPLA2 gene expression and/or activation. 
 
 
Figure 4.10 PA inhibited IL-1β-induced cPLA2 gene activation.  A549 cells were 
pretreated with DMSO or 10 µM PA for 1 h, and then challenged with IL-1β (1 ng/ml) for 3 h.  
Total mRNA was extracted, reverse transcribed, and amplified by PCR as detailed in 













Figure 4.11 PA suppressed IL-1β-enhanced cPLA2 enzyme activity.  A549 cells were 
treated with 10 µM PA or 10 µM general PLA2 inhibitor DEDA or vehicle control (DMSO) 
for 1 h and then stimulated with IL-1β (1ng/ml) for 5 h.  cPLA2 enzyme activity was 
determined using a cPLA2 assay kit as detailed in materials and methods.  Columns, means 
of two independent experiments repeated in duplicate; bars, standard deviation.  † p < 0.05 
versus DMSO control; * p < 0.05 versus DMSO + IL-1β.  
 
 
4.3.5 Inhibition of IL-1β-induced COX-2 mRNA and protein expression by PA at 
non-lethal concentrations 
Prostaglandin production is regulated by both the substrate availability of arachidonic 
acid and activity of COX-2.  As described in Section 4.3.4, PA brought about negative 
modulation of cPLA2 expression.  Therefore, it was hypothesized that PA treatment could 
reduce downstream conversion of arachidonic acid to prostaglandins.  Indeed, experiments 
performed demonstrated that PA effectively decreased IL-1β-induced PGE2 production in 
A549 cells in a concentration-dependent manner, with PGE2 levels reduced by around 40 % at 







Figure 4.12 PA reduced IL-1β-stimulated PGE2 production.  A549 cells were pretreated 
with different concentrations of PA or U0126 for 1h, and then challenged with IL-1β (1 ng/ml) 
for 24 h.  The medium was collected and subjected to PGE2 analysis using a PGE2 assay kit 
as detailed in Materials and Methods.  Columns, mean of three independent experiments 
repeated in duplicate; bars, standard deviation.  † p <0.05 versus DMSO control; * p <0.05 
versus DMSO + IL-1β. 
 
Although PA was found to be not as effective as U0126 (Figure 4.12), a MEK1/2 
inhibitor reported to inhibit IL-1β-induced COX-2 expression and PGE2 production (Favata et 
al. 1998; Yang et al. 2002), the results implied that PA might regulate PGE2 production by 
reducing COX-2 expression.  To investigate this possibility, the effect of PA treatment on 
endogenous COX-2 expression in A549 cells exposed to IL-1β was evaluated.  As shown in 
Figure 4.13A, the expression of COX-2 protein increased in a time-dependent manner 
following exposure of A549 cells to IL-1β for 24 h.  Expectedly, pretreatment of A549 cells 
with non-lethal concentrations of PA reduced IL-1β-induced COX-2 protein expression in a 
concentration-dependent manner (Figure 4.13B).  This inhibition in COX-2 expression also 
occurred at the transcriptional level as pretreatment of A549 cells with 10 µM of PA caused 










Figure 4.13 PA inhibited IL-1β-induced COX-2 mRNA and protein expression.        
(A) Time-dependent increase of COX-2 protein expression by IL-1β treatment.  A549 cells 
were starved in serum-free medium for 24 h and then treated with IL-1β (1 ng/ml) for 
different time periods.  Cell lysates were immunoblotted with antibody specific for COX-2 
proteins.  (B) Dose-dependent inhibition of PA on IL-1β-induced COX-2 protein expression.  
A549 cells were pretreated with different concentrations of PA for 1 h, and then challenged 
with IL-1β (1 ng/ml) for 24 h.  Cell lysates were immunoblotted using anbibodies against 
COX-2.  (D) Inhibitory effect of PA on IL-1β-induced COX-2 mRNA transcription.  A549 
cells were pretreated with DMSO or 10 µM PA for 1 h, and then challenged with IL-1β (1 
ng/ml) for 3 h.  Total mRNA was extracted, reverse transcribed, and amplified by PCR as 
detailed in Materials and methods.  Images are representative of three independent 
experiments with similar results. 
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4.3.6 The effect of PA on IL-1β-induced MAPKs signaling pathway 
Results thus far had positively shown that PA exerted inhibition on IL-1β-induced 
protein expression and activity of cPLA2 and COX-2.  To probe further, the possible 
involvement of upstream signal transduction pathways responsible for this inhibition was next 
investigated.  In view that MAPKs have been shown to regulate cPLA2 and COX-2 
activation (Lin et al. 1993; Choudhury et al. 2000; Chun and Surh 2004), the effect of PA on 
MAPKs signaling pathways (including ERK, JNK and p38) was explored herein.  Firstly, it 
was verified that IL-1β treatment indeed resulted in activation of ERK, JNK and p38 MAPK , 
as shown by the enhancement in phosphorylation of each respective protein (Figure 4.14). 
Pre-incubation of A549 cells with non-lethal concentrations of PA was able to suppress 




Figure 4.14 PA inhibited IL-1β-induced MAPKs activation in A549 cells.  After 
pretreatment of A549 cells with PA (1 µM, 3 µM, 10 µM) for 1 h, A549 cells were challenged 
with 1 ng/ml of IL-1β for 30 min.  Cell lysates were subjected to immunoblotting analysis 
using corresponding antibodies.  The analyses were repeated three times with similar results 
and a representative immunoblot is shown. 
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To examine the role of MAPKs in the activation of cPLA2 and COX-2, specific 
MAPK inhibitors, namely U0126 (MEK1/2 inhibitor) and SP600125 (JNK inhibitor), were 
used to investigate the relationship.  As shown in Figure 4.15A and 4.15B, both U0126 and 
SP600125 suppressed the phosphorylation of cPLA2 and protein expression of COX-2.  
Taken together, the results suggested that PA suppressed the MAPK signal transduction 
pathway to inhibit IL-1β-induced activation of cPLA2 and COX-2. 
A                                   B 
 
Figure 4.15 Effect of specific MAPK inhibitors on IL-1β-induced phosphorylation of 
cPLA2 and COX-2 protein expression.  After pretreatment with U0126 (A) or SP600125 
(B) for 1 h, A549 cells were challenged with 1 ng/ml of IL-1β for 24 h.  Cell lysates were 
subjected to immunoblotting analysis using corresponding antibodies.  The analyses were 
repeated three times with similar results and a representative immunoblot is shown. 
 
4.3.7 The effect of PA on IL-1β-induced NF-κB signaling pathway 
NF-κB signaling pathway has been shown to be involved in the activation of both 
cPLA2 and COX-2 by various stimuli including IL-1β (Catley et al. 2003; Luo et al. 2008).  
To examine whether PA inhibited cPLA2 and COX-2 activation through NF-κB signaling 
pathway, the effect of PA on NF-κB nuclear translocation was studied.  As shown in Figure 
4.16A, treatment of A549 cells with IL-1β resulted in a marked translocation of NF-κB p65 
catalytic subunit from the cytoplasm to the nucleus as well as a reduction in the steady state 
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levels of inhibitor of kappaBα (IκBα) in the cytosol, whereas PA (10 µM) pretreatment 
effectively impeded both the reduction of IκBα protein and p65 nuclear translocation induced 
by IL-1β (Figure 4.16A).   
To investigate whether the effect of PA on IκBα was through the upstream signal, IκB 
kinase (IKK), all lysates were analyzed using a specific antibody against the phosphorylated 
(active) form of IKK.  As shown in Figure 4.16B, IKKβ phosphorylation increased after 
IL-1β-treatment and this effect was suppressed by PA in a dose-dependent manner.  These 
results suggested that PA brought about inhibition of IL-1β-induced NF-κB nuclear 
translocation by suppressing IKK activation.  Furthermore, a dose-dependent decrease in the 
protein expression of phosphorylated NF-κB p65 by PA pretreatment was observed (Figure 
4.16B).  Since p65 phosphorylation at Ser536 regulates NF-κB activation, nuclear 
localization and transcriptional activity (Buss et al. 2004), data from Figure 4.16B further lent 
support to the suppressive effect of PA on the NF-κB signaling pathway.   
To examine the role of NF-κB in PA’s inhibition of cPLA2 and COX-2, Bay 11-7082 
(a known inhibitor of IκB phosphorylation) was also used in the experiments.  cPLA2 protein 
expression induced by IL-1β was found to be almost completely prevented by pretreatment of 
A549 cells with 5 µM of Bay 11-7082, while COX-2 protein induction was partially reversed 
by Bay 11-7082 (Figure 4.16C); these effects of Bay 11-7082 on cPLA2 and COX-2 were 
similar to that exerted by PA.   
Therefore, taken together, results obtained indicated that inhibition of the NF-κB 
signaling pathway by PA would contribute at least in part to its inhibitory effect on 






Figure 4.16 PA inhibited IL-1β-induced NF-κB activation in A549 cells.             
(A) Inhibition of PA on IL-1β-induced NF-κB p65 subunit nuclear translocation.  A549 cells 
were pretreated with PA (10 µM) for 1 h and then challenged with IL-1β (1 ng/ml) for 30 min.  
Cytosolic lysates were immunoblotted against IκBα antibody.  Nuclear lysates were 
immunoblotted with NF-κB p65 antibody.  (B) Blockade of IKKβ activation and inhibition 
of NF-κB p65 phosphorylation by PA treatment.  A549 cells were pretreated with PA for 1 h 
and then challenged with IL-1β (1 ng/ml) for 30 min.  Whole cell lysates were 
immunoblotted against p-IKKα/β or p-p65 antibody.  (C) Suppression of NF-κB inhibitor, 
Bay 11-7082, on IL-1β-induced cPLA2 and COX-2 protein expression.  A549 cells were 
pretreated with Bay 11-7082, followed by treatment with IL-1β (1 ng/ml) for 24 h.  Whole 
cell lysates were collected and subjected to western blot analysis.  These analyses were 




In this study, an interesting finding was made about PA’s interference with the MTT 
assay where the antiproliferative activity of PA was falsely exemplified.  MTT assay has 
been widely used to assess cytotoxicity because it is the simplest, most rapid as well as a 
sensitive method for estimation of cell viability.  As reported in the previous chapter 
(Chapter 3), in the treatment of A549 cells with PPAC, a general consistent trend of change 
between the visual confluence of cells and the data obtained from assay was observed.  In 
addition, the MTT assay also applied well to anticancer drugs such as 5-fluouracil and 
doxorubicin, as previously demonstrated in the laboratory.  As such, this would mean that 
PA might have a special incompatibility with the MTT assay.  It has been reported that 
cholesterol interferes with MTT assay in A549 cells by enhancing exocytosis of formazan 
crystals (Ahmad et al. 2006).  Having a similar chemical structure with cholesterol, PA thus 
might interfere with the MTT assay in a similar mechanism.  Indeed, a highly similar 
morphological change in A549 cells treated with PA was observed as that reported in the 
literature (Ahmad et al. 2006).  
Other cell viability assays like the CCK-8 and LDH assays were undertaken and 
results obtained, being consistent with trypan blue staining assay, confirmed that only PA at 
concentrations higher than 30 µM exhibited cytotoxicity on A549 cells.  Similar with its 
reported effects on prostate cancer cells, PA induced mitochondria-mediated apoptosis in lung 
cancer A549 cells.    
On the other hand, the effect of PA on arachidonic acid metabolism was evaluated 
using non-lethal concentrations.  Studies have shown that PA is capable of inhibiting PLA2 
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isolated from snake venom and this inhibition has been linked to its anti-inflammatory and 
anticancer effect (Cuella et al. 1996).  However, attributing these effects of PA to its 
inhibition on PLA2 enzyme activity remains to be established for two reasons.  Firstly, the 
effective concentration of PA shown to inhibit PLA2 enzyme activity (IC50 = 2.89 mM) is too 
high to be achievable in vivo.  Secondly, the inhibition of PLA2 by PA is examined in a 
cell-free assay involving a direct chemical reaction using snake venom-originated PLA2, 
which may not correlate with endogenous arachidonic acid signaling pathways in humans.  
In contrast, in this study, activity of cPLA2, the enzyme considered to be primarily 
responsible for the liberation of arachidonic acid from membrane phospholipids in a wide 
variety of cells, was measured in a cell-based assay using A549 cells.   
It has been shown that both cPLA2 and COX-2 are activated by proinflammatory 
factors, such as IL-1β (Croxtal et al. 1996), an important “alarm cytokine” secreted by 
macrophages that initiates inflammation.  In this study, it was observed that the induction of 
cPLA2 by IL-1β was suppressed at both the mRNA and protein level by non-lethal levels of 
PA.  Furthermore, the phosphorylation of cPLA2 by IL-1β was also reversed by PA treatment.  
This downregulation of cPLA2 by PA also correlated with reduced cPLA2 enzyme activity in 
A549 cells.  Taken together, these results indicated a suppressive role of PA on 
IL-1β-induced cPLA2 activation.  Notably, PA  was shown to cause inhibition of both 
IL-1β-induced COX-2 expression and PGE2 production in A549 cells in a dose-dependent 
fashion, suggesting that PA might potentially inhibit inflammation and carcinogenesis by 
blocking arachidonic acid release and its subsequent conversion to PGE2. 
MAPKs have been reported to play a pivotal role in the phosphorylation and 
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activation of cPLA2 as well as induction of COX-2 (Choudhury et al. 2000; Chun and Surh 
2004).  Immunoblot analysis revealed that treatment of IL-1β-induced A549 cells with PA 
produced a decrease in the level of phosphorylated ERK, JNK and p38 MAPK.  Since each 
of these three MAPKs has been previously reported to phosphorylate cPLA2 induced by 
various stimuli, it was postulated that the inhibition of MAPKs by PA would at least in part 
contribute to the observed suppression of cPLA2 phosphorylation.  Apart from their kinase 
activities, these MAPKs have been shown to activate transcription of genes including cPLA2 
and COX-2 through regulation of AP-1 activation.  For instance, JNK induces the expression 
and phosphorylation of c-Jun; ERK simulates AP-1 activity by inducing c-Fos, which 
heterodimerizes with c-Jun; p38 MAPK induces AP-1 through phosphorylation of ATF-2 
(Whitmarsh and Davis 1996).  It was observed that PA suppressed IL-1β-induced gene 
transcription of both cPLA2 and COX-2.  Based on published reports that cPLA2 and COX-2 
genes share several identical promoter elements, it was hypothesized that PA might suppress 
the transcription of these genes through regulation of one or more of these promoter elements.  
Therefore, it would be reasonable to relate that the transcription of cPLA2 and COX-2 genes 
might be suppressed by PA, at least partially, through inhibition of AP-1 activity.  Taken 
together, it was rationalized that the inhibition of cPLA2 and COX-2 in A549 cells by PA 
might be mediated in part through inhibition of ERK, JNK and p38 signal transduction 
pathways.  
NF-κB is a key mediator of inducible transcription initiated by various stimuli, 
including IL-1β (Luo et al. 2008).  Pertaining to the experimental system employed herein, 
the link between NF-κB signaling and induction of cPLA2 and COX-2 expression had been 
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demonstrated using a NF-κB-specific inhibitor.  Results also showed that PA pretreatment 
brought about suppression of IL-1β-induced nuclear translocation of NF-κB, which would 
expectedly result in reduced p65 binding to the promoter region of cPLA2 and COX-2 genes.  
Further analysis revealed that NF-κB nuclear translocation was likely suppressed due to the 
inhibitory effect of PA on IKK activation; PA was found to prevent IKK-induced 
phosphorylation and reduction of IκBα that would lead to reduced NF-κB translocation into 
the nucleus.  As such, it could be concluded that NF-κB would serves as a molecular target 
for PA.   
In summary, the findings presented in this chapter demonstrate the chemotherapeutic 
and chemopreventive properties of PA against lung cancer.  Importantly, PA at non-lethal 
concentrations effectively suppressed IL-1β-induced cPLA2 and COX-2 expression and 
activation, thus leading to reduced prostaglandin formation.  This suppression appeared to 
be mediated through the inhibition of the MAPK family and NF-κB signaling pathways.  
Collectively, data presented in this chapter had highlighted PA as a potential cancer 














In this chapter, the potential of several Poria cocos-originated triterpenoids against breast 
cancer invasion was investigated.  Using human breast cancer MDA-MB-231 cells whose 
invasiveness was stimulated by phorbol ester, the possible anti-invasive activities of PA, 
PPAC and dehydropachymic acid were investigated.  Gelatin zymography was used as a 
convenient screening method for anti-invasive capacity of these triterpenoids.  It was found 
that PA, PPAC and dehydropachymic acid inhibited MMP-9 secretion with different 
capacities.  Since PA exhibited the strongest anti-invasive effect at non-lethal concentrations, 
it was selected for more detailed mechanistic study.  PA at non-lethal concentrations 
significantly inhibited TPA-stimulated migration of MDA-MB-231 cells in an in vitro 
Matrigel invasion assay.  In addition, PA’s downregulation of MMP-9 secretion was found to 
be due to its inhibitory effect on MMP-9 synthesis at the transcriptional level.  The 
mechanism for this inhibition of PA on MMP-9 transcription was elucidated through PA’s 
inhibition on TPA-induced transcriptional activity of NF-κB, but not that of AP-1.  The 
inhibition of PA on NF-κB transcriptional activity was further attributed to PA-mediated 
diminution in TPA-induced degradation of IκBα through preventing phosphorylation of the 
upstream signal IKK.  A decrease in p65 nuclear translocation was resulted, which led to 
attenuation of NF-κB transactivation.  These findings suggest that by targeting NF-κB 




Tumor metastasis is the leading cause of mortality in cancer patients (Hanahan and 
Weinberg 2000).  It involves a complex series of events, of which degradation of 
extracellular matrix by proteolytic enzymes and subsequent cancer invasion are the essential 
early steps (Steeg 2006).  MMPs, a family of zinc-dependent endoproteinases, have been 
suggested to play a central role in the degradation of extracellular matrix (Coussens et al. 
2002).  Among them, MMP-2 (gelatinase-A) and MMP-9 (gelatinase-B) are key enzymes 
for degradation of type IV collagen and thus are believed to be the most relevant enzymes for 
tumor invasion (Brinckerhoff and Matrisian 2002).  The regulation of MMPs can occur at 
multiple levels, including gene transcription, proenzyme activation and inhibition by 
endogenous inhibitors (Sternlicht and Werb 2001).  While MMP-2 is usually constitutively 
expressed and mainly regulated by its inhibitors, MMP-9 is highly inducible by various 
stimuli including growth factors, cytokines, UV and TPA (Sternlicht and Werb 2001).  It has 
been revealed that the MMP-9 promoter region contains multiple DNA binding sites for 
transcription factors, such as AP-1 (-533 bp, -79 bp), NF-κB (-600 bp) and stimulatory 
protein-1 (SP-1; -588 bp) (Sato and Seiki 1993).  Upon stimulation, one or more 
transcription factors are activated and they bind to the promoter region to regulate MMP-9 
transcription (Sato and Seiki 1993).  Therefore, the down-regulation of MMP-9 expression 
may be a useful strategy for intervention of tumor metastasis. 
Studies have shown that Poria cocos-originated triterpenoids possess remarkable 
anti-inflammatory effects in animal models and human subjects (Kaminaga et al. 1996; 
Cuellar et al. 1997; Giner-Larza et al. 2000; Giner et al. 2000; Fuchs et al. 2006).  However 
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to date, the role of triterpenoids from Poria cocos against tumor invasion and metastasis has 
not been reported.  Since tumor invasion is usually accompanied by a pro-inflammatory 
environment (Federico et al. 2007), it was proposed that suppression of inflammatory 
stimulation in the cellular environment may alleviate cancer invasion by preventing 
inflammatory factor-induced expression of key enzymes involved in tumor invasion.  
Therefore, it was our objective to evaluate whether these triterpenoids could inhibit cancer 
invasion by reducing MMP-9 activity.  TPA, also commonly known as phorbol 12-myristate 
13-acetate (PMA), is a classic inducer of inflammation as well as a potent tumor promoter.  
As such, it was used as a model agent to stimulate MMPs expression and invasiveness in this 
study.  PA, PPAC and dehydropachymic acid were chosen due to their relatively larger yield 
and availability (refer to results represented in Chapter 2).  The compounds were first 
screened for MMP-9 extracellular secretion by human breast cancer MDA-MB-231 cells 
using gelatin zymography.  PA, the most effective compound was selected and subjected to 
further studies to characterize its anti-invasive property.  As a result, it was found that PA, at 
non-lethal concentrations, inhibited TPA-stimulated invasiveness of MDA-MB-231 cells 
through reduction of MMP-9 gene and protein expression, which in turn resulted in a decline 
in MMP-9 secretion.  In addition, it was demonstrated that this down-regulation of MMP-9 







5.2 Materials and methods 
Reagents  
Reagents also used in Chapter 3 and 4 had been described in the previous chapters. 
TPA and gelatin were purchased from Sigma (St. Louis, MO).  BD BioCoat™ Matrigel™ 
Invasion Chambers were obtained from BD Biosciences (San Jose, CA).  SB203580 (p38 
inhibitor) was from Calbiochem (San Diego, CA).  Antibodies specific for JNK, p38, NF-κB 
p65, phospho-IκBα (Ser32), IKKα and IKKβ were purchased from Cell Signaling Technology 
(Beverly, MA).  Antibodies for MMP-9, histone H1, goat anti-rabbit IgG-conjugated to 
horseradish peroxidase, horse anti-mouse IgG-conjugated to horseradish peroxidase and 
rabbit anti-goat IgG-conjugated to horseradish peroxidase were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  GeneJuice® Transfection Reagent was from Novagen 
(Nottingham, UK). 
    
Cell culture and treatment 
The MDA-MB-231 human breast cancer cell line was purchased from American Type 
Culture Collection (Manassas, VA) and propagated at 37 °C in a 5% CO2 humidified 
incubator in RPMI medium (Sigma Aldrich, St. Louis, MO) containing 10% fetal bovine 
serum, 10 mM HEPES and antibiotics.  Tested compounds were reconstituted in DMSO at a 
stock concentration of 20 mM and subsequently diluted to the working concentrations for 
experimental procedures.  For experiments using TPA, cells were always maintained in 




Cell viability assay 
The antiproliferative effect of PA on MDA-MB-231 cells was evaluated using CCK-8 
as described in Chapter 4.  
 
Gelatin Zymography 
Gelatin zymography was preformed according to published procedures with slight 
modifications (Liotta and Stetler-Stevenson 1990).  MDA-MB-231 cells were seeded onto 
six-well plates in RPMI with 10% FBS, and allowed to propagate to 80% confluence.  The 
cells were then maintained in serum-free medium for at least 12 h prior to designated 
treatments with triterpenoids and TPA.  Following 20 h incubation of cells with TPA, 
conditioned medium was collected and centrifuged at 400 × g to remove cells and debris.  
Equal volumes of conditioned medium were mixed with non-reducing Laemmli sample 
buffer [62.5 mM Tris HCl (pH 6.8), 2% SDS, 25% glycerol, 0.01% (w/v) bromophenol blue], 
placed at room temperature for 10 min, and subjected to electrophoresis on a 10% 
SDS-PAGE gel containing 0.1% (w/v) gelatin.  After electrophoresis, the gels were washed 
in renaturing buffer (2.5% Triton X-100) for 30 min and then equilibrated for 30 min in 
developing buffer (50 mM Tris–HCl, pH 7.5, 0.2 M NaCl, 10 mM CaCl2, and 1 mM ZnCl2).  
The gels were subsequently incubated in fresh developing buffer at 37 °C for 24 h to allow 
gelatin digestion.  The gelatinolytic activity of MMPs was visualized by staining the gels 
with 0.5% Coomassie blue R-250 in 45% methanol, 10% acetic acid (v/v) and destained with 
45% methanol, 10% acetic acid (v/v) until clear bands suggestive of gelatin digestion were 
present.  For the experiments evaluating direct effect of PA on MMP-9 activity, the collected 
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TPA-conditioned medium was incubated directly with different concentrations of PA at 37 °C 
for 10 min.  Equal volumes of incubated medium were then subjected to gelatin zymography 
analysis as detailed above. 
 
Cell invasion assay 
The cell invasion assay was conducted using BD BioCoat™ Matrigel™ Invasion 
Chambers according to the manufacturer’s instructions.  5 × 104 MDA-MB-231 cells 
suspended in 500 µl of serum-free medium were seeded into the upper chamber of 
Matrigel-coated filter inserts.  After treatment with different concentrations of PA or DMSO 
for 1 h, 750 µL of serum-free medium containing 80 nM of TPA was added to the bottom 
wells as a chemoattractant.  The Matrigel Invasion Chambers were incubated at 37 °C in a 
5% CO2 humidified incubator for another 20 h.  After incubation, the filter inserts were 
removed from the wells and the cells on the upper side of the membrane were removed using 
cotton swabs.  Cells that had invaded to the lower surface of the membrane were fixed with 
methanol for 15 minutes, and stained with 2% ethanol containing 0.2% crystal violet powder 
for 15 minutes.  The inserts were washed with water, allowed to dry, and the invaded cells 
were detected and enumerated under a light microscope. 
 
RNA extraction and reverse transcription - PCR (RT-PCR) 
RNA extraction and RT-PCR were performed as described in Chapter 4.  The primer 
sequences used for MMP-9 and GAPDH, and their product sizes were as follows - MMP-9 
(620 bp): forward 5'-CGATGACGAGTTGTGGTCCCTGGGC-3', reverse, 
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5'-AATGATCTAAGCCCAGCGCGTGGC-3' (Zhang et al. 2006); GAPDH (325 bp): forward, 
5'-TGAAGGTCGGAGTCAACGGATTTGGT-3', reverse, 
5'-AAATGAGCCCCAGCCTTCTCCATG-3'.   
 
AP-1 and NF-κB-dependent luciferase reporter assay 
MDA-MB-231 cells were seeded in 24-well culture plates.  At approximately 50% 
confluency, cells were cotransfected with 0.7 μg pAP-1-Luc or pNF-κB-Luc plasmids 
(PathDetect luciferase cis-reporting system containing 7 x AP-1 and 5 x NF-κB enhancer 
elements respectively; purchased from Stratagene, La Jolla, CA) and 14 ng pRL-CMV 
(Promega, Madison, WI) per well for 24 h.  After transfection, the cells were maintained in 
serum-free medium, pretreated with PA for 1 h and followed by TPA stimulation for an 
additional 20 h.  Firefly and renilla luciferase activities were assayed using the Dual 
Luciferase Assay System (Promega, Madison, WI), and results were expressed as firefly 
luciferase activity normalized to renilla luciferase activity.   
 
Preparation of whole cell lysates and nuclear fractions 
As described in Chapter 3 and 4.   
 
Western blot 
Western blot analysis was carried out as described in Chapter 3.  For detection of 
MMP-9 protein level in the medium, conditioned medium was collected and centrifuged at 
400 × g to remove cells and debris.  Equal volumes of conditioned medium were mixed with 
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4 × Laemmli Sample Buffer [250 mM Tris-HCl (pH 6.8), 8% w/v SDS, 40% glycerol, 0.02% 
(w/v) bromophenol blue, 20% 2-mercaptoethanol], heated for 5 min at 100 °C, and subjected 
to electrophoresis on a 10% SDS-PAGE.  After transferring resolved proteins to 
nitrocellulose membranes, the levels of MMP-9 protein were determined using a specific 
antibody against MMP-9. 
 
Statistical analysis 
As described in Chapter 3. 
 
5.3 Results 
5.3.1 Effects of PA, PPAC and dehydropachymic acid on TPA-stimulated MMP-9 
secretion in MDA-MB-231 cells 
Three triterpenoids from Poria cocos, namely PA, PPAC and dehydropachymic acid 
were evaluated for their potential anti-invasive effects against human breast cancer cells.  
MDA-MB-231, a breast cancer cell line with high invasive capacity, were pretreated with the 
compounds for 1 h, followed by TPA stimulation for another 20 h.  Conditioned medium 
was collected and subjected to gelatin zymographic analysis for detection of secreted MMP-9.  
Consistent with previous reports (Zhang et al. 2006; Liang et al. 2009), treatment of 
MDA-MB-231 cells with TPA (80 nM) resulted in a striking increase in the proteolytic band 
intensity corresponding to the molecular size of pro-MMP-9 (92 kDa) (Figure 5.1).  
Pretreatment of MDA-MB-231 cells with each of the three tested compounds decreased 
MMP-9 band intensity in a dose-dependent manner (Figure 5.1), indicating that these 
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triterpenoids reduced MMP-9 extracellular expression.  These compounds clearly possessed 
different potencies in reducing MMP-9 activity.  For instance, slight reduction in MMP-9 
proteolytic activity was initiated at 10 µM of PA; PPAC demonstrated suppression of MMP-9 
activity at ≥ 40 µM; dehydropachymic acid only reduced MMP-9 activity at 60 µM (Figure 
5.1).  Considering the better efficacy in reducing MMP-9 gelatinolytic activity, PA was 






Figure 5.1 Dose-dependent decrease in MMP-9 gelatinolytic activity mediated by PA, 
PPAC and dehydropachymic acid.  MDA-MB-231 cells were pretreated for 1 h, and then 
challenged with PMA for 20 h.  The conditioned medium was analyzed by gelatin 
zymography for MMP detection as described in Materials and methods. 
 
The medium samples of cells co-incubated with PA and TPA were also analyzed by 
western blotting, which showed a dose-dependent decrease in MMP-9 protein levels (Figure 
5.2A).  This result suggested that PA caused an inhibition of MMP-9 cellular secretion.  To 
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further investigate whether the observed decrease in MMP-9 gelatinolytic activity was due to 
inhibitory interaction between PA and MMP-9, TPA-conditioned medium was collected from 
control cells (non PA-treated), then mixed with PA (final concentrations 2.5, 5, 10, 20 µM) 
and finally subjected to gelatin zymography analysis.  Results, as shown in Figure 5.2B, 
showed that there was no significant difference between PA-treated and –untreated group, 
indicating that PA failed to inhibit directly MMP-9 gelatinolytic activity.  Therefore, it was 
concluded that PA caused reduction in MMP-9 gelatinolytic activity through inhibiting 






Figure 5.2 PA reduced extracellular expression of MMP-9.  (A) Reduction of 
TPA-induced MMP-9 secretion by PA.  After pretreatment of cells with PA, and then TPA 
for 20 h, conditioned medium was subjected to western blot analysis for MMP-9 detection as 
detailed in Materials and methods.  (B) Lack of direct inhibition by PA on MMP-9 
gelatinolytic ability.  MDA-MB-231 cells were treated with 80 nM TPA for 20 h, and 
conditioned medium was subsequently incubated with PA for 10 min.  Samples were 
analyzed using gelatin zymography.          
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To rule out the possibility that this MMP-9 inhibition by PA was due to its 
cytotoxicity, CCK-8 cell viability assay was carried out to evaluate PA’s antiproliferative 
effects on MDA-MB-231 cells.  As shown in Figure 5.3, following 24 h drug exposure, PA 
did not alter cell viability at concentrations ≤ 20 µM.  PA at 30 µM reduced cell viability to 
90%, but this effect was not statistically significant.  At 40 µM, PA exhibited notable 
cytotoxicity (p < 0.05) on MDA-MB-231 cells, reducing viability to 80% (Figure 5.3).  
These results, taken together, showed that the reduction of MMP-9 activity mediated by PA 




Figure 5.3 Cytotoxicity profile of PA on MDA-MB-231 cells.  Cells were exposed to PA 
for 24 h and cell viability was determined by CCK-8.  Columns, mean of three independent 
experiments repeated in triplicate; bars, standard deviation; * p < 0.05. 
 
5.3.2 Inhibition of TPA-stimulated invasion of MDA-MB-231 cells by PA 
To investigate whether PA’s reduction of MMP-9 extracellular secretion indeed led to 
reduced invasiveness of cancer cells, an invasion assay using Matrigel-coated transwell plates 
to measure cell migration following TPA stimulation was carried out.  As shown in Figure 
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5.4A, the invasive capacity of MDA-MB-231 cells was enhanced by 4.5-fold upon TPA 
treatment.  Pretreatment of cells with 10 µM of PA significantly decreased TPA-induced 
invasiveness from 4.5-fold to 2.8-fold (Figure 5.4A).  Further increase of PA to 20 µM 
decreased the invasion to 1.4-fold as compared to basal cell invasion without TPA stimulation 
(Figure 5.4A).  These results clearly demonstrated that PA was able to impede invasion of 
breast cancer cells through the gelatin-rich extracellular matrix.  This data further supported 
the notion that reduction of MMP-9 secretion might decrease cancer invasive capacity and 

























Figure 5.4 PA inhibited TPA-induced invasion of MDA-MB-231 cells.  Cells suspended 
in serum free medium were seeded onto upper chamber of Matrigel-coated filter inserts.  
Following PA treatment of cells for 1 h, TPA was added to the bottom chamber for another 20 
h to stimulate cell invasion.  Upon staining with crystal violet, invaded cells were counted 
under microscope as detailed in Materials and methods.  Results were expressed as relative 
percent of cell invasion to that of basal invasion of TPA-untreated cells (A).         
Columns, means of three independent experiments; bars, SD; † p < 0.05 versus DMSO 
control; ** p < 0.01 versus TPA only-treated group.  (B) Representative images showing the 




5.3.3 Inhibitory effect of PA on TPA-stimulated MMP-9 protein and gene expression 
MMP-9 is known to be synthesized intracellularly and then secreted into the 
extracellular environment.  Since PA had been found to reduce extracellular MMP-9 protein 
expression (Figure 5.2A), it was deduced that this reduction might be a result of decreased 
MMP-9 intracellular synthesis.  Therefore, the intracellular expression of MMP-9 following 
treatments with TPA and PA was investigated.  As shown in Figure 5.5A, treatment of 
MDA-MB-231 cells with PA decreased TPA-provoked MMP-9 protein expression.  It should 
be pointed out that the two bands observed were all latent MMP-9 enzymes, the upper band 
(92 kDa) corresponding to a mature form and the lower band (85 kDa) representing a 
glycosylated form (Toth et al. 1997).  The results were in agreement with the observed 
reduction in MMP-9 gelatinolytic activity and secreted levels in conditioned medium as 
presented in Figure 5.1 and 5.2A respectively.  To further evaluate whether this inhibition of 
PA on MMP-9 protein expression in MDA-MB-231 cells occurred at the transcriptional level, 
semiquantitative RT-PCR was next performed to monitor MMP-9 gene expression.  As 
shown in Figure 5.5B, while the expression of house-keeping gene GAPDH remained 
unaffected, TPA-induced MMP-9 mRNA expression was dose-dependently prevented by PA 
treatment.  These results thus indicated that PA-mediated regulation of MMP-9 expression 














Figure 5.5 PA inhibited TPA-induced MMP-9 protein and gene expression.           
(A) Inhibition of PA on TPA-induced MMP-9 protein expression.  MDA-MB-231 cells were 
incubated with PA for 1 h, followed by TPA treatment for another 20 h.  Whole cell lysates 
were analyzed by western blotting.  Upper and lower bands represented latent mature form 
and precursor form of latent MMP-9 respectively.  (B) Dose-dependent decrease of 
TPA-induced MMP-9 gene expression by PA treatment.  MDA-MB-231 cells were incubated 
with PA for 1 h, followed by TPA treatment for another 20 h.  MMP-9 gene expression was 







5.3.4 Lack of effect of PA on the AP-1 signaling pathway 
The promoter region of the MMP-9 gene contains binding sites for multiple 
transcription factors, including AP-1 and NF-κB.  To elucidate the mechanism responsible 
for the inhibition of PA on MMP-9 transactivation, the effect of PA on AP-1 signaling 
pathway was examined.  MDA-MB-231 cells transiently transfected with AP-1 luciferase 
reporter plasmids were exposed to PA and TPA for 20 h.  Luciferase reporter assays 
performed showed that AP-1 transcriptional activity was significantly induced by TPA 
treatment.  However, this induction was not affected by PA at concentrations of 10 µM or 20 
µM (Figure 5.6A), suggesting that AP-1 would unlikely be involved in the inhibitory effect of 
PA on TPA-induced MMP-9 expression.  MAPKs, the main signaling molecules responsible 
for AP-1 activation (Shaulian and Karin 2002), were also examined.  Consistent with the 
observation obtained from the luciferase-based reporter assay, PA treatment failed to inhibit 
TPA-induced phosphorylation of MAPKs including ERK, JNK and p38 kinase (Figure 5.6B).  
Together, these results showed that the inhibition of PA on TPA-induced MMP-9 expression 








Figure 5.6 PA lacked effect on TPA-activated AP-1 signaling.  (A) Firefly and renilla 
luciferase activity of cells cotransfected with pAP-1-Luc and pRL-CMV and incubated in the 
presence or absence of TPA and PA was measured (details as described in Materials and 
methods).  AP-1 firefly luciferase activity was normalized to renilla luciferase activity for 
each drug treatment, and the fold induction brought about was expressed relative to untreated 
control.  Columns, means of three independent experiments; bars, standard deviation; † p 
<0.05 versus untreated control.  (B) Effect of PA on TPA-induced MAPKs phosphorylation.  
Cells were incubated with PA 1 h prior to TPA addition for another 1 h.  Whole cell lysates 
were obtained and analyzed by western blotting using antibodies specific for total or 
phosphorylated ERK, JNK and p38 kinase.  Images are representative of three independent 
experiments. 
 
5.3.5 Suppression of the NF-κB signaling pathway by PA 
The possible effect of PA on the NF-κB transcriptional activity on MMP-9 gene was 
next investigated.  MDA-MB-231 cells transfected with NF-κB reporter construct were 
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treated with TPA with or without presence of PA.  Subsequent measurement of 
NF-κB-dependent luciferase activity revealed that transcriptional activity was induced to  
3.2-fold by TPA and this induction was effectively suppressed dose-dependently by PA 
(Figure 5.7).  The results therefore implied the involvement of the NF-κB signaling pathway 




Figure 5.7 PA suppressed TPA-induced NF-κB transactivation.  Firefly and renilla 
luciferase activity of cells cotransfected with pNF-κB-Luc and pRL-CMV and incubated in 
the presence or absence of TPA and PA was measured.  NF-κB firefly luciferase activity was 
normalized to renilla luciferase activity for each drug treatment, and the fold induction 
brought about was expressed relative to untreated control.  Columns, means of three 
independent experiments; bars, standard deviation; † p <0.05 versus untreated control;     
** p < 0.01 versus TPA only-treated group.   
 
In agreement with its inhibition on NF-κB transcriptional activity, PA blocked 
TPA-induced nuclear accumulation of p65 (Figure 5.8A) and prevented TPA-induced 
degradation of IκBα protein (Figure 5.8B).  As degradation of IκBα is primarily a result of 
IκBα phosphorylation at serine 32 and serine 36 (Ghosh and Baltimore 1990), it was 
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postulated that this prevention by PA might be due to its inhibition on IκBα phosphorylation.  
Indeed, PA induced a dose-dependent decrease in TPA-induced IκBα phosphorylation at 
serine 32 (Figure 5.8B).  The effect of PA on the upstream signal IKK was further 
determined.  PA suppressed IKKα/β phosphorylation in a dose-dependent manner without 
affecting total protein level of IKKα (Figure 5.8C).  Taken together, the results indicated that 
the inhibitory effect of PA on NF-κB signaling could be attributed to its inhibition on IKK 
phosphorylation, which in turn led to a consequential decrease in p65 nuclear translocation 
















       
 
Figure 5.8 PA suppressed TPA-induced signaling molecules involved in the NF-κB 
transactivation cascade.  (A) Prevention by PA on TPA-induced NF-κB p65 nuclear 
translocation.  Cells were incubated with PA 1 h prior to TPA addition for another 1 h.  
Nuclear fractions extracted from cells were analyzed by western blotting for detection of 
nuclear p65 protein.  (B) Dose-dependent effect of PA on TPA-induced IκBα 
phosphorylation and steady state levels of IκBα.  Cells were incubated with PA 1 h prior to 
TPA addition for another 1 h.  Whole cell lysates collected were analyzed by western 
blotting using antibodies specific for total or phosphorylated IκBα.  (C) Inhibitory effect of 
PA on TPA-induced IKK phosphorylation.  Cells were incubated with PA 1 h prior to TPA 
addition for another 1 h.  Whole cell lysates collected were analyzed by western blotting 
using antibodies specific for total IKKα or phosphorylated IKKα/β.  Images are 
representative of three independent experiments. 
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5.3.6 Reduction of TPA-stimulated MMP-9 expression by NF-κB inhibitor 
To address the causal relationship between NF-κB signaling and MMP-9 expression 
in MDA-MB-231 cells, the effect of NF-κB inhibitor Bay 11-7082 on MMP-9 expression was 
investigated.  The inhibitory effect of Bay 11-7082 as a specific inhibitor of IκBα 
phosphorylation was first confirmed by the demonstration that TPA-induced IκBα 
phosphorylation was effectively prevented, which in turn resulted in the reversal of 
TPA-induced IκBα degradation (Figure 5.9A).  The effect of Bay 11-7082 on TPA-mediated 
MMP-9 induction was next examined.  In a similar manner as of PA, MDA-MB-231 cells 
were subjected to treatment of 5 µM Bay 11-7082 1 h prior to TPA (80 nM) addition for a 
duration of 20 h.  Notably, a reduction in TPA-induced MMP-9 protein expression was 
detected in the treated cells (Figure 5.9B).  The result was in corroboration with analysis of 
the corresponding conditioned medium by gelatin zymography and immunoblotting, which 
showed a respective decrease in MMP-9 gelatinolytic activity and extracellular secretion 
(Figure 5.9B).  Combined together, these results clearly showed that NF-κB signaling was 















Figure 5.9 Specific NF-κB inhibitor Bay 11-7082 reduced TPA-induced MMP-9 
expression and activity.  (A) Effect of Bay 11-7082 on TPA-induced IκBα phosphorylation 
and steady state levels of total IκBα.  Cells were incubated with 5 µM Bay 11-7082 for 1 h 
prior to TPA addition for another 1 h.  Whole cell lysates were collected and subjected to 
western blot analysis using antibodies specific for total or phosphorylated IκBα.  (B) 
Decrease of MMP-9 expression and activity by Bay 11-7082.  MDA-MB-231 cells were 
incubated with 5 µM Bay 11-7082 for 1 h prior to TPA treatment for another 20 h.  
Conditioned medium was collected and subjected to gelatin zymography and western blot 
analysis (lower panel).  Whole cell lysates were also collected and subjected to western blot 
analysis using MMP-9 antibody (upper panel).  The analyses were performed in three 




In this study, the effects of Poria cocos-derived triterpenoids against in vitro breast 
cancer invasion were investigated.  All three selected compounds PA, PPAC and 
dehydropachymic acid, were found to reduce TPA-stimulated MMP-9 extracellular 
expression, among which PA exhibited the greatest efficacy.  PA was further demonstrated to 
inhibit MMP-9 gene transcription at non-lethal concentrations.  The anti-invasive 
mechanism was determined to be mediated through PA’s inhibitory effect on the NF-κB 
signaling pathway.   
Both of MMP-2 and MMP-9 digest collagen IV in the basement membrane and are 
believed to be the most important enzymes responsible for tumor invasion (Brinckerhoff and 
Matrisian 2002).  In addition, accumulating evidence suggests that MMP-2 and MMP-9 
expression are highly correlated with breast cancer cell invasion (Brown et al. 1993; Duffy et 
al. 2000).  On the other hand, agents that can downregulate MMP-2 or MMP-9 have been 
demonstrated to inhibit tumor invasion (Overall and Lopez-Otin 2002; Park et al. 2007; Lin et 
al. 2008).  TPA is a commonly used pro-inflammatory stimulus as well as a tumor promoter.  
Previous studies have shown that TPA promotes cancer invasion and metastasis, and thus can 
be used to investigate anti-invasive capacity of tested compounds (Gomez et al. 1999; Shimao 
et al. 1999).  Here, TPA treatment was found to markedly increase MMP-9 gelatinolytic 
activity, but not that of MMP-2.  This result was consistent with similar observations made 
in a number of previous studies where MMP-9 was found to be highly inducible but not 
MMP-2 (Woo et al. 2004; Zhang et al. 2006; Lin et al. 2008; Weng et al. 2008; Liang et al. 
2009; Park et al. 2009).  It is known that the MMP-9 promoter region contains DNA-binding 
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sites for AP-1 and NF-κB, while MMP-2 does not contain these regulating elements (Overall 
and Lopez-Otin 2002).  Therefore, the difference observed in their responses to TPA can be 
explained by the structural differences in the regulatory sequences of their genes.  
However, it should be noted that latent MMP pro-enzymes can be activated during 
zymography, and thus digestive effect observed by gelatin zymography may not represent the 
natural enzyme activity of the active form of MMP-9 (Hibbs et al. 1985; Toth et al. 1997; 
Fridman et al. 2003).  Interestingly, in this study, the extracellular secretion of the 92 kDa 
pro-MMP-9, but not the presumably active MMP-9 (which has a molecular weight of 82 kDa) 
was observed.  Similar findings were reported in previous studies (Toth et al. 1997; Woo et 
al. 2004; Liang et al. 2009).  Indeed, there has been a consistent inability to detect active 
MMP-9 (82 kDa) in cultured cells (Fridman et al. 2003).  To date, how the extracellular 92 
kDa MMP-9 protein leads to enhanced MMP-9 functional ability and subsequent tumor 
invasion remains elusive.  An alternative mechanism for pro-MMP-9 activation in which the 
propeptide domain be disengaged from the active site without removal of the inhibitory 
propetide domain, if confirmed, might explain at least in part the MMP-9 enzymatic activity 
in the absence of a change in molecular mass (Fridman et al. 2003).  Nonetheless, this study 
demonstrated a clear down-regulation of extracellular MMP-9 protein by PA.  
In the promoter region of the MMP-9 gene, there are multiple cis-acting regulatory 
elements, including two AP-1 binding sites and one NF-κB binding site (Sato and Seiki 1993; 
Overall and Lopez-Otin 2002).  Previous studies suggested that AP-1 and NF-κB were 
intensively involved in TPA-stimulated MMP-9 expression (Huang et al. 2004; Woo et al. 
2004; Takada et al. 2006; Lin et al. 2008; Park et al. 2009).  Here, in agreement with 
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previous studies, TPA was shown to increase transcriptional activity of both AP-1 and NF-κB.  
Importantly, PA selectively inhibited TPA-induced NF-κB transcriptional activity, but had no 
effect on AP-1 transcription.  In addition, activation of MAPKs by TPA treatment was 
observed, further supporting the activation of AP-1 signaling pathway by TPA treatment.  In 
accordance with the obtained data from the luciferase reporter assays, PA did not change 
protein levels of TPA-activated MAPKs.  These results underpinned NF-κB signaling as the 
molecular target for PA’s inhibitory action on MMP-9 expression.    
NF-κB is an important transcription factor in a large variety of genes related to 
inflammation, cancer development and tumor invasion.  It has been suggested to be a target 
for many biologically active phytochemicals such as curcumin, resveratrol and 
epigallocatechin gallate (Nomura et al. 2000; Chun et al. 2003; Woo et al. 2004).  In most 
resting cells, NF-κB is sequestered in the cytoplasm with IκBα and remains inactive.  
Exposure of cells to inflammatory stimuli such as TPA leads to activation of IKK complex, 
which in turn phosphorylates IκBα.  Subsequently, phosphorylated IκBα is targeted and 
degraded by the ubiquitin-proteasome machinery.  The degradation of IκBα allows NF-κB 
p65 subunit to translocate freely to the nucleus and bind to the MMP-9 promoter to initiate 
MMP-9 gene transcription (Overall and Lopez-Otin 2002).  Here, PA was found to bring 
about a reduction in TPA-induced p65 nuclear translocation through its inhibition on IKKα/β 
phosphorylation, followed by a decrease in IκBα phosphorylation and prevention of IκBα 
proteasomal degradation.  Moreover, it was ascertained that a specific NF-κB inhibitor Bay 
11-7082 could effectively decrease MMP-9 expression, thus validating the role of NF-κB in 
PA’s inhibition on MMP-9.  
Chapter 5 
 187
In conclusion, in this chapter, it was found that PA at sub-lethal concentrations 
inhibited TPA-induced MDA-MB-231 breast cancer cell invasion through down-regulation of 
MMP-9 expression.  Furthermore, it was revealed that the molecular mechanism by which 
PA inhibited MMP-9 expression was mediated through its suppressive effect on NF-κB 
activation.  In the light that tumor metastasis is often associated with poor prognosis and 
high mortality among cancer patients, the need to discover and develop new therapeutic 
strategies that target early tumor invasiveness and/or metastasis is crucial.  PA, having found 
to impair invasiveness of cultured breast cancer cells, would serve as a potential 














Chapter 6: General discussion, conclusion and future work 
 
6.1 General discussion 
6.1.1 Cancer therapeutic potential of triterpenoids from Poria cocos 
Among the eight triterpenoids isolated from Poria cocos, most of them showed 
moderate cytotoxicity against human cancer cells.  In this project, PA and PPAC were 
evaluated for their apoptosis-inducing effects in human lung cancer cells.  PA induced 
apoptosis through a pathway mediated by mitochondria, whereas PPAC induced apoptosis 
without involvement of mitochondria.  Despite these mechanistic differences, both of these 
compounds effectively inhibited lung cancer cell proliferation by inducing apoptotic cell 
death.  The apoptosis-inducing effect of PA was also demonstrated in prostate cancer cells 
by our previous lab members (Gapter et al. 2005).  In addition, dehydrotrametenolic acid, one 
natural triterpenoid isolated from Poria cocos has been demonstrated to induce apoptosis in 
H-ras transformed rat2 cells (Kang et al. 2006).  Therefore, it could be inferred that 
triterpenoids from Poria cocos exerted cytotoxicity through inducing apoptotic death of 
cancer cells.  However, the cytotoxicity exerted by these triterpenoids was not comparable to 
that of clinically used chemotherapeutic drugs.  Most of the reported triterpenoids from 
Poria cocos exhibit modest cytotoxicity on cancer cells with IC50 value larger than 20 µM (Li 
et al. 2004; Mizushina et al. 2004; Gapter et al. 2005; Kang et al. 2006).   
Due to limited studies conducted on these triterpenoids, the in vivo bioavailability 
profiles of these compounds remain unknown.  Whether an effective concentration can be 
achieved in vivo needs to be determined before these compounds can be considered as 
Chapter 6 
 189
possible anticancer agents.  It is possible that the relatively high concentrations needed for 
their chemotherapeutic effectiveness may hinder these compounds to become useful 
anticancer agents themselves.  However, considering the successful synthesis of CDDO 
from oleanolic acid (a natural pentacyclic triterpenoid with weak anticancer activity), 
chemical modification performed on triterpenoids from Poria cocos may yield more potent 
cancer therapeutic agents.   
 
6.1.2 Cancer chemopreventive potential of triterpenoids from Poria cocos 
Triterpenoids purified from Poria cocos have been reported by different research 
groups to inhibit skin tumor formation in a two-stage carcinogenesis mouse model.  
Moreover, EBV-EA activation by TPA has been shown to be inhibited by most of the tested 
triterpenoids from Poria cocos (Kaminaga et al. 1996; Kaminaga et al. 1996; Akihisa et al. 
2007).  In summary, these findings have highlighted the chemopreventive activity of Poria 
cocos-originated triterpenoids.  However, the mechanism(s) underlying their 
chemopreventive effects has not been well clarified.  Notably, there is a discrepancy 
between the observed preventive efficacy of these compounds as evaluated by carcinogenesis 
model and the proposed mechanism in which their chemopreventive effects are attributed to 
their inhibition of PLA2 enzyme activity.  According to the study by Kaminaga et al, PA 
significantly inhibited TPA-stimulated skin tumor formation in a two-stage carcinogenesis 
model (Kaminaga et al. 1996).  In that study, 0.2 µmol of PA dissolved in 100 µl vehicle was 
spread onto mouse skin (final concentration 2 µM).  After 20 weeks, PA reduced occurrence 
of skin tumor from 73% to 27% and reduced the average number of papillomas per mouse 
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from 7.2 to 1.2.  This chemopreventive effect of PA is comparable to that of resveratrol, a 
grape-originated stilbene compound intensively studied for its anticancer activity (Jang et al. 
1997).   
On the other hand, the attribution of biological effects of Poria cocos-originated 
triterpenoids to PLA2 enzyme inhibition to date is based on a report showing the inhibitory 
effect of PA and dehydrotumulosic acid to the enzymatic activity of PLA2 from snake venom 
(Cuella et al. 1996).  However, the IC50 (2 mM) required to inhibit PLA2 enzymatic activity 
is too high to be achievable in vivo.  Clearly, this enzymatic inhibitory efficacy by PA does 
not agree with PA’s chemopreventive activity observed in the study by Kaminaga et al.  
Although in vivo dosages cannot be directly compared with concentrations obtained in in 
vitro experiments, the differences in effective concentrations (2 mM versus 2 µM) between 
the studies are too vast to establish a good correlation.  In our study, we found that PA 
modulated arachidonic acid metabolism in A549 cells at non-lethal concentrations.  PA 
effectively inhibited IL-1β-induced arachidonic acid release and PGE2 formation.  
Considering the role of arachidonic acid and prostaglandins in cancer, it would be reasonable 
to infer that PA might inhibit promotion of pro-inflammatory factors on cancer development 
through downregulation of key enzymes involved in arachidonic acid metabolism.   
In addition, we observed significant reduction of arachidonic acid metabolism by PA 
at 3 µM, which is biologically more relevant to the dosages used in the animal study by 
Kaminaga et al.  As such, it would be likely that the chemopreventive effect of PA was due 
to reduced arachidonic acid metabolism.  Although PA did not completely inhibit PGE2 
production at tested concentrations (≤ 10 µM), repeated application of PA might result in the 
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constant suppression of PGE2 release, and thus eventually lead to prevention of tumor 
formation.  From a general prospective, triterpenoids from Poria cocos seemingly possess 
an ability to alleviate or reduce the harmful response elicited by foreign stimuli.  This ability 
is also reflected by the anti-inflammatory and anti-rejection effects of these triterpenoids as 
demonstrated in previous studies (Nukaya et al. 1996; Yasukawa et al. 1998; Giner-Larza et al. 
2000; Schinella et al. 2002; Zhang et al. 2004; Fuchs et al. 2006).  Interestingly, these 
findings share much similarity with the so-called “sedative” effect of Poria cocos in the 
principles of Traditional Chinese Medicine.   
 
6.1.3 Anti-metastatic potential 
Tumor invasion and metastasis is an advanced stage of cancer development, which 
has accounted for the majority of cancer-related mortalities.  In this project, we examined 
the effects of triterpenoids isolated from Poria cocos on MMP-9 expression and tumor 
invasion.  PA was found to inhibit tumor invasion, presumably through its downregulation of 
MMP-9.  MMP-9 is a key enzyme involved in degradation of extracellular matrix.  The 
downregulation of MMP-9 would result in an extracellular environment unfavorable for 
cancer cells to invade into nearby tissues or blood vessels.  In addition, MMP-9 has been 
found to play an important role in angiogenesis, which is essential for metastatic tumor to 
survive at metastatic sites (Egeblad and Werb 2002).  Our findings that PA reduced MMP-9 
expression therefore might also indicate an inhibitory effect of PA on angiogenesis.  On this 
basis, it was postulated that PA could act as an effective anti-metastatic agent by remodeling 
extracellular matrix and inhibiting tumor neovascularization.  In this PhD study, to exclude 
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the interference of PA’s antiproliferative effect on tumor invasiveness, non-lethal 
concentrations of PA were used for the experiments performed.  It is anticipated that 
combination of PA’s cytotoxicity and inhibitory effect on tumor invasion could result in 
enhanced anticancer effects when lethal doses were to be used.  In addition, other 
triterpenoids originated from Poria cocos may have similar effects, which warrants the in 
vitro and in vivo evaluation of their anti-metastatic potential. 
 
6.1.4 NF-κB signaling pathway as the main molecular target 
In our investigation of PA’s modulation of arachidonic acid metabolism, we found 
that inhibition of the NF-κB and MAPK signaling pathways were the underlying mechanisms 
of PA’s biological effects.  In the study examining PA’s anti-invasive effect, we found that 
NF-κB signaling pathway, but not AP-1 signaling, was targeted by PA.  This discrepancy 
may be due to utilization of different stimuli and different cell lines in these two studies.  In 
the study investigating PA’s effect on arachidonic acid metabolism, IL-1β was employed as 
the stimulant and this study was carried out in human lung cancer A549 cells.  In the 
anti-invasive study, PA’s effect was evaluated by TPA stimulation of a highly invasive human 
breast cancer cell line MDA-MB-231.  Although both IL-1β and TPA bring about activation 
of MAPK and NF-κB signaling, mediation of the two signal transduction pathways are 
distinctly different.  IL-1β binds to IL-1 receptor, and activates MAPK and NF-κB signaling 
pathways through mediator proteins such as IL1RAP, IRAK, TRAF6 and MYD88 (Kuno and 
Matsushima 1994; Jiang et al. 2002).  TPA, a strong PKC activator, has been reported to 
induce activation of MAPK and NF-κB signaling pathways through mediation of PKC 
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isotypes or proteins such like CaMKII (Lallena et al. 1999; Hughes et al. 2001).  The 
different activation mechanisms by IL-1β and TPA could explain at least in part PA’s different 
effects on MAPK activation in these two experimental systems.  The discrepancy might also 
be due to the different cell lines used in these two studies.  Nonetheless, we had observed 
PA’s inhibitory effects on NF-κB signaling in both studies, thus indicating NF-κB signaling as 
the main target of PA.   
As an important transcriptional factor, NF-κB has been found to be highly involved in 
a variety of inflammatory conditions (Karin 2008).  It responds to most of the inflammatory 
stimuli and activates downstream transcription of inflammatory proteins.  Correspondingly, 
inhibition of NF-κB will reduce the inflammatory response elicited by a variety of stimuli 
(Karin 2008).  Therefore, our findings demonstrating triterpenoids’ inhibition of the NF-κB 
activation cascade would provide possible explanation to their anti-inflammatory effects as 
reported by numerous studies (Kaminaga et al. 1996; Nukaya et al. 1996; Cuellar et al. 1997; 
Giner-Larza et al. 2000; Giner et al. 2000).  However, the exact molecular target inhibited by 
these triterpenoids remains elusive.  Based on the observations made in this study that IKK 
phosphorylation was downregulated by PA, we proposed that PA’s molecular target could be 
an upstream signal of IKK.  
 
6.2 Conclusion 
From the above discussion, we could conclude that triterpenoids from Poria cocos 
exerted moderate cytotoxicity against cancer cells.  We had focused on PA and PPAC, and 
found that they might inhibit cancer growth by causing apoptotic death of cancer cells.  On 
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the other hand, triterpenoids from Poria cocos might exert their chemopreventive effects 
through downregulation of key enzymes involved in arachidonic acid metabolism, which led 
to reduced prostaglandin production.  In addition to their cytotoxicity and chemopreventive 
capacity, these triterpenoids might also possess anti-metastatic activity through their 
downregulation of MMP-9.  Our results had suggested that inhibition of the NF-κB 
signaling pathway would account for their chemopreventive and anti-metastatic effects.  The 
findings in this project will not only expand our understanding of the anticancer potential of 
triterpenoids from Poria cocos, but also encourage more studies examining anticancer 
















6.3 Future work 
6.3.1 Structure-activity relationship study 
In this PhD project, we have shown that PA and PPAC exhibit different mechanisms 
of induction of apoptosis in cancer cells.  PA activates intrinsic apoptotic pathway which 
needs the mediation of mitochondria; PPAC triggers extrinsic pathway and activates caspase 
cascade without involvement of mitochondria.  Considering their structural similarities but 
distinct acting mechanisms, these two compounds are worthwhile for more in-depth 
structure-activity relationship study.  In addition, Poria cocos is a rich source of 
lanostane-type triterpenoids sharing chemical similarities.  For instance, the eight 
triterpenoids obtained in this project are structurally similar to one another, with only minor 
differences on some chemical groups.  This makes it possible to analyze the function of 
certain chemical group(s) to gain insight of structure-activity relationship of lanostane-type 
triterpenoids.  Elucidation of the structure-activity relationship will allow the synthesis and 
development of novel anticancer compounds with more superior chemotherapeutic potencies. 
 
6.3.2 Elucidation of the exact molecular target(s) of PA 
NF-κB signaling pathway has been demonstrated to be the main target of PA for its 
chemopreventive and anti-invasive activity.  However, the exact cellular protein(s) inhibited 
by PA remain elusive.  Although we had shown that IKK phosphorylation was blocked by 
PA treatment, the precise mechanism underlying this blockade is not known.  NF-κB 
signaling has been intensively investigated and found to be the target for many 
anti-inflammatory or anti-cancer compounds (Garg and Aggarwal 2002; Karin 2008).  
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However, the molecular mechanism of IKK activation has not been thoroughly studied 
(Ghosh and Karin 2002).  Clarification of the exact molecular target of PA will not only help 
understand PA’s anticancer mechanism, but also provide valuable insight into mechanisms of 
many other active compounds with similar effects.  Moreover, it will make it possible to 
design potent inhibitors of this target and yield better anticancer agents targeting NF-κB 
signaling. 
 
6.3.3 Evaluation of possible synergistic effect of PA with other anticancer drugs 
Activation of NF-κB signaling is one common feature of therapeutic treatment of 
cancer (Nakanishi and Toi 2005).  Since NF-κB regulates cell survival, NF-κB activation 
contributes to resistance of cancer cells to chemotherapeutic agents, and thus compromises 
apoptotic potential of these agents (Nakanishi and Toi 2005).  In our study, we have found 
that PA is an inhibitor of NF-κB signaling.  Combination of PA with other chemotherapeutic 
agents that unnecessarily activate NF-κB may thus result in synergistic effects in killing 
cancer cells.   Therefore, studying the combinatorial effect of PA with other 
chemotherapeutic agents may represent a feasible research direction.  In vivo experiments 
can be carried out upon observation of such synergistic effects in in vitro studies.   
 
6.3.4 Pharmacokinetic study on PA and PPAC 
In this PhD project, we have shown that PA and PPAC inhibit lung cancer cell 
proliferation and induce apoptosis in lung cancer cells.  However, it is not known whether 
the concentrations effective for these biological effects can be achieved in vivo.  A 
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pharmacokinetic study will provide useful information on the pharmacokinetic profiles of 
these two compounds.  It can also be used to facilitate dosage determination in tumor 
xenograft studies. 
 
6.3.5 Evaluation of in vivo efficacy of PA and PPAC against lung tumor xenograft 
growth 
PA and PPAC have been shown to induce apoptotic cell death of human lung cancer 
cells.  They are also effective in inhibiting colony formation of lung cancer cells, suggesting 
that these compounds may inhibit cancer growth in vivo.  In addition, PA has been 
demonstrated to modulate arachidonic acid metabolism, thereby possibly impeding cancer 
progression.  Therefore, in vivo evaluation of these two compounds on xenograft tumor 
model is warranted.  To determine whether PA or PPAC is able to repress or reduce the size 
of an established tumor, a dose-escalation study can be carried out in nude mice carrying lung 
tumor xenografts.   
 
6.3.6 Determination of in vivo efficacy of PA against breast cancer metastasis 
In this project, we have demonstrated the potential of PA against breast cancer cell 
invasion using in vitro experiments; we showed that PA inhibits MMP-9 gene transcription, 
and thus reduces MMP-9 protein synthesis and the subsequent extracellular secretion of 
MMP-9.  Our results therefore suggest that PA is an effective anti-invasive agent, and future 
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Appendix VIII 13C NMR spectrum of Compound 8 (29-hydroxypolyporenic acid) 
 
 
